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Abstract 
 
Bone is a specialized tissue characterized by its rigidity and hardness, yet light weighed to 
fulfill diverse functions as mineral storage, organ protection or body support and locomotion. 
Despite its extraordinary healing ability, bone response may be unsuccessful to repair severe 
damage caused by injury or degenerative diseases. Furthermore, when bone is affected, other 
tissues and interfaces might be quite distressed as well. Cartilage and bone interface of the 
joints (osteochondral interfaces) is particularly affected by traumatic injuries and aging 
diseases. The challenge lies in balancing the structural, functional and biological needs of bone 
and cartilage in a stable milieu. As currently used therapies do not provide the ideal treatment, 
the development of biological substitutes through tissue engineering (TE) approaches may 
provide the ultimate solutions to restore, maintain, or improve bone and osteochondral tissue 
function.  
Scaffolds play an imperative role in most TE strategies, where they are expected to guide 
cellular distribution and colonization, similarly to the natural occurring communications 
between cells and tissue, and to provide mechanical support during tissue regeneration. 
Nevertheless, in large damaged areas, scaffolding alone might be insufficient to promote a 
satisfactory healing response. Culturing stem cells onto the scaffolds has demonstrated to 
promote the regeneration of damaged tissues. Stem cells (SCs) can be found in almost every 
tissue, evidencing their role in repairing injuries. Bone marrow stem cells (BMSCs) are the most 
studied, and promising candidates for autologous TE approaches minimizing disease 
transmission risks but shown to be donor age-affected and had limited self-renewal capability. 
These limitations directed research into other stem cells sources, such as amniotic fluid (AF), 
that have shown to be an almost unlimited SCs source with high proliferative and osteogenic 
potential. Along with the almost endless ability to expand without telomere shortening, 
amniotic fluid stem cells (AFSCs) share with embryonic stem cells some markers and a high self 
renewal capacity.  
In this Thesis several potential approaches were considered aiming at bone and 
osteochondral TE, focusing on distinct scaffold design and composition, previously or newly 
developed, and distinct stem cells sources. Different animal models were used to evaluate the 
proposed strategies with scaffolds and/or cell-scaffold constructs. 
As a first approach, a multilayered scaffold was developed composed of tricalcium 
phosphate (TCP) granules entrapped in a polycaprolactone (PCL) nanofiber mesh, inspired 
from the natural organic-inorganic nanostructure of bone. A synergistic effect of PCL-TCP 
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scaffolds and mechanical stimulation was observed in the osteogenic differentiation of BMSCs 
cultured onto these scaffolds, resulting in the production of a mineralized ECM, even in basal 
medium. Composite multilayered scaffolds showed an interesting behavior under dynamic 
conditions using cell culturing media without osteogenic supplements.  
Another approach consisted in the combination of wet-spinning technology and a calcium 
silicate solution to produce SPCL (starch and polycaprolactone blend) wet-spun fiber meshes 
with functionalized silanol groups (SPCL-Si). The purpose was to developed new bioactive 
materials linking the properties of classical bioactive ceramics, and the processability and 
degradability of an organic polymer. SPCL-Si scaffolds own intrinsic properties to sustain in 
vitro osteogenic features, and thus holding a great potential for bone engineering approaches. 
Additionally, this Thesis aimed at designing a new construct for the repair of osteochondral 
(OC) interfaces, proposing a novel bilayered scaffold, combining the well described agarose 
gels for cartilage and the promising SPCL scaffolds for bone, encapsulated/seeded with 
amniotic stem cells (AFSCs). An OC engineered system was successfully developed, where both 
osteo- or chondrogenic differentiated AFSCs maintained long term viability and phenotypic 
expression, even in basal medium after assembling of the bilayered construct.  
Another major original objective of this Thesis was to explore the potential of amniotic 
fluid stem cells (AFSCs), as compared to bone marrow stem cells (BMSCs), for bone TE 
applications. Besides their source, the environmental conditions are known to influence cell 
response, and thus, both AFSCs and BMSCs were seeded/cultured in either 2D or 3D (using 
SPCL scaffolds) conditions. AFSCs and BMSCs expressed different bone-related markers at 
different time points. This study demonstrated that the selection of a particular stem cell type 
may not be a simple and direct process and relies on the target TE strategy. 
Finally, non-critical sized defects were induced in goat femurs so as to understand the role 
of the scaffold material -SPCL- and the influence of culturing autologous mesenchymal cells 
with/without pre-culture in osteogenic medium. Neobone formation and cellular distribution 
was increased in cell seeded SPCL scaffolds (pre-differentiation condition), showing the 
relevance of implanted cells in the bone regeneration process, and suggesting the importance 
of the stage of osteogenic differentiation of seeded cells.  
In a similar approach, femoral critical sized defects were induced in nude rats and SPCL 
scaffolds were implanted with or without AFSCs under different stages of osteogenic 
differentiation. The bridging effect between the bone segments was more prominent in 
scaffolds with osteogenic committed cells, and large blood vessels were observed, especially in 
SPCL scaffolds seeded with undifferentiated cells or osteogenic-like cells. Both in vivo studies 
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showed the potential of SPCL scaffolds as a tissue 3D support for the regeneration of bone and 
underlined the importance of stem cells and stem cells stage of differentiation for achieving 
enhanced bone tissue regeneration. 
In summary, the described scaffold design and composition show a great potential to be 
tailored to specific applications in bone tissue regeneration strategies. Nevertheless, SPCL 
meshes obtained from melt spun fibers are clearly one step ahead as scaffold structures, 
showing to provide the necessary support for bone and osteochondral TE strategies using 
different sources of stem cells. Most importantly, the work described in this Thesis clearly 
demonstrated that bone tissue engineering requires the presence of stem cells, and that their 
pre-differentiation into the osteoblastic phenotype facilitates bone regeneration. 
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Resumo 
 
O osso é um tecido especializado, caracterizado pela sua rigidez e dureza embora a sua 
estrutura leve permita a realização de diversas funções, incluíndo a reserva de minerais, 
protecção de órgãos ou suporte do organismo e locomoção. Apesar da sua capacidade 
regenerativa extraordinária, a resposta natural do osso revela-se, por vezes, limitada na 
reparação de danos severos resultantes de traumas graves ou doenças degenerativas. Além 
disso, quando o osso se deteora, outros tecidos e interfaces poderão estar igualmente 
comprometidos. A interface cartilagem-osso presente nas articulações (interfaces 
osteocondrais) é particularmente afectada por traumas e doenças associadas ao 
envelhecimento. Uma vez que as terapias convencionais não garantem o tratamento ideal 
destes tecidos, o desenvolvimento de substitutos biológicos através da engenharia de tecidos 
propõe-se como uma alternativa para restaurar, manter ou melhorar a funcionalidade do osso 
e do sistema osteocondral. 
Na maioria das estratégias em engenharia de tecidos, as estruturas tridimensionais de 
suporte ou scaffolds desempenham um papel fundamental, conduzindo a distribuição e 
colonização celulares, de modo semelhante à comunicação que ocorre naturalmente entre as 
células e o tecido, proporcionando também um suporte mecânico durante o processo de 
regeneração. No entanto, em áreas danificadas de grandes dimensões, as estruturas 
tridimensionais de suporte poderão ser insuficientes para promover uma resposta terapêutica 
satisfatória. A cultura de células estaminais nestas estruturas tem demonstrado estimular a 
regeneração de tecidos lesados; células estas que podem ser encontradas em quase todos os 
tecidos, evidenciando o seu papel na reparação de lesões. Actualmente, as células estaminais 
da medula óssea (bone marrow stem cells, BMSCs) têm sido as mais estudadas, revelando-se 
candidatas promissoras para aplicações autólogas em engenharia de tecidos, reduzindo o risco 
de transmissão de doenças, embora o seu potencial possa ser comprometido pela idade do 
dador e pela limitada capacidade de auto-renovação. Estas limitações conduziram a 
investigação científica na procura de novas fontes de células estaminais, como o fluído 
amniótico que demonstrou ser uma fonte quase inesgotável de células estaminais com grande 
potencial de proliferação e de diferenciação osteogénica. Além disso, as células estaminais do 
fluído amniótico (amniotic fluid stem cells, AFSCs) partilham com as células estaminais 
embrionárias marcadores genéticos e uma elevada capacidade de auto-renovação. 
Nesta Tese foram estudadas diferentes estratégias de engenharia de tecidos, considerando 
o seu potencial para aplicação em osso e em interfaces osteocondrais. Estas estratégias 
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baseiam-se na utilização de estruturas distintas de suporte tridimensionais (scaffolds), 
desenvolvidos prévia ou especificamente para este projecto, e em células estaminais de 
diferentes fontes. Também foram analisados vários modelos animais para avaliação in vivo das 
estratégias desenvolvidas, nomeadamente as estruturas de suporte tridimensionais na 
presença/ausência de células estaminais. 
Numa primeira abordagem, desenvolveu-se uma estrutura de suporte tridimensional 
constituída por grânulos de fosfatos de tricálcio envolvidos numa matriz de nano fibras de 
policaprolactona (PCL). Esta estrutura foi inspirada na nanoestrutura orgânica-inorgânica do 
osso. Observou-se um efeito sinergístico das estruturas de suporte tridimensional de PCL-
fosfatos e da estimulação mecânica no processo de diferenciação osteogénica das BMSCs 
cultivadas nestes suportes, resultando na produção de uma matriz extracelular mineralizada, 
mesmo em meio de cultura basal. As estruturas compósitas de suporte tridimensional de 
multi-camada demonstraram ser relevantes em condições dinâmicas utilizando meios de 
cultura celular sem suplementos osteogénicos. 
Numa segunda estratégia, combinou-se a tecnologia de extrusão líquida (wet-spining) e 
uma solução de silicato de cálcio para produzir uma matriz de suporte tridimensional de uma 
mistura polimérica de amido e policaprolactona (starch-polycaprolactone blend, SPCL) com 
grupos funcionais de silanol (SPCL-Si). O objectivo consistiu no desenvolvimento de novos 
materiais bioactivos, reunindo as propriedades dos materiais cerâmicos clássicos e a 
processabilidade e degradabilidade de um polímero orgânico. As matrizes desenvolvidas 
apresentam propriedades intrínsecas capazes de sustentar as propriedades osteogénicas das 
células in vitro, e, consequentemente, com potencial para engenharia de tecidos ósseos. 
Nesta Tese foi também investigado o desenvolvimento de estruturas de suporte 
tridimensionais híbridas com células estaminais para a regeneração de interfaces 
osteocondrais, através da criação de uma estrutura de suporte tridimensional de bi-camada, 
combinando os géis de agarose, já estudados para a cartilagem, e as estruturas de suporte 
tridimensionais promissoras de SPCL para osso, cultivados ou encapsulados, respectivamente 
com AFSCs. Foi desenvolvido um sistema osteocondral, no qual as células estaminais do fluído 
amniótico se diferenciaram nas linhagens condro- e osteogénicas, mantendo a viabilidade e a 
expressão fenotípica ao longo do tempo, após a montagem do sistema de bicamada e em meio 
de cultura basal.  
O potencial das células estaminais do fluído amniótico (AFSCs) foi também explorado e 
comparado com as células estaminais da medula óssea (BMSCs) para aplicações em 
engenharia de tecido ósseo. A origem e o meio envolvente são condicionantes da resposta 
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celular e, assim sendo, as AFSCs e as BMSCs foram cultivadas em ambientes de duas e três 
dimensões (utilizando as estruturas de suporte tridimensionais de SPCL). Os dois tipos 
celulares revelaram diferentes perfis de expressão de vários marcadores associados à 
diferenciação osteogénica, analisados ao longo do tempo em cultura, demonstrando que a 
selecção de um tipo de células estaminais não é uma escolha simples e directa, e que se 
encontra dependente da estratégia específica que se pretende. 
Em seguida, estudos de defeitos ósseos não-críticos foram realizados em fémures de cabras 
com o propósito de analisar o papel das estruturas de suporte tridimensionais de SPCL e da 
influência do cultivo de células autólogas da medula óssea, com ou sem pré-cultura em meio 
de diferenciação osteogénico. A formação de novo tecido ósseo e a distribuição celular foram 
mais pronunciadas nos locais implantados com os suportes tridimensionais híbridos com 
células pré-diferenciadas, evidenciando a importância das células implantadas e sugerindo 
também a relevância do estadio de diferenciação celular no processo regenerativo ósseo. 
Posteriormente, foram induzidos defeitos críticos em fémures de ratos atímicos, onde se 
implantaram também estruturas de suporte tridimensionais de SPCL, na presença ou ausência 
de AFSCs, em diversos estadios de diferenciação osteogénica. A aproximação dos dois 
segmentos ósseos no defeito criado foi mais pronunciado na presença das estruturas de 
suporte tridimensionais híbridas com AFSCs comprometidas com o fenótipo osteogénico, 
enquanto que os maiores vasos sanguíneos foram observados nos defeitos preenchidos com 
estruturas de suporte tridimensionais hibridadas com AFSCs no estadio indiferenciado ou com 
AFSCs no estadio considerado osteogénico. Ambos os estudos in vivo demonstraram o 
potencial das estruturas tridimensionais de SPCL para suporte e regeneração de tecido ósseo, 
salientando uma vez mais a importância das células estaminais e do estadio de diferenciação 
celular numa melhor regeneração tecidular. 
Resumidamente, o design e composição das estruturas de suporte tridimensionais, 
descritos anteriormente, demonstraram potencial para aplicação em estratégias de 
regeneração óssea. No entanto, as matrizes de SPCL obtidas por melt spun, estão um passo à 
frente como estruturas de suporte uma vez que demonstraram garantir o suporte 
tridimensional de estratégias para osso e interface osteocondral, utilizando células estaminais 
de diferentes origens. Em conclusão, o trabalho descrito nesta Tese demonstra claramente 
que a engenharia de tecidos do osso requer a presença de células estaminais e que a sua pré-
diferenciação no fenótipo osteogénico facilita a regeneração óssea. 
_____________________________________________________________________________ 
O resumo em português desta Tese não se encontra redigido segundo o novo acordo ortográfico. 
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Chapter I 
CURRENT STRATEGIES FOR OSTEOCHONDRAL REGENERATION: 
FROM STEM CELLS TO PRE-CLINICAL APPROACHES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.1.  Abstract 
 
Damaged cartilage tissue has no functional replacement alternatives and current therapies 
for bone injury treatment are far from being the ideal solutions emphasizing an urgent need 
for alternative therapeutic approaches for osteochondral regeneration. 
The tissue engineering field provides new possibilities for therapeutics and regeneration in 
rheumatology and orthopaedics, holding the potential for improving the quality of life of 
millions of patients by exploring new strategies towards the development of biological 
substitutes to maintain, repair and improve osteochondral tissue function. Numerous studies 
have focused on the development of distinct tissue engineering strategies that could result in 
promising solutions for this delicate interface. In order to outperform currently used methods, 
novel tissue engineering approaches propose, for example, the design of multi-layered 
scaffolds, the use of stem cells, bioreactors or the combination of clinical techniques. 
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I.2.  Introduction 
 
Osteochondral (OC) interfaces are part of the joint, being a specialized and integrated 
structure consisting of multiple connective tissue elements, including muscles, tendons, 
ligaments, synovium, cartilage, and bone, organized to permit stability and movement of the 
human skeleton.  
OC injuries can lead to joint malfunction and ultimately to the development of degenerative 
diseases such osteoarthritis. With an increasing aging population, OA represents a significant 
socio-economical burden worldwide. Although several procedures are available on the clinical 
market, an ideal solution has yet to be found in order to fulfill all necessary requirements for a 
long term successful regenerative approach. 
This paper is aimed at reviewing distinct strategies aiming at a successful OC regeneration, 
involving cells, scaffolds, bioreactors or a combination of these elements. The rationale for 
currently used techniques as well as some promising studies in animal models will be also 
discussed in this review in order to highlight the state-of-the-art in OC over the past few years 
(Figure I.2.1). 
 
Figure I.2.1 – Clinical and Tissue Engineering strategies to promote the regeneration of 
osteochondral defects. 
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One of the most challenging goals in bone and cartilage tissue engineering (TE) is the 
creation of an engineered OC interface to repair damaged areas. Similarly to the natural 
milieu, an engineered interface should distribute everyday mechanical stresses with low-
friction load bearing, while interacting with different structural and biological needs in a stable 
environment. This is particularly more demanding and unique if one considers the distinctive 
requirements of bone and cartilage tissues as well as the several OC systems found in the 
human body, dependent on their location and functionality.  
Several materials, shapes, stiffness and chemical compositions were described for bone[1-
8] and cartilage scaffolds[8-21], considering the relevance of scaffold architecture to sustain 
the mechanical stresses of the joint as well as to guide the cells into the desired phenotype, 
and promoting a complete integration of the OC system in order to restore tissue functionality. 
The selection of cells plays also an important element in this delicate interface headed for 
engineered grafts. Several potential cells sources were successfully described for bone[22-26],  
and cartilage[17, 22-27], which are likely  to be useful for OC strategies[8].  
The subsequent step towards the clinical application is the up-scale and custom made 
production of the OC implants to fit perfectly to the injured area and to provide the biological 
and structural needs required to restore tissue function. In order to automate and make the 
system cost-effective, several bioreactor models[28, 29] were designed and have been 
showing promising results. 
 
I.2.1.  Osteochondral defects (OCD) 
 
Most OC lesions or defects (OCD) and OC injury-associated diseases lead to loss of integrity 
or stability at the articular surface with resultant decrease range of motion of the involved 
joint, and, ultimately, premature osteoarthritis[30]. Although OCDs occur as a result of 
repetitive trauma within the joint, several factors, such as ischemia, genetics, abnormal 
vasculature, and metabolic disorders are associated to body processes leading to loss of 
cartilage[31] or to relevant changes in the architecture or composition of the bone[32]. 
Furthermore, joint healing is strongly dependent on age, as age is the strongest known risk 
factor for development of OA[33] and depth of injury is also age associated[34]. Aged cartilage 
also induces changes in chondrocyte function and material properties, and responds 
differently to cytokines and growth factors[33]. 
The location of a particular defect[35] does influence repair response of the cartilage as 
well as the mechanical alignment of the joint[36]. OC lesions are identified most frequently in 
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the femoral condyles[37], capitellum of the elbow[38], dome of the talus[30], and the dorsal 
surface of the patella[37]. 
 
I.2.2.  Weight bearing influence in biomechanics of the joint 
 
Homeostasis of articular cartilage depends on mechanical loads generated during daily 
activity. Some joint areas are particularly more affected by weight pressure than others, which 
may progress to a more degenerative and diffuse joint involvement that translates to the 
patient by causing pain, swelling, clicking, and instability. Ultimately, inappropriate joint loads 
are associated to focal stress and result in focal degeneration of cartilage, as occurs in OA, and 
increase the stress on subchondral bone. Changes in pressure and shear stress induced by joint 
movement may induce changes in matrix protein expression and in the release of nitric oxide 
associated to joint pathogenesis[39].  
The stress may also vary throughout the cartilage on a joint surface, because loading is not 
completely uniform, leading to gradients in stress and pressure[40]. This effect is evident in 
most patients, where the surface of the joints does not conform perfectly under loading and 
may result in an increased risk for OA progression[33]. 
 
I.2.3.  Current treatments in clinical field 
 
Currently available treatments depend upon the size of the OC defect and the condition of 
the overlying cartilage. Using reparative surgery, cartilage treatments include arthroscopic 
debridement, abrasion arthroplasty and microfracture. These procedures stimulate the body 
to heal the injury, mainly resulting in the formation of fibrocartilage[41]. Fibrocartilage is a scar 
tissue presenting diminished resilience, reduced stiffness, and poor wear characteristics when 
compared to hyaline cartilage. Thus, fibrocartilage is unlikely to withstand physiological 
loading and cannot guarantee to function successfully in long term. Nevertheless, other 
options are available with restorative surgery, namely, autografts recurring to mosaicoplasty 
procedures, allografts[42, 43] and biologic replacement using cultured autologous 
chondrocytes[44, 45]. The biggest challenge with autografts is to achieve a final round shape 
that mimics the surface of the articular joints. Allografts procedure is similar to autografts[46] 
and mostly used after other surgeries have failed. It is not recommended for patients with OA, 
and the limited supply of donor tissue is a major problem of this practice. 
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Autologous chondrocyte transplantation/implantation[44] has also been described to help 
restoring the structural make up of the articular cartilage. The intermediate and long-term 
functional and clinical results are promising, especially regarding the durability of the repair in 
human patients follow up[45].  
More recently[47], tissues from the covering of bone and cartilage are implanted into the 
lesion through periosteal and perichondral grafting to promote the repair and functionality of 
cartilage.  
Despite the availability of procedures, all current treatment options inflict further tissue 
destruction before any therapeutic effect can be achieved.  
 
I.2.4.  TE strategies to improve available treatments 
 
I.2.4.1.  Cells to promote healing 
 
Despite current knowledge in OC field, the selection of a cell source to promote efficient OC 
regeneration is a major issue that must to be considered. Ideally, a cell source should enable 
insignificant donor morbidity or tissue scarcity, resurface joints with cartilage, have no 
limitations in the amounts available and be easy to maintain/expand in vitro, be readily 
available, have no issues of immunogenicity or diseases transmission risks and be of low cost. 
Tissue insufficient supply and morbidity, and host immune responses and disease 
transmission risks limit condrocyte and osteoblast as ideal cells in OC strategies. Among adult 
stem cells, bone marrow mesenchymal stem cells (BMSCs)[15, 16, 19, 20, 22 ,48-51] and 
adipose-derived stem cells (ASCs)[9, 12, 26, 48, 50, 52] are the most investigated. 
Nevertheless, some studies described a higher chondro-[50] and osteogenic[48] potential of 
BMSCs when compared to ASCs. The effectiveness of autologous BMSCs transplantation for 
the repair of full-thickness articular cartilage defects was assessed in patellae lesions of two 
human patients[53]. A similar approach was also considered to repair full thickness femoral 
condyle defect in an athlete, who had reattained his previous activity level and experienced 
neither pain nor other complications[27]. 
Other cell sources, including synovial tissue and periosteum-derived stem cells have also 
showed potential for osteo- and chondro-genic differentiation[24, 54]. Cells from synovial 
membrane are harvested with minimal complications at the donor site due to a high self-
regenerative capability[24] of synovial tissue. The periosteum is a specialized fibrous tissue 
composed of fibroblast, osteoblast, and progenitor cells that may also be a possible cell source 
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for OC TE based on its accessibility, rapid proliferation and differentiation potential[54]. 
Furthermore, after skeletal surgery procedures, periosteum is often used as a covering layer 
over tissue to stimulate local regeneration. Despite the potential, periosteum-derived cells 
should be more investigated for cellular therapies[55]. 
Umbilical cord stem cells (UCSCs) together with amniotic fluid derived stem cells (AFSCs) 
were also introduced to cartilage and bone TE [8, 23, 25] presenting interesting characteristics, 
since they are easier to obtain and represent an almost unlimited stem cell sources. Some risks 
were associated to human AFSCs harvesting but, as pregnant women are older than ever 
before, amniocentesis is likely to become a routine procedure in future years. More recently, 
cells from human fetal membranes and placenta, with similar features to human UCMSCs and 
AFSCs, have also been successfully differentiated into osteogenic and chondrogenic 
lineages[56]. Although embryonic stem cells (ES)[57] hoped for a promising future in 
regenerative medicine, its use is still ethically controversial and has major ethical 
considerations associated. Notwithstanding that human ES cells express molecules which could 
cause immune rejection[57] and present a high genomic instability[57], ES cells transplantation 
in a collagen gel have shown to  induce the formation of cartilage tissue[17] under mechanical 
condition in rats aiming at OC regeneration. 
More recently, iPS technology, where iPS cells are generated by reprogramming of somatic 
cells through the exogenous expression of transcription factors, holds great promise for 
regenerative medicine in autologous cell replacement therapies and in genetic defects by 
restoring cellular function[58]. Nevertheless and due to iPS recent development, cell 
characterization and in vivo functionality are to be addressed in bone and cartilage fields.  
Stem cells obtained from different sources are likely to enable the most successful 
outcomes in OC regenerative approaches. Besides intrinsic characteristics of stem cells from a 
particular source, other factors should be monitored aiming at a successful strategy; such as 
final application, patient age, defect location and damage size. Cell culture media to induce 
chondrogenesis and osteogenesis of undifferentiated cells or maintain and proliferate primary 
chondrocytes and osteoblasts in an ex vivo atmosphere is commercially available. However, a 
common osteochondrocytic medium to co-culture or simultaneously differentiate bone and 
cartilage cells was not fully established yet, although some attempts have been described [8, 
15, 59]. This approach can be advantageous to simplify cell culturing procedures and, 
simultaneously, reduce the time and production costs of an engineered graft towards a clinical 
scenario.  
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I.2.4.2.  Biomaterials: human designs to mimic natural extracellular material 
 
The implantation of cells in the afflicted area could be a direct approach in OC strategies, 
but the request for a support material to promote regeneration, especially in large sized 
defects, is to be critically considered. This idea is inspired in nature itself as, in the body, the 
majority of cells subsist in a 3D world, anchored onto a network of extracellular matrix (ECM), 
which scaffolding design proposes to recreate.  
Scaffold characteristics will greatly influence cells and should mimic the complex and 
demanding environment to which cells are exposed to. Besides the tissue structural support 
and stimulation, either chemically or mechanically, the optimal scaffold should assist tissue 
functionality promoting the easy diffusion of nutrients, growth factors and cellular waste 
products[60]. Additionally, the ideal scaffold should be biocompatible and its biodegradability 
adjustable to the time required for tissue regeneration[60]. 
In the last few years, thousands of scaffolds have been proposed for reparative strategies 
made from different materials and production methodologies, with varying properties and 
composition. An OC scaffold should combine the better of the two worlds in a functional and 
integrated system. Lots of effort has been undertaken to achieve this goal and the most 
common approach is an independent cartilage or bone strategy, likely because chondrocytes 
and bone cells present different function-related characteristics including metabolic and 
structural features, yet communicating and interacting, in a unique culturing system.  
Natural based polymers such as agarose[15, 61], starch[9], chitosan[9, 13, 14, 62], silk[14], 
gellan gum[12], hyaluronic acid[16], collagen[17, 63] or blends of these materials[9, 14, 18, 
21], and synthetic materials such as polylactic acid (PLA)[8], polycaprolactone (PCL)[20] and 
oligo-polyethylene-glycol fumarate[49] have been proposed for cartilage applications. Most of 
these materials are processed into hydrogel and gel based matrices, which hold particular 
relevance for cartilage strategies because of their high water content, tissue-like elastic 
properties and the ability to encapsulate cells[64]. Also, gel structures partially tolerate shock 
absorption and deformation mimicking articular cartilage characteristics.  
However, cartilage repair in OC interfaces should be accompanied by an adequate 
restoration of the underlying subchondral bone, enhancing the in locus integration of the OC 
system. 
The minerals and the collagen fibers in the matrix are responsible for bone hardness and 
resistance. Nevertheless, the constant remodeling makes bone very plastic and capable of 
internal structural changes according to the stresses it is subjected to. Thus, bone regeneration 
Chapter I – Current strategies for osteochondral regeneration: from stem cells to pre-clinical approaches 
- 12 - 
 
requires scaffolds with high mechanical and osteoconductive properties, and structurally 
strong enough to sustain weight bearing loads and avoid cartilage calcification, which leads to 
tissue malfunction and death. Scaffolds should also be biodegradable to keep up with the 
natural bone remodeling process. Despite the brittle behaviour and low tensile strength, 
inappropriate for significant torsion areas such as long bones, hydroxyapatite (HA) and 
tricalcium phosphate (TCP) are the most studied ceramics due to their osteoconductive and 
high mechanical properties, and are already used in some clinical aplications[4,6]. Other 
materials, including silk[2, 7] , PCL and PCL blends[1, 3, 5], and PLA[8], have also been 
effectively tested as delivery systems[2] or artificial ECM[8], mimicking and recreating in some 
extend the structural organization of bone[1, 3, 7].   
Some OC approaches successfully evaluated the in vivo application of scaffolds made of 
collagen fibrils with HA nanoparticles without implanted cells[65], which can be of particular 
importance if one considers the practical and commercial standpoint, as the engineered 
product could be a ready-to-use graft for surgery procedures. Furthermore, this approach 
would avoid tissue morbidity and scarcity of autologous cell sources or even immune reactions 
from allogenic sources and problems related to cell culturing methodologies (e.g., animal 
origin supplements).  
Other strategies focus on the cellular interactions of implanted cells in the tissue 
surroundings, considering the reduced metabolism of cartilage. Chondrocytes in adult 
individuals do not divide or establish cell-to-cell contacts but are responsible to produce 
cartilage dense ECM[34], thus maintaining cartilage integrity. 
Especially in elder patients, implanted cells could meliorate the native ECM properties, and 
improve the functionality of damaged tissue by stimulating fresh ECM production. In bony 
defects, the integration of cells in the implant may stimulate bone marrow cells and establish a 
metabolic balance favoring the neobone formation. Furthermore, in critical sized defects, cells 
are likely to participate in a molecular communication level bridging the native tissues to the 
implant towards a successful OC regeneration. 
Different approaches to design an OC scaffold including hydrogels[49], combination of two 
distinct layers[21, 29, 62, 63] or a gradient scaffold[65], usually an association of a gel or a 
foam and a ceramic, have been developed as alternatives to this problem (Table I.2.1).  
These complex scaffolds favor the integration into the native tissue after implantation and 
guide the cells, into the desired phenotype, according to the prearranged environment created 
from scaffold physical and chemical properties.  
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Table I.2.1 - Overview of the scaffold-cells constructs that have been studied for osteochondral 
tissue applications in pre-clinical models in the past 5 years.  
Scaffolds Cells ref. 
OPF with gelatin microparticle hydrogel Cell-free / marrow mesenchymal stem cells [49] 
PCL/TCP-PCL scaffold Cell-free / marrow mesenchymal stromal cells [20] 
Hyaluronic acid gel sponges Autologous mesenchymal stromal cells [16] 
Hyaluronate-type I collagen-fibrin 
scaffold 
Cell-free /autologous chondrocytes [18] 
Hyaluronic acid-atelocollagen/ß-TCP 
bilayered scaffold 
Cell free / chondrocytes [21] 
Collagen/HA gradient scaffold Cell free / autologous chondrocytes  [65,66] 
Poly(lactide-co-glycolide)/nano-HA 
scaffold 
Cell free / marrow mesenchymal stem cells [51] 
Polylactic acid (PLA)- coated polyglycolic 
acid (PGA) scaffold 
Cell free / Autologous marrow mesenchymal 
stem cells 
[19] 
Collagen /-TCP bilayered scaffold Cell free [63] 
 
More recently, emerging approaches include the incorporation of bone and/or cartilage 
growth factors in scaffolds[49, 63] to stimulate native tissue formation and differentiation in 
vivo. The inclusion of growth factors can ultimately recruit host cells into the damaged site, 
initiating a healing pathway, which could be promising for the treatment of OCDs.  
 
I.2.4.3.  Assisted Devices: bioreactor systems   
 
The limited diffusion in static culture environments may constrain tissue ingrowth in 
engineered scaffolds. Bioreactors are usually designed to control the transport of nutrients 
and oxygen to cells in constructs promoting cellular expansion, and in some cases, enabling 
mechanical stimulation of cultured cells, thus enhancing cell differentiation and ECM 
formation.  
The challenge is, once again, finding a compromise considering the different intrinsic 
properties of cartilage and bone tissues. In a bioreactor system, dynamic compression should 
be applied for cartilage ECM stimulation while, for bone, medium perfusion is required to 
control mass transport and provide shear-stress to stimulate neobone formation. To overcome 
this issue, studies have focused on the development of double chamber bioreactors with 
physical separation; described to fulfil the needs of tissue-specific mechanical forces for OC 
stimulation[28, 29].  
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The next step, barely explored, would be the automation of bioreactors controlled by 
computer software. The customization of engineered grafts through the development of 
anatomically moulded surfaces[61] have showed potential results headed to translational OC 
interfaces. As follows bioreactors would be a reliable system of automation and 
standardization of cell and scaffold methodologies reducing the time and production costs of 
functional custom-designed grafts.  
 
I.2.5.  In vivo models for osteochondral tissue engineering  
 
Animal studies still represent an essential tool to understand the biologic behavior of 
healing and tissue regeneration in vivo, though differences in the anatomy and metabolism of 
animal models must be considered in an experimental setup with human correlations.  
Different animal models have been used in OC studies [16, 18-21, 49, 51, 63, 65]. Rats 
present distinctive characteristics, such as athymic nude or transgenic animals, not easily 
available in larger animal models. This model has been used to test the efficacy of a 
poly(lactide-co-glycolide)/nano-HA scaffold seeded with undifferentiated mesenchymal stem 
cells in OC defects[51]. After 12 weeks, defects treated with these constructs showed smooth 
and hyaline cartilage with abundant glycosaminoglycan and collagen type II deposition. 
Rabbit also demonstrated to be a successful model for OC [16, 20, 21, 49], especially in 
femoral regions with the successful application of hyaluronate-atelocollagen/beta-TCP-
hydroxyapatite scaffolds in the patellar grove[21], which promoted, in some extent, OC 
regeneration without the formation of fibrocartilage. 
Sheep is also a popular animal model due to their weight-bearing limbs and with metabolic 
and bone remodelling rates similar to that of humans as well as the sequence of events in 
bone graft incorporation and healing capacities. An OC interface was evaluated in sheep by the 
implantation of a composite scaffold of collagen and HA with or without autologous 
chondrocytes into a condyle critical defect[65]. Both conditions showed to support neobone 
formation and hyaline-like cartilage regeneration. With a similar implant, collagen/TCP, OC 
regeneration was evaluated in the trochlear groove of minipigs[63]. Although cells were 
absence in this strategy, the incorporation in situ of growth factors in the construct leads to 
fibrocartilage formation and partial reconstruction of the subchondral bone integrity in a short 
term follow up. 
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A pilot clinical trial with 13 patients using the collagen/HA cell free tri-layer scaffold[66] 
mentioned above, indicated promising results with tissue recovery in some extent after a six-
month follow up. 
 
 
I.3.  Conclusions 
 
The currently available treatments based on “damage to heal approaches”, have a limited 
success. With an increasing aging population, tissue engineering strategies provide important 
cues and hope for the treatment of OC degeneration. Ultimately, the tissue engineered 
implant should be able to stimulate and replace old tissue and native lethargic cells in order to 
accomplish both regeneration and restoring function for a successful clinical achievement. 
The challenge stands for the replication of the natural functional architecture and the 
translation of promising strategies towards patients needs. Success lies on the delicate balance 
of cartilage and bone characteristics combined in an engineered graft, and its integration in 
vivo. The implant must participate in the regenerative process, considering the specific 
properties of each OC interface, which can only be achieved through the design of scaffold 
materials accommodating the specific characteristics of bone and cartilage tissues, and 
providing stem cells with the necessary cues to satisfy both tissue cellular needs. The 
application of cells in critical defects or elder patient injuries is likely to be beneficial in 
stimulating native cells into the regenerative process. The use of bioreactors can improve the 
functionality of such constructs, accelerate the production, create custom-made systems, and 
reduce time costs for obtaining implants for OC applications. 
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Chapter II 
MATERIALS AND METHODS 
 
 
II.1. Abstract 
 
This chapter describes all experimental methods and techniques as well as biomaterials and 
cell protocols related to the scientific studies performed under the scope of this PhD Thesis. 
Despite the fact that methodologies to be addressed in this chapter are succinctly 
described in each of the following experimental chapters, herein are provided fully detailed 
procedures complemented with the rationale for the selection of the materials and cells.  
 
 
II.2. Materials   
 
II.2.1.  Polycaprolactone 
 
Polycaprolactone (PCL) can be synthetized by a ring opening polymerization of a cyclic 
lactone monomer such as ε-caprolactone (Figure II.2.1), resulting in a semicrystalline polymer 
with a melting point of 59-64 ºC and a glass-transition temperature of -60 ºC[1].  
 
Figure II.2.1 – Ring opening polymerization of ε-caprolactone to polycaprolactone. 
 
Synthetic polymers, such as PCL, are typically more versatile in tailoring a wide range of 
properties and structure features. Also, they represent a reliable source of raw materials, 
degraded by hydrolysis of its ester linkages in physiological conditions[2, 3], and avoid 
immunogenicity problems[4, 5]. Although not produced from renewable raw materials, PCL is 
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fully biodegradable, with a slow degradation rate[1]. PCL also forms compatible blends and 
copolymers with a wide range of polymers producing materials with unique elastomer 
properties[4]. For all of these reasons, PCL is used to produce Food and Drug Administration 
(FDA) approved medical devices, and widely studied for several tissue engineering (TE) 
approaches and for other biomedical applications[6-10] including long term implantable 
devices. 
The PCL used in this Thesis is commercially available as TONE™ polymer purchased from 
Union Chemicals and Plastics Divisions (Bound Brook, New Jersey, USA). 
 
II.2.2.  Starch-polycaprolactone blend 
 
Natural polymers have been presented as an interesting option to the currently used metal 
and synthetic materials, due to a higher biodegradability rate, non-cytotoxicity, and good 
mechanical properties. These polymers are synthesized involving enzyme-catalyzed, chain 
growth polymerization reactions of activated monomers, which are typically formed within 
cells by complex metabolic processes.  
Starch is a biopolymer produced by green plants as an energy store. It is quite abundant in 
nature, and an almost unlimited source and low cost associated raw material. Starch consists 
of multiple glucose units linked by glycosidic bonds, resulting in a combination of two 
polymeric carbohydrates (polysaccharides) amylose (A), a linear and helical structure, and the 
branched amylopectin (B) (Figure II.2.2). 
 
A B  
Figure II.2.2 – Chemical structure of starch components: amylose (A) and amylopectin (B). 
 
Scaffolds, based on blends of starch polymer with several different synthetic polymers, 
have been developed by our group using several methodologies[11-14], including by melt-
based[15-17] and wet-spun[17-19] routes. Some of these scaffolds have previously shown 
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great potential for TE strategies aiming at bone[11, 14-16, 18, 20, 21] and cartilage[22, 23] 
applications.  
Specifically, scaffolds based on blends of starch and polycaprolactone (SPCL) have been 
successfully used in a great number of studies showing to support the adhesion and 
proliferation of endothelial cells[21], chondrocytes[22] or osteoblasts, as well as the 
proliferation and differentiation of mesenchymal stem cells[16, 20, 23] obtained from different 
sources into osteoblasts[12] or chondrocytes[23]. Furthermore, in vivo studies not only 
indicate a good integration of the starch based materials in the host[17] but also that these 
biomaterials have a weak potential to stimulate an inflammatory reaction[24]. 
The 30:70 (wt %) SPCL blend used for the experimental studies described in the following 
chapters was obtained from Novamont (Novara, Italy). 
 
II.2.3.  Tri-calcium phosphates 
 
Ceramic materials have shown important scaffolding properties aiming at bone TE 
strategies[22, 25, 26]. These achievements are supported by fact that hydroxyapatite (HA) is 
the essential crystalline part of the calcified components of the skeleton, and is the principal 
mineral in bone, enamel, dentin, and cementum[26].  
Ceramic materials evidence a high modulus yet brittle behavior[27] and their processability 
is limited. However, these materials offer advantages over most polymers regarding their 
stimulating biological properties, such as osteoconductivity, and cell bioactivity[28]. Among 
ceramics, HA and tri-calcium phosphates (TCPs) are the most commonly used in biomedical 
research, being HA the preferred ceramic for bone strategies[9, 29, 30]. However, the 
osteoconductive and bioreabsorvable nature of beta-TCPs are associated to an earlier 
incorporation into surrounding bone in vivo may be advantageous to HA, which remains 
unremodelled despite long periods upon implantation[31]. 
 
II.2.4. Agarose 
 
Agarose is a natural based polysaccharide obtained from agar (Figure II.2.3) used for a 
variety of life science applications, including immune-isolation purposes.  
Agarose is heated to 90 ºC to form a polymeric solution by solving agarose powder with 
water or phosphate saline buffer. When the temperature is lowered to close to room 
temperature (fluctuations may take place considering the several commercially available 
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agarose products) gelation occurs. Notwithstanding the wide application of agarose, gels 
produced from agarose have been used as cell encapsulation systems for cartilage TE. Despite 
the slow degradation profile, the soft and flexible structure provided by these gels recreates a 
better 3D environment, suitable for chondrocyte maintenance[32] and mesenchymal stem cell 
differentiation into the chondrogenic lineage[32]. 
 
 
Figure II.2.3 – Structure of agarose molecule 
 
In this Thesis, agarose gels (2 %, Invitrogen) were used as encapsulating systems for hAFSCs, 
as described in chapter V, by dissolving a 2 % agarose solution in ultra-pure water and cooling 
it down in a flat plastic surface before cutting the hydrogel discs. 
 
 
II.3. Scaffold fabrication 
 
The design of a scaffold ultimately determines the functionality of the grown tissue. 
Scaffold design comprehends the combination of the selected materials and methods, 
considering a set of structure-properties specification for a target application. Several 
techniques were considered in the experimental chapters of this Thesis, namely fiber bonding 
of melt spun fibers, electro-spinning, and wet-spinning. The purpose of using these different 
methodologies was to try to develop a range of scaffold designs/properties and determine the 
ones that are likely to direct cell behavior in the most appropriate manner, considering the 
aimed application.  
Scaffolds produced by fiber bonding of melt spun fibers presented a microporous structure 
with high porosity and interconnectivity so that cells can colonize the entire scaffold while 
communicating with each other; these scaffolds were studied in chapter V, VI, VII, and VIII. 
Conversely, electrospun scaffolds, studied under chapter III, resulted in a nanofiber mesh, 
resembling the biological scale of extracellular matrix (ECM), where calcium phosphates were 
included to improve the osteogenic potential of the mesh. Wet-spinning is another interesting 
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methodology to develop scaffolds with high porosity and interconnectivity allowing to, 
simultaneously, introduce chemical modifications, such as functionalizing scaffold surface for 
stimulating the communication between scaffold and cells. Scaffolds obtained by wet spinning 
were studied in chapter IV. 
 
II.3.1.  Melt fiber extrusion - Fiber bonding 
 
SPCL (a blend of starch with polycaprolactone, 30/70 % wt) fiber mesh scaffolds were 
produced by a fiber bonding process consisting of cutting and sintering the fibers, which were 
previously obtained by an extrusion/melt spinning process. Briefly, a selected amount of fibers 
was placed in a glass mould and heated in an oven at 150 ºC. Immediately after removing the 
moulds from the oven, the fibers are slightly compressed by a Teflon cylinder (which runs 
within the mould) and then cooled at –20 ºC. Then, samples were cut into cylinder discs, 
according to the experimental needs following sterilization by ethylene oxide. Scaffolds 
previously produced by this method showed interesting results for bone and cartilage TE 
applications[16, 20, 21, 23], and their mechanical and degradation profiles have also been 
described elsewhere[15]. 
 
II.3.2.  Electrospinning  
 
The use of nanotechnology to tailor orthopaedic scaffolds arises from the need to mimic 
the ECM structure and complexity at a biological scale, since bone matrix is mainly composed 
of an intricate nanofiber structure of nonstoichometric HA integrated in collagen fibers. 
Electrospinning is an interesting approach for biomaterial processing enabling to control 
morphology, porosity and composition of the polymer with nanoscale properties[8, 33]. 
Composite scaffolds were developed in chapter III, combining electrospinning with β-TCP 
powder as indicated in the following section. PCL fiber meshes were produced using a 
polymeric solution of 17 % (wt/v) of PCL in a mixture of chloroform (Aldrich) and N,N-
Dimethylformamide (Aldrich) at a 7:3 ratio. This solution was electrospun at 9-10 kV, with a 
flow rate of 1.0 mL/h collecting a random fiber mesh (20 cm away from the collector) on a flat 
aluminum foil. 
The electrospinning experiments were conducted at room temperature, as well as the 
drying of the electrospun nanofiber meshes. PCL single layered membranes were used as 
negative controls of the multi-layered PCL-β-TCP study. 
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II.3.3. Tricalcium Phosphates production by solid state reaction 
 
β-TCP can be produced through a solid state reaction[34], an interesting synthesis route 
given its simplicity and yield. In our studies, the ceramic material, -TCP, was obtained from a 
solid state reaction between stoichiometric amounts of calcium phosphate dibasic anhydrous 
(Fluka) and calcium carbonate (Sigma) followed by a 24 h sinterization at 800 ºC. The powders 
were hand-sieved with stainless steel sieves (mesh 225-106 μm). 
After obtaining β-TCP powder, a polymeric solution of 17 % (wt/v) PCL was electrospun to 
produce the polymeric nanofiber mesh layer and the TCPs were subsequently spattered over. 
Composite scaffolds were developed by assembling a total of three stacked layers of 
electrospun PCL-β-TCPs at a ratio of 0.5 g β-TCP/130 cm2 PCL meshes.  
 
II.3.4. Wet-spinning 
 
Wet-spinning technology requires polymer dissolution prior to scaffold formation and, 
consequently, depends on polymer solubility and on solvent volatility. The development of 
SPCL wet spun scaffolds was described previously[18]. Briefly, to obtain a polymer solution 
with proper viscosity, SPCL was dissolved in chloroform (Sigma-Aldrich) at a concentration of 
30 % (wt/v) followed by injection (internal diameter of 0.8 mm) to induce the formation of 
fiber structures by precipitation in a methanol (Sigma-Aldrich) coagulation bath. A 
programmable syringe pump (KD Scientific, World Precision Instruments) with a controlled 
pumping rate of 2.5 ml/hour was used to run fibres formation. The fiber mesh structure was 
formed by random movements of the syringe in the coagulation bath. 
Scaffolds were air-dried at room temperature overnight to remove remaining solvent 
residues. 
 
II.3.4.1. Designing of an in situ functionalized surface 
 
Silicon ion plays a significant role in bone and cartilage development of higher 
organisms[35]. Furthermore, the release of silicon and calcium was reported to up-regulate 
and activate genes in osteoprogenitor cells[36]. Thus, in chapter IV, we propose to evaluate 
the relevance of the incorporation of silanol groups (Si-OH) in wet spun fiber mesh scaffolds of 
SPCL. 
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SPCL scaffolds with functionalized Si-OH groups were produced in a similar way to SPCL 
scaffolds described in the previous section. The main difference is the coagulation bath; 
instead of methanol, a calcium silicate solution was used with a molar ratio of 
Si(OC2H5)4:H2O:C2H5OH:HCl:CaCl2, of 1.0 : 4.0 : 4.0 : 0.014 : 0.20 [18, 37] to assure the 
osteoconductivity of the polymeric scaffolds. Afterwards, fiber meshes were air-dried at 60 ºC 
for 24 h, and designated as SPCL-Si.  
 
 
II.4. Scaffold characterization 
 
Scaffold characterization is part of the process of designing a strategy for biomedical 
applications. Physic-chemical properties provide important information about the biomaterial 
and the manufacture of a 3D matrix while predicting some biological outcomes.  
In the following sections, technical information is provided concerning analytic procedures 
selected for scaffold evaluation, either chemical or physical techniques, under the scope of this 
Thesis.  
 
II.4.1.  In vitro bioactivity of SPCL-Si wet-spun fiber mesh scaffolds 
 
The concept of bioactivity is defined as one of the characteristics of an implant material 
which allows it to form a bond with living tissues[38, 39]. The assessment of apatite formation 
on the surface of a material in simulated body fluid (SBF) is useful for predicting the in vivo 
bioactivity of the material not only qualitatively but also quantitatively. SBF solution presents 
ion concentration of Na+ 142.0, K+ 5.0, Ca2+ 2.5, Mg2+ 1.5, Cl- 147.8, HCO3
- 4.2, HPO4
2- 1.0, SO4
2- 
0.5 mM, similar to blood plasma’s.  
Bioactivity of SPCL-Si wet-spun fiber meshes was determined by soaking the scaffolds in 10 
mL of SBF at 36.5 ºC for up to 7 days. The SBF solution was prepared by dissolving reagent-
grade chemicals of NaCl, NaHCO3, KCl, K2PO4
.3H2O, MgCl2
.6H2O, CaCl2 and NaSO4 into distilled 
water, at pH 7.40 buffered with tris-hydroxymethyl-aminomethane ((CH2OH)3CNH3) and 1 M 
hydrochloric acid at 36.5 ºC. After soaking, the substrates were removed from SBF, rinsed in 
distilled water and air-dried.  
The bioactivity assay was conducted in order to assess in vitro the bioactive potential of 
wet-spun fiber meshes functionalized with silanol groups for bone TE applications. 
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II.4.2. Scanning electron microscopy  
 
The scanning electron microscopy (SEM) was used as complementary method to evaluate 
the morphology of the scaffolds, including pore shape, size and distribution as well as the 
interconnectivity between these pores. The morphology of multilayered scaffolds of PCL-TCP 
from chapter III was evaluated by SEM to determine the distribution and integration of TCP 
granules in the PCL fiber meshes. Additionally, in chapter IV, film morphology as well as the 
presence of different elements was analyzed before and after immersing the scaffolds in 
simulated body fluid. 
Prior to SEM analysis, the scaffolds were sputter coated with gold (Fisons Instruments, 
model SC502, England) for 2 minutes at 15 mA. Samples were assessed in a SEM (Leica 
Cambridge, model S360) equipment and micrographs recorded at 15 kV ranging from 100 to 
1000x magnification. 
 
II.4.3.  Dynamic Mechanical Analysis  
 
Cells and tissues exhibit a viscoelastic behavior[40], which an implantable scaffold or 
construct should match at physiological conditions[41] in order to participate in biophysical 
and biological responses.  
Dynamic mechanical analysis (DMA) measures the vistoelastic properties of materials as a 
response to stress, temperature and frequency, and determines their time-dependent 
mechanical performance. 
Dynamic mechanical analysis of SPCL-Si scaffolds from chapter IV was performed using a 
TRITEC8000B DMA from Triton Technology, equipped with a tensile mode. Before the analysis, 
scaffolds were immersed in PBS until equilibrium was reached. After equilibration at 37 ºC, 
DMA spectra were obtained with a frequency scan between 0.1 and 25 Hz. The experiments 
were performed under constant strain amplitude (30 µm) and a static pre-load of 0.7 N was 
applied to keep the sample tight. During DMA analysis, scaffolds were immersed in a liquid 
bath in a Teflon® reservoir. Triplicates were used for each condition. 
 
II.4.4. Micro-computed tomography  
 
Micro-computed tomography (m-CT, µ-CT or micro-CT) has been successfully used in 
different branches of science for the study of porous or cavity-containing structures. Micro-CT 
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is a non-destructive model that uses x-rays to create multiple micrometer cross-sections of a 
3D sample that later can be used to recreate a virtual 3D model. This technique is extremely 
useful for scaffold characterization in view of the fact that besides the morphological aspect of 
the scaffold, other properties such as porosity, pore interconnectivity or thickness can be 
quantitatively determined. 
Micro-CT is also an interesting tool for those studies where a calcified layer is an expected 
result, either produced by the cells or as a precipitation coating as for bioactivity assays.  
Calcified areas are easily detected in polymeric matrices by micro-CT due to the significant 
differences found in the density of polymer scaffolds and calcium phosphates present in the 
matrix[18]. Additionally, in small dimensioned scaffolds the distribution of the ECM over the 
scaffold can be observed and measured with appropriate software. 
Micro-CT, using a Skyscan 1072 scanner (Skyscan, Kontich, Belgium), was performed to 
characterize SPCL-Si scaffolds after the bioactivity studies from chapter IV so as to observe the 
distribution of the apatite layer on the scaffolds after simulated body fluid immersion. X-ray 
scans were performed in triplicate using a resolution of 5.86 µm and integration time of 1.9 
sec. The X-ray source was set at 40 keV / 248 μA. Approximately 400 projections were acquired 
over a rotation range of 180 º with a rotation step of 0.45 º. Data sets were reconstructed 
using standardized cone-beam reconstruction software (NRecon v1.4.3, SkyScan). Data sets of 
200 slices were segmented into binary images with a dynamic threshold of 50 to 255 (grey 
values) to identify the organic and inorganic phase. This data was used for morphometric 
analysis (CTAnalyser, v 1.5.1.5, SkyScan) and to build 3D models (ANT 3D creator, v2.4, 
SkyScan).  
 
II.4.5.  Thin-film X-ray diffraction  
 
X-Ray Diffraction Analysis (XRD) is a versatile, non destructive tool for investigating the 
crystallographic structure and sub-nanometric morphology of natural and synthetic materials. 
Thin-film X-ray diffraction (TF-XRD, Philips X'Pert MPD, The Netherlands) was used to 
identify any crystalline phase present on the scaffolds from chapter III and IV. 
 In the case of PCL-TCP nanofiber meshes, XRD provides information about the type of 
calcium phosphate obtained by solid state reaction, whose granules were integrated in the 
multilayered structure. Results were compared to membranes of PCL, the negative control of 
this experiment. 
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In chapter IV, XRD was performed to characterize the crystalline/amorphous nature of the 
apatite films formed on the polymeric wet-spun fiber mesh after soaking in the calcium silicate 
solution or after immersion in simulated body fluid (results were compared to non immersed 
controls).  
The data collection was performed by 2 scan method with 1 º as incident beam angle 
using CuK X-ray line and a scan speed of 0.05 º/min in 2. 
 
II.4.6. Fourier transform infrared spectroscopy with attenuated total reflectance  
 
Fourier transform infrared spectroscopy with attenuated total reflectance (FTIR-ATR) is a 
non-destructive, fast and highly sensitive tool for material analysis, providing an infrared 
spectrum of absorption, emission, photoconductivity or Raman of a solid, liquid or gas. Data 
obtained from the infrared spectrum represents the molecular absorption and transmission of 
a specimen, creating a unique molecular fingerprint of the sample, thus permitting its 
identification, quality and the amount of components in a mixture.  
FTIR–ATR was performed using an IRPrestige-21 (Shimadzu, Japan) with an attenuated total 
reflectance in PCL-TCP fiber mesh samples from chapter III, to determine if calcium phosphate 
granules were integrated in the PCL-TCP fiber mesh.  
All spectra were recorded using at least 64 scans and 2 cm−1 resolution, in the spectral 
range 4000–600 cm−1. 
 
II.4.7. Inductively coupled plasma optical emission spectrometer  
 
Inductively coupled plasma optical emission spectrometer (ICP-OES) uses the inductively 
coupled plasma to produce excited atoms and ions that emit electromagnetic radiation at 
wavelengths characteristic of a particular element. The intensity of this emission is indicative 
of the concentration of the element within the sample. 
Elemental concentrations of calcium, phosphorus and silicium were measured by 
inductively coupled plasma atomic emission spectrometry (JY2000-2, Jobin Yvon, Horiba, 
Japan). Samples were firstly collected and 0.22 µm filtered and kept at -80 ºC until usage. This 
technique was used to analyse the simulated body fluid solution before and after immersing 
the wet-spun fiber meshes with or without the silanol groups (bioactivity tests), in chapter IV. 
Triplicate samples were considered for ICP analysis. 
 
Chapter II – Materials and Methods 
- 35 - 
 
II.5. Scaffold sterilization prior to cell culturing studies 
 
Prior to cell culture experiments, samples were cut into discs, whose dimensions were 
defined accordingly to the experiments to be performed, and ethylene oxide sterilized at 
Pronefro (Maia, Portugal) or at the WFIRM (Winston-Salem, North Carolina, USA). Typical 
conditions included a cycle temperature of 37 ºC, a moisture level of 50 %, a cycle time of 14 
hours, and a chamber pressure of 50 kPa. 
The multi-layered PCL-β-TCP scaffolds (developed on chapter III) were cut into 5 mm discs 
followed by two 30 minute-cycle of UV radiation, instead of ethylene oxide sterilization. 
 
 
II.6. Biological assays 
 
II.6.1.  Harvesting, isolation and culture of stem cells  
 
The interest in the potential of adult stem cells has been increasing due to the limited 
availability of tissue specific progenitor cells. 
Bone marrow represents a source of mesenchymal adult stem cells[42-44] due to the 
availability of established culture techniques to isolate and expand cell populations from 
human donors. Additionally, expansion of bone marrow stem cells overcomes the tissue 
morbidity and donor tissue scarcity, minimizing the problems associated with other types of 
primary cells. In autologous strategies, the implantation of cells from the individual also 
reduces disease transmission risks. 
Conversely, amniotic fluid is arising as an interesting source of stem cells. Amniotic fluid 
cells (AFSCs) are used for prenatal diagnosis of fetal abnormalities caused by genetic 
mutations. Along with the almost endless ability to expand without telomere shortening, 
AFSCs share with embryonic stem cells some markers and a high self renewal capacity without 
associated ethical concerns[45].  
 
II.6.1.1. Harvesting and isolation of goat bone marrow stromal cells 
 
Goat bone marrow stromal cells (gBMSCs) were used in the studies described in chapter III, 
IV, and VII. This animal model was selected for these studies, firstly due to their analogy to 
human bone marrow stem cells (hBMSCs), and also because goats are a high level vertebrate 
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with metabolic and bone remodelling rates similar to that of humans. The sequence of events 
in bone graft incorporation and healing capacities[46] are also comparable to humans, which 
explain how goats became increasingly popular as an animal model in the orthopaedic field. 
Goats have been widely used in studies of biocompatibility, and bone formation and 
regeneration[47-49]. Furthermore, the use of gBMSCs allows performing autologous 
experiments, as goat bone marrow aspirates can be obtained by a biopsy procedure, and the 
isolated cells can be cultured using serum from the same animal where ultimately, the same 
cells or cell-scaffold constructs will be implanted.  
The methodology optimized for harvesting goat bone marrow (BM) was based on the 
techniques used to perform human BM biopsies from the iliac bone. Thus, through 
percutaneous puncture, bone marrow was aspirated from the iliac wings of goats using a 
biopsy needle, without erythrocyte contamination (Figure II.6.1).  
 
 
Figure II.6.1 - Harvesting marrow from the goat iliac crest. 
 
The experimental protocol for BM aspirate was performed according to the national 
guidelines and after approval of the National Ethical Committee for Laboratory Animals from 
Direcção Geral da Agricultura. Prior to general anesthesia, goat iliac regions were shaved and 
disinfected. Animals were submitted to a pre-anesthetic medication with acepromazine 
maleate (5 mg EV, Calmivet, Vetóquinol) and placed under general anesthesia by induction 
with thiopenthal sodium (20-25 mg/Kg EV, Pentothal sodium, Abbott Labs), maintained by 
inhalation of a mixture of 1.5 % isoflurane (IsoFlo, Abbott Labs, USA) and oxygen for a 
maximum of 30 minutes. 
A bone marrow aspiration needle (Inter.V, Medical Device Technologies, Inc., Denmark) and 
a 10 mL syringe, already containing 1 mL heparin (5.000 U.I., Heparin sodium, B. Braun 
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Medical, Inc.) to avoid marrow coagulation, was used to collect 10 mL of bone marrow from 
the iliac crest of adult goats (Figure II.6.1), transferred into a sterile tube and resuspended in 
30 mL of RPMI-1640 culture medium (Sigma-Aldrich), containing 1 % penicillin/streptomycin 
(Gibco) plus 1 mL of heparin (5.000 U.I.).  
Afterwards, goat marrow stromal cells (gBMSCs) were centrifuged for 10 minutes at 1200 
rpm and a dense cellular pellet was collected and cultured in a basic culture medium – DMEM 
(Dulbecco’s Modified Eagle’s Medium) (Sigma-Aldrich) supplemented with 10 % FBS (Gibco) 
and 1 % A/B (Invitrogen). Four days after the harvesting procedure, cells were rinsed in sterile 
PBS (Sigma) and medium was exchanged. Following gBMSCs expansion up to 90 % of 
confluence, cells were cryopreserved at 1 passage (Pa) in a solution of FBS with 10 % DMSO 
until needed for experimental purposes.  
The advantage of this methodology is based on the acquisition of a higher quality of bone 
marrow samples with a simple technique that, after optimization, can be systematically used in 
subsequent experiments. The achieved optimization of this technique constitutes the first 
report in the scientific literature of harvesting bone marrow aspirate from percutaneous 
puncture in the goat model.  
 
II.6.1.2.  Harvesting and isolation of human amniotic fluid stem cells 
 
Human amniotic stem cells (hAFSCs) were used in the studies described in chapters V, VI, 
and VIII. AFSCs were obtained from human amniotic fluid specimens collected from 
amniocentesis procedures, using backup cells that would otherwise be discarded. AFSCs were 
immunoselected with magnetic microspheres isolating the c-Kit–positive population[45], as C-
kit or CD 117 has been described to be the receptor for stem cell factor. The protocol has been 
described in detail elsewhere[45]. AFS cells were grown in α-MEM medium (Gibco, Invitrogen) 
containing 15 % embryonic stem cell screened FBS (ES-FBS, HyClone, USA), 1 % glutamine and 
1 % penicillin/streptomycin (Gibco), supplemented with 18 % Chang B (Irvine Scientific), and 2 
% Chang C (Irvine Scientific) at 37 ºC with 5 % CO2 atmosphere.  
 
II.6.2.  Cell culturing and expansion 
 
Samples obtained from body tissues such as bone marrow or amniotic fluid usually have a 
cell number that is not sufficient for TE applications. Thus, stem cells should be isolated, 
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selected, and expanded towards the achievement of cell numbers enough to perform in vitro 
studies, and eventually a cell number relevant for clinical applications. 
 
II.6.2.1.  Goat bone marrow stromal cells  
 
Cryopreserved cells to be used in experimental studies were thawed by placing the frozen 
cell vial in a 37 ºC water bath. When the vial was almost defrosted, gBMSCs were removed 
from the bath and pipetted into cell culture flasks, and let to attach for 24 hours prior medium 
exchange. In general, cells were expanded up to 90 % confluence and sub-cultured to 2 Pa 
(Figure II.6.2) in basic medium (DMEM, 10 % FBS and 1 % A/B) before seeding/encapsulation 
procedures. 
 
Figure II.6.2 - 2D culture of gBMSCs after 10 days in basal medium. 
 
In autologous approaches (chapter VII), gBMSCs were expanded in 10 % autologous serum 
instead of FBS. Autologous serum was isolated from goat peripheral blood every 3 weeks and 
centrifuged at 3,000 rpm for 10 minutes. Serum was stored at -20 ºC until usage.  
 
II.6.2.2.   Human amniotic fluid stem cells  
 
Human AFSCs were isolated as previously described[45] and cultured in basic amniotic fluid 
cell (BAFC) medium composed of α-MEM (HyClone) with 18 % Chang B (Irvine Scientific) and 1 
% Chang C (Irvine Scientific) media as well as 2 % L-glutamine (HyClone) and 15 % ES-FBS. 
 
II.6.2.3.   Human mesenchymal stem cells from bone marrow  
  
Human mesenchymal stem cells from bone marrow (hBMSCs) were purchased from Lonza® 
and expanded as indicated in manufacturer datasheet. Basal culture medium was composed of 
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α-MEM (HyClone) supplemented with 10 % ES-FBS (HyClone) and 1 % penicillin/streptavidin 
solution. 
 
II.6.3.  Osteogenic differentiation  
 
The osteogenic differentiation of mesenchymal stem cells is dependent on mechanical and 
biochemical stimuli from their micro-environment. Dexamethasone, ascorbic acid and ß-
glycerol phosphate are known to induce osteogenic differentiation, and thus commonly used 
as osteogenic supplements provided in cell culture medium. Dexamethasone is a synthetic 
glucocorticoid shown to induce osteogenic differentiation of osteoprogenitors cells from fetal 
calvaria-derived cells[50] and adult bone marrow stromal-derived cells[51, 52]. In human body, 
ascorbic acid is an essential nutrient required for collagen synthesis, thus playing an essential 
role in the structure and function of skeletal tissues. When ß-glycerol phosphate, a potential 
source of phosphate ions[52], is also present, a zone of hydroxyapatite-containing mineral is 
formed within collagen fibrils[53].  
Thus, in order to induce the osteogenic phenotype, gBMSCs were cultured in minimal 
essential medium Eagle’s α-modification (α-MEM; Sigma-Aldrich), A/B (1 %), FBS (10%) and 
supplemented with osteogenic factors, namely dexamethasone (10−8 M; Sigma-Aldrich), 
ascorbic acid (50 μg/ml; Sigma) and β-glycerophosphate (10 mM; Sigma) for up to 3 weeks. 
Minor variations in medium composition are indicated in experimental studies performed 
at WFIRM, USA (chapter V, VI and VIII). In this case, osteogenic medium prepared for hBMSCs 
and hAFSCs was composed of DMEM (HyClone) supplemented with 10 % FBS (HyClone), L-
ascorbic acid (50 µM; Sigma), dexamethasone (100 nM; Sigma), and glycerol 2-phosphate 
disodium salt hydrate (10 mM; Sigma). 
 
II.6.4. Osteochondral differentiation  
 
The composition of the co-culture media used to maintain the osteogenic and 
chondrogenic phenotype of differentiated AFSCs (as described in chapter V) was prepared 
considering the inclusion of both osteo- and chondrogenic factors usually used in osteo- or 
chondrogenic culture media.  
Several media from the literature were analyzed, and the most frequent supplements 
combined to obtain a co-culture medium composed of DMEM-LG (HyClone), 2 % FBS 
(HyClone), sodium pyruvate (1x, Sigma), ITS (1x, Sigma), 5 mM glycerol 2-phosphate (Sigma), 
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50 µg/ml ascorbic acid (Sigma), 10 mM dexamethasone (Sigma), 40 g/ml L-proline (Sigma), 
either in the presence or absence of 100 ng/ml IGF-1 (Invitrogen).   
Since TGF- was removed from the media, another factor was added and its presence 
tested in the medium: IGF-1. IGF-1 or insulin growth factor-1 has been described to participate 
in both bone and cartilage development, which could maintain the induced phenotype of 
AFSCs. After 7 or 14 days in the co-culture media, constructs were removed and characterized 
for osteo- and chondrogenic specific markers. BAFC medium[45] was used as control of this 
experiment. 
 
II.6.5.  Seeding on 2D cultures 
 
In order to compare the potential of hBMSCs and hAFSCs for bone tissue engineering 
applications (chapter VI), both cells were seeded onto culture treated 6-well plates (Costar) at 
passage 5 and passage 24, respectively, at a concentration of 30,000 cells/well. Both type of 
cells were cultured for 3 days with basal medium, and then, exchanged to osteogenic medium, 
composed of DMEM (HyClone Laboratories Inc.) supplemented with 10 % FBS (HyClone), 100 
nM dexamethasone (Sigma), 50 µM L-ascorbic acid (Sigma) and 10 mM glycerol 2-phosphate 
disodium salt hydrate (Sigma), for up to 3 weeks (0, 7, 14 or 21 days). Before the osteogenic 
characterization, cells were briefly rinsed in PBS (HyClone Laboratories Inc.), and fixed in 10% 
neutral buffered formalin (Surgipath Medical Ind.). 
 
II.6.6. Seeding cells onto 3D matrices  
 
II.6.6.1. gBMSCs, hAFSCs or hBMSCs onto SPCL scaffolds 
 
In chapter VII, a gBMSCs suspension of 2,500,000 cells/mL was prepared and seeded onto 
the SPCL porous scaffolds in a drop-wise manner, at a cellular density of 500,000 cells per SPCL 
scaffold (6 mm diameter x 2 mm height discs). Seeding chambers were used to improve cell 
seeding efficiency by avoiding cellular dispersion. Afterwards, constructs were cultured in non-
treated 12-well plates (Costar, Becton Dickinson), to reduce cellular adhesion to the plates. 
Osteogenic medium described in previous sections was selected for 1 or 7 days of cell culturing 
prior to implantation. In chapter VII, autologous sera (10 %) were used. Autologous culture 
medium was changed twice a week. 
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In a similar way to gBMSCs, hBMSCs (only in chapter VI) and hAFSCs were seeded onto 
SPCL scaffolds (5 mm x 4 mm, 7 mm x 4 mm, and 6 mm x 3.8 mm cylinders in chapter V, VI and 
VIII, respectively) at a concentration of 8.6 x105, 1.2 x106, and 1.2 x106 cells/scaffold, 
respectively, and cultured in basal medium for 3 days before adding osteogenic media for up 
to 3 weeks.  
In chapter VI, hBMSCs and hAFSCs were seeded on culture treated 6-well plates (Costar) at 
a concentration of 30,000 cells per well in order to compare their behaviour with cells cultured 
in 3D SPCL scaffolds. Cells seeded on the 6-well plates were cultured for 3 days in basal 
medium, and then, exchanged to osteogenic medium, for up to 3 weeks (0, 7, 14 or 21 days). 
 
II.6.6.2. gBMSCs onto SPCL-Si scaffolds 
 
In chapter IV, gBMSCs were seeded onto SPCL-Si scaffolds (5 mm diameter discs) before 
and 7 days after scaffold immersion in a SBF solution, at a concentration of 100,000 cells per 
scaffold. After the seeding, constructs were cultured in osteogenic medium for 7 or 14 days. 
 
II.6.6.3.  Encapsulating hAFSCs into agarose gels 
 
In chapter V, a 2 % agarose solution was used as encapsulating gel. Firstly, the agarose 
solution was prepared and kept at 37 ºC while hAFSCs were tripsinized and counted. Then, 
hAFSCs were resuspended at a concentration of 2 x106 cells/mL of agarose. Cell-agarose 
system was left to gelify for a couple of minutes at room temperature inside a biological hood. 
Afterwards, 4 mm diameter discs were cut off from the cell encapsulated gel and placed in non 
treated 24 multi-well plates (Costar) with basal medium.  
After 2 days, chondrogenic medium was prepared with DMEM (HyClone) supplemented 
with antibiotic/antimicotic solution, 50 µg/ml ascorbic acid (Sigma), 1 mM dexamethasone 
(Sigma), 40 g/ml L-proline (Sigma), 100 g/ml sodium pyruvate (Sigma), 1 % ITS (100x, Sigma) 
and 10 ng/ml TGF-ß1 (Sigma), and added to the encapsulated system. Medium was exchanged 
once a week for up to 4 weeks in chondrogenic culture. 
 
II.6.7.  Characterization of cell-scaffold constructs  
 
Cell seeded matrices were characterized in terms of cellular viability and proliferation as 
well as of osteo- or chondro-genic differentiation markers to assess cellular phenotypes, after 
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several pre-determined periods of culture. Cell viability was assessed by MTS or Calcein AM 
methodologies while proliferation was determined by a double strand DNA quantification kit.  
Osteogenic differentiation was evaluated based on the activity of alkaline phosphatase 
(ALP) and the expression of RunX-2, a transcription factor involved in bone development. 
Furthermore, morphological features and the production of a mineralized matrix in bone 
strategies were also considered by SEM and EDS analysis, Alizarin Red staining as well as the 
expression of collagen I, the major organic component of bone ECM, and osteocalcin, and 
FTIR-ATR to assess chemical groups that may be present in the bony calcified matrix.  
Chondrogenic differentiation was assessed through histological stains as Safranin O as well 
as immunochemistry for collagen II, and aggrecan, major molecules present on the cartilage 
ECM. 
Techniques selected for cell-scaffold characterization are described in detail within the 
following sections of this chapter. 
 
II.6.7.1.  Cell viability methods – MTS and Calcein AM 
 
The MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay is a colorimetric method for determining the number of viable cells in 
proliferation or cytotoxicity assays, and was used in chapter IV. The MTS compound is 
bioreduced by cells, when reductase enzymes are active, into a colored formazan product that 
is soluble in culture medium. The quantity of formazan product measured at 490 nm 
absorbance, is directly proportional to the number of living viable cells in culture. 
 Calcein AM (Calcein acetoxymethyl ester) (Figure II.6.3) is a cell-permeant and non-
fluorescent compound widely used for determining cell viability. In live cells the non-
fluorescent calcein, AM is hydrolyzed by intracellular esterases into the strongly green 
fluorescent anion calcein. The fluorescent calcein is well-retained in the cytoplasm in live cells, 
and the fluorescence intensity is proportional to the amount of live cells. Calcein is a 
photostable reagent not influenced by intracellular pH. Its bright green fluorescence can be 
monitored at Ex/Em = 494 nm /520 nm.  
This method was used in chapters V, VI, and VIII. After cell culturing according to 
predefined end points, hAFSC- and hBMSC-SPCL constructs were rinsed in PBS (HyClone) and 
incubated in culture medium with 3 µM Calcein AM (Molecular Probes, Invitrogen) for 30 
minutes at 37 ºC in a  5 % CO2 environment. Afterwards, constructs were rinsed again in PBS 
and fixed in 10 % buffered formalin (Surgipath Medical Industries, Inc.) overnight at 4 ºC, 
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before observed under a confocal microscope. DAPI (Molecular Probes, Invitrogen), a 
fluorescent marker that binds to nucleic acids, DNA and RNA, and can enter live or dead cells, 
was used in chapter VI. 
 
 
Figure II.6.3 – Calcein AM cleavage by viable cells. 
 
The main difference in these methods is that MTS is a quantitative method, while Calcein 
AM is qualitative. Small absorbance variations can be detected among samples with MTS 
assay. Although counting cells with Calcein AM method is possible, it is very time consuming, 
and with an intense fluorescence signal, counting individual cells can be a difficult task to 
perform. Nevertheless, Calcein AM procedure presents additional advantages as it enables, for 
instance observing the distribution and colonization of viable cells population on a scaffold or 
plate. 
 
II.6.7.2. Cellular proliferation assay (DNA quantification) 
 
The cell proliferation assay described in this Thesis (chapter III, IV and VII) is an ultra-
sensitive fluorescent nucleic acid stain for quantitating double-stranded DNA (dsDNA) by 
measuring the fluorescence produced when PicoGreen dye (Molecular Probes, P-7589) is 
excited by UV light and bounds to double-stranded DNA (dsDNA) present in the tested sample.  
In this assay, the constructs were harvested from the culture medium, rinsed in PBS, 
followed by cell lysis in ultra pure water. Samples were kept at -80 ºC until testing. Afterwards, 
samples were thawed and briefly sonicated for 15 minutes to rupture any remaining cell 
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membrane. Cell lysate is incubated with a dye that fluoresces when bounds to DNA. The 
intensity of the fluorescence from the DNA–dye complex is then measured with a standard 
fluorometer. The number of cells in the sample is determined by comparing the fluorescence 
intensity of the sample to a previously generated standard curve (concentrations ranging from 
0.0 to 1.5 µg/mL). The standard curve relates the number of cells in a sample to the intensity 
of the fluorescence from the DNA–dye complex. The fluorescence is read using a microplate 
ELISA reader (Synergie HT, BioTek) at an excitation of 485/20 nm and an emission of 528/20 
nm. 
 
II.6.7.3. Histology 
 
Histological analysis was performed in in vitro cultured AFSC-agarose systems from chapter 
V to assess the chondrogenic differentiation through staining and immunostaining procedures. 
Samples for histological analysis were firstly rinsed in PBS and fixed in a 4 % buffered 
formalin solution overnight. Afterwards, samples were included in histological cassettes and 
dehydrated in a series of ethanol concentration followed by xylene solution to remove water 
from tissues in tissue processor equipment (Microm STP120, MICROM International GmbH, 
Germany). AFSC-agarose constructs were wrapped in foam before placed inside the cassettes. 
The foam encloses delicate and very small samples that could be lost or damaged during the 
procedure. 
Samples were then embedded in paraffin wax (Microm EC 350-2, ThermoScientific, Spain), 
and included in blocks, and stored at room temperature. Blocks were then cut into 10 m thick 
sections using a microtome, and then depparaffined. Since most stains and antibodies are 
aqueous solutions, deparaffinization (removing paraffin wax and re-hydration of samples) is a 
common step prior staining or immune-detection described below. After the histological 
protocol is completed, sections must be mounted before observed under a microscope. 
 
II.6.7.4. Osteogenic markers 
 
II.6.7.4.1.  Alkaline Phosphatase Activity (ALP) 
 
Alkaline Phosphatases (ALP) are a group of enzymes found in several organs but the 
isoenzyme ALP-2 is primarily found in the bone, with a particular influence in bone 
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metabolism.  As the name implies, this enzyme works best at an alkaline pH (a pH of 10), acting 
by splitting off phosphorus (an acidic mineral) creating an alkaline pH. 
 Bone ALP is present in vesicles secreted by osteoblasts to induce bone mineralization, and 
has been associated to the in vitro ECM development and maturation[54]. Consequently, ALP 
activity has been considered a marker of the osteogenic differentiation process of stem cells. 
ALP can be detected by different methods based on enzymatic reaction followed by 
colorimetric analysis or by fast red violet dye. In this Thesis, ALP was evaluated according to 
the procedures mentioned above; fast red violet dye in constructs with BMSCs- and AFSCs 
seeded onto SPCL scaffolds from chapter VI and VIII, and a colorimetric assay using an ELISA 
microplate reader in samples with gBMSCs- seeded onto TCP-PCL nanofibers or seeded onto 
SPCL- and SPCL-Si- scaffolds from chapter III, VII, and IV, respectively. 
The principle of the ALP staining, considered in chapter VI and VIII, relies on immersing the 
samples in a Napthol AS-MX phosphate alkaline solution; a histochemical substrate used for 
the detection of ALP activity, commonly used in conjuction with Fast Violet B salt (Sigma). After 
each end point, cells were fixed in 10 % buffered formalin solution overnight at 4 ºC, and then 
rinsed and kept in PBS until incubating the cells in a staining solution of 0.25 % Napthol AS-MX 
phosphate alkaline solution (Sigma-Aldrich) and Fast Violet B salt (Sigma) for 30 minutes. To 
remove the excess of non-specific staining, samples were rinsed in PBS and observed under an 
inverted microscope (Leica, DMI4000B). Sample images were acquired using a camera Q-
Imaging (Retiga-2000RV) or, in the case of full sized constructs, observed directly and images 
acquired using an Olympus SP-570UZ digital camera. 
Beside the staining approach, ALP activity can be quantitatively evaluated using a 
colorimetric development assay, which was used in chapter III, IV, and VII. Despite the fact that 
this method is more sensitive to small ALP activity variations, it is an indirect evaluation 
method as only ALP molecules released into the sample solution can be measured. Thus, 
constructs were harvested from the culture medium, rinsed in PBS and placed in a microtube 
containing 1 mL of ultra-pure water and kept frozen at -80 ºC until testing. Afterwards, 
samples were thawed and briefly sonicated for 15 minutes in order to rupture any cell that 
might have kept the membrane integrity after the osmostic treatment followed by a 
freezing/thawer cycle. Then, a substrate solution consisting of 0.2 % (wt/v) p-nytrophenyl 
phosphate (Sigma) in a substrate buffer with 1 M diethanolamine HCl (Merck), at pH 9.8 was 
added to each sample, at a proportion of 60 l of solution to 20 l of sample. 
The plate containing the samples was incubated in the dark for 45 minutes at 37 ºC, 
followed by the addition of a stop solution (2 M NaOH (Panreac) plus 0.2 mM EDTA (Sigma)) to 
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end the color development reaction. Standards were prepared with p-nytrophenol (10 
µmol.ml-1) (Sigma) in order to achieve final concentrations ranging between 0.0 - 0.3 µmol.ml-
1. Samples and standards were analyzed in triplicates. The colorimetric assay measures the 
conversion of the colorless substrate p-nitrophenol phosphate into the yellow soluble product 
p-Nitrophenol by the enzyme ALP. P-nitrophenyl phosphate absorbs at 405 nm, and is the 
preferred substrate for high sensitivity detection of ALP in ELISA assays. The absorbance was 
read in a microplate ELISA reader (Synergie HT, BioTek) at 405 nm and concentration values 
determined by intrapolation using a standard curve established by the standards. 
 
II.6.7.4.2.  Alizarin Red Staining 
 
Alizarin red or 1,2-dihydroxyanthraquinone is an organic compound used for decades to 
identify calcium-rich deposits[55] in tissue sections or cells in culture. The reaction is not 
strictly specific for calcium, since magnesium, manganese, barium, strontium, and iron may 
interfere, but these elements usually do not occur in sufficient concentration to interfere with 
the staining. Calcium forms an Alizarin Red S-calcium complex in a chelation process, and the 
end product is birefringent. Alizarin red staining is particularly versatile since the method can 
be both qualitative and semi-quantitative as the dye can be extracted, dragging with it the 
calcium ions, and readily assayed. Then, using a calibration curve and appropriate standards, 
calcium concentration values can be achieved.  
Alizarin Red was directly evaluated as a staining in constructs from chapter III and VI; 
gBMSCs seeded onto PCL-TCP nanofibers and hAFSCs- and hBMSCs- seeded onto 6-well plates, 
respectively. An alizarin red solution (0.2 % to 2 %, depending on specimens, Sigma-Aldrich) 
was prepared, pH adjusted to 4.1-4.3 and samples stained by immersion for 2 minutes.  
The alizarin red stain found in BMSC- and AFSC- samples from chapter VI, and in the BMSC- 
and AFSC-SPCL constructs from chapter VI and VIII, was solubilized in cetylpyridinium chloride 
(Sigma) at pH 7.0 for 15 minutes under milt agitation and calcium-bounded to alizarin red 
quantified at 562 nm, using a plate reader (SpectraMax MS, Molecular Devices).  
 
II.6.7.4.3.  Fourier Transformed Infrared Spectroscopy with Attenuated Total Reflectance  
 
FTIR spectroscopy has been successfully used to analyze the changes in minerals and 
components of bone tissue since vibrational spectroscopy in the mid-infrared region can 
provide molecular structure information about mineralized tissue[56]. 
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The composition of the human AFSC-SPCL constructs considered in chapter VIII was 
analyzed by FTIR-ATR in order to detect molecular groups associated to ECM mineralization. 
Before the analysis, samples were dehydrated in a series of ethanol concentrations and air-
dried at room temperature. FTIR-ATR was performed in the spectral range of 1800-600 cm-1 
using the Spectrum 400 FT-IR/FT-NIR spectrometer (Perkin Elmer). Results were compared to 
cell-free scaffolds in order to exclude the contributions from the scaffold composition. 
 
II.6.7.4.4. Immunocytochemistry: Collagen I and Osteocalcin  
 
Immunocytochemistry for Collagen I and Osteocalcin was performed on gBMSCs- PCL-TCP 
samples from chapter III. Collagen I is the most abundant collagen of the human body and the 
major protein present in bone ECM, responsible for strengthen and support of bone tissue. On 
the other hand, osteocalcin (OCa) is a non-collagenous protein, produced by osteoblasts, that 
participates in the matrix mineralization of bone[57] as OCa binds to hydroxyapatite in a 
calcium-dependent manner[58]. 
Immunocytochemistry was performed according to R.T.U. Vectastain Universal Elite ABC kit 
(PK 7200) from VectorLabs, using R.T.U Normal Horse Serum to avoid unspecific reactions, a 
biotinilated secondary antibody (R.T.U. Biotinylated Universal Antibody, one-hour incubation), 
and a Peroxidase Substract Kit (Vector SK-4100). 3,3’-Diaminobenzidine (DAB) was the 
colorimetric substrate used in the assays.  
Primary antibodies used included Collagen I (MAB339, Chemicon) and Osteocalcin 
(Ab13418, Abcam), which were prepared using a 1/100 dilution. With the exception of primary 
antibodies, which were incubated overnight at 4ºC, all the other steps of this procedure were 
performed at room temperature. 
 
II.6.7.4.5. Immunofluorescence: Collagen I and RunX-2 
 
Immunofluorescence for Collagen I was performed on BMSC- and AFSC-SPCL constructs 
from chapter VI and VIII, while RunX-2 expression was assessed in BMSC- and AFSC-SPCL 
constructs from chapter V and VI. Cbfa1/RunX-2 is a key transcription factor associated with 
osteoblast differentiation, essential for osteoblastic differentiation and skeletal 
morphogenesis[59]. 
Collagen I from Southern Biotech (1310-01) and RunX-2 (ab23981) purchased to Abcam 
were diluted to 1:100 and 1:20 ratio, respectively, and incubated overnight at 4 ºC.  
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AlexaFluor 488 and 594 (Molecular Probes, Invitrogen; 1:200 dilution, one-hour incubation) 
were used as fluorescent secondary antibodies.  
Instead of animal serum, blocking step was performed using protein block serum free 
(Dako). After the procedure, constructs were then observed under a confocal microscope 
(Axiovert 100 M, Zeiss) equipped with argon/He-Ne laser sources.  
 
II.6.7.5. Chondrogenic markers 
 
II.6.7.5.1. Safranin O staining 
 
Safranin, Safranin O or basic red 2 is a cationic dye frequently used as a counterstain, and 
for the detection of mucin, cartilage[60] and mast cells.  
Following deparaffinization of AFSC-agarose sections from chapter V, slides were stained 
with Weigert’s iron hematoxylin working solution (Merck) for 7 minutes. Samples were rinsed 
in tap water for 10 minutes, and subsequently rinsed quickly in 1 % acetic acid solution for 
about 10 to 15 second and stained in 0.1 % safranin O solution (Fluka) for 5 minutes.  
 
II.6.7.5.2. Immunofluorescence: aggrecan and collagen II 
 
Immunofluorescence for aggrecan and collagen II was performed on AFSCs encapsulated in 
agarose hydrogels from chapter V.  
Aggrecan and collagen II, two of the main cartilagineous proteins, were evaluated to assess 
the chondrogenic differentiation under the scope of this Thesis. Aggrecan is a chondroitin 
sulfate proteoglycan that along with collagen II forms a major structural component of 
cartilage. About 90 % of articular cartilage is made of Collagen II, a protein responsible to 
entrap proteoglycan aggregates and provide the characteristic tensile strength to the tissue. 
Samples were prepared as described previously in section II.6.7.6. Primary antibodies 
Collagen II (MAB1330, Chemicon) and Aggrecan (MCA1452 Serotec) were prepared with a 
1/100 dilution. AlexaFluor 488 (Invitrogen; 1:200 dilution, one-hour incubation) was used as 
the fluorescent secondary antibody.  
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II.6.7.6.  Evaluation of cell morphology and distribution  
 
Cell morphology and distribution throughout a 3D matrix was evaluated in cell-scaffold 
constructs with confocal microscopy and scanning electron microscopy. 
 
II.6.7.6.1.  Confocal laser scanning microscopy (CLSM) 
 
Confocal laser scanning microscopy (CLSM) is an optical imaging technique used to increase 
contrast and optical resolution, overcoming the limitations of conventional widefield 
microscopy. Simultaneously, CLSM facilitates the generation of high resolution 3D images from 
a relatively thick sample[61]. In some cases, the 3D reconstruction allows a better 
understanding of the distribution, organization or morphology of cells, or molecules of 
interest.   
Confocal microscopy was a very useful technique to assess cellular viability by Calcein AM in 
human AFSCs and BMSCs seeded onto SPCL scaffolds and AFSCs encapsulated in agarose gels, 
described in chapter V and VI. CLSM was also used for the detection of specific bone markers, 
such as RunX-2 or collagen I in SPCL constructs seeded with AFSCs or BMSCs (chapter V, VI and 
VIII).  
Samples were prepared accordingly to Calcein AM and immunofluorescence protocols 
above mentioned, before analyzed under a confocal microscope (Axiovert 100 M, Zeiss) 
equipped with argon/He-Ne laser sources. 
 
II.6.7.6.2. SEM 
 
Cell seeded constructs[18,62] were also examined by SEM to assess cellular morphology, 
distribution and relative proliferation between samples from different end points. In some 
cases, it is also possible to assess ECM mineralization by energy dispersion spectroscopy (EDS) 
coupled to SEM equipment. 
All cell-scaffold constructs described in experimental chapters (chapters III, IV, V, VI, VII and 
VIII), namely gBMSC-PCL-TCP, gBMSC-SPCL and gBMSC-SPCL-Si samples, as well as hBMSC- and 
AFSC- seeded onto SPCL scaffolds, were observed by scanning electron microscopy (Leica 
Cambridge, model S360 or Hitacho S-2600N, Hitachi Science Systems, Ltd).  
Constructs were fixed in formalin, and the samples from chapter III, IV and VII were 
dehydrated in a series of ethanol concentrations followed by air-dried. Conversely, constructs 
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from chapter V, VI and VIII were critical point dried (EMS850X, Electron Microscopy Sciences) 
after fixed in a formalin solution and dehydrated to 100 % ethanol.  
All samples were gold sputtered (Fisons Instruments, model SC502 or Hummer 6.2 
sputtering system, Anatech Ltd) for 2 minutes at 15 mA. Samples were further assessed by 
SEM and micrographs recorded at 15 kV ranging from 100x to 5000 x magnification. 
 
II.6.7.6.3. Energy dispersive X-ray analysis or EDS analysis 
 
Energy dispersive X-ray analysis or EDS is a technique used to identify the elemental 
composition of a sample, including bone tissue[63]. In terms of biological samples in this 
Thesis, EDS analysis proved to be very useful for the detection of a calcified/mineralized ECM 
(with calcium and phosphorus elements) produced by osteoblastic cells, when seeded in non-
ceramic scaffolds. 
Since samples for SEM can be used for EDS analysis, constructs preparation is the same as 
mentioned in the previous section. EDS and EDAX (Pegasus X4M) were used to determine the 
presence/absence of calcium and phosphorus in the ECM matrix produced by hAFSCs and 
hBMSCs cultured onto SPCL scaffolds (chapter V and VIII, respectively). 
 
 
II.7. Animal models studies 
 
II.7.1.  Goat model – non critical defects 
 
The selection of goat as an animal model was justified in a previous section (II.6.1.1.). The 
primary goal of this study was to analyse the role of the scaffold material and of BMSCs in a TE 
strategy aimed at bone regeneration. Thus, SPCL scaffolds, seeded or not seeded with gBMSCs 
under different stages of osteogenic differentiation were implanted in non-critical sized 
femoral defects.  
Although many studies are conducted ectopically, orthotopic implants provide more 
relevant data since implants are located in the tissue/area of their target application and thus, 
any eventual site specific reaction such as cell recruitment or growth factor release either 
associated to the tissue healing or to an inflammatory process is expected to be similar to the 
ones that are likely to occur in a real clinical situation. 
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Four skeletally adult female goats weighing 30-45 kg were used in the study described in 
chapter VII. The housing care and experimental protocol were performed according to the 
national guidelines, after approval by the National Ethical Committee for Laboratory Animals 
(2007-07-27, document number 018939) and conducted in accordance with international 
standards on animal welfare as defined by the European Communities Council Directive of 2 
November 1986.  
 
II.7.1.1.  Implantation surgery 
 
After general anaesthesia, each goat was positioned in lateral recumbency, prepared and 
draped in a sterile manner to perform a surgical access to the lateral diaphysis of femur.  
A skin incision was then performed from the greater throcanter and continued distally to 
the lateral femoral condyle. The subcutaneous tissue, tensor fascia lata and lateral fascia of the 
vastus muscle were incised. Biceps femoris muscles were retracted posteriorly, and the vastus 
muscle was retracted anteriorly, after being detached from the linea aspera and femora shaft, 
like the periosteum.  
Non-critical size defects ( 6 mm and 3 mm depth) were drilled in the lateral diaphysis of 
both posterior femurs of the 4 adult goats with a bone drill (Synthes, Switzerland). The drill-
hole technique selected was based on the one described by Hallfeldt et al.[64].  
Eight drills were created bilaterally in the posterior femurs, with a separation distance 
between drills of 3 cm, in two non parallel sections to avoid fracture tension or neobone 
formation among drills. Two drills were left empty and 2 filled with scaffolds without cells, the 
control for this experiment. The remaining drills were filled in with constructs osteogenically 
cultured for 1 day (2 defects) or 7 days (2 defects).  
Implants were gently pressed fit (Figure II.7.1). The muscle was replaced over the bone, and 
the fascia lata and skin were closed with resorbable and non-resorbable sutures, respectively. 
During the first post-operative week, animals were medicated with flunixin meglumin (1 
mg/kg IM, Finadyne P.A., Schering-Plough II) for 2 days and amoxicillin (15 mg/kg IM, 
Clamoxyl L.A., Pfizer) for 7 days. After implantation, animals were kept in a room, where 
goats could move freely and full weight-bear on the posterior limbs during the complete post-
operative period. 
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Figure II.7.1 - Non-critical size defects drilled in the posterior femur of a goat model. 
 
II.7.1.2.  Imprinting new bone with fluorescent dyes 
 
Fluorochrome sequential labelling of mineralizing tissues is commonly used in different 
fields of clinical and basic research[65]. Fluorochrome use in animal models makes it possible 
to determine the onset time and location of osteogenesis, which are the fundamental 
parameters in bone tissue engineering studies. 
Intravital fluorescence markers, namely, xylenol orange (90 mg/kg, Aldrich), calcein green 
(10 mg/kg, Sigma) and tetracycline (25 mg/kg, Sigma) were injected subcutaneously after 2, 4 
and 6 weeks of follow up, respectively, for monitoring bone formation and mineralization 
along with the implantation period. 
 
II.7.1.3. Explant retrieval and characterization 
 
Six weeks after surgery, and 24 h after tetracycline injection, animal euthanasia was 
performed using an overdose of pentobarbital sodium (Eutasil, Sanofi). The femurs were 
explanted and cut into single-defect segments, which were fixed in a 4 % formaldehyde 
solution (pH 7.2) (Sigma) until further usage. 
 
II.7.1.3.1.  Histological characterization 
 
 Single-defect segments were processed and embedded in glycol methacrylate solution 
(Technovit 7200® VLC–Heraus Kulzer GmbH) for histologic assessment of calcified bone. 
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Sections of 30 µm were prepared according to Donath et al. technique[66] using an Exakt-
Cutting® System (Aparatebau GMBH, Germany). 
 Only the mid section of each bone segment was observed at the fluorescence microscope 
(Olympus BX51) for fluorochrome detection, and then selected for histomorphometric 
analysis.  
Additional sections were stained with Lévai-Laczkó[67] to differentiate between native 
bone and the new bone formation using a stereo microscope (Olympus SZX9).  
Quantitative measurement for bone neoformation was carried out after selecting relevant 
drill surrounding areas and quantified using Microimage 4.0 software. 
 
 
II.7.2. Nude rat model - non-union defects 
 
Non-unions or critical sized defects were induced in a nude rat model using human AFSCs. 
The purpose of selecting the rat instead of the goat, one step backwards in the philogenetic 
scale, relies on the fact that the rat is another popular subject in the TE field, and in particular 
in orthopaedics research. Regardless of the size, rat’s popularity is mainly due to its low cost, 
easy handling, housing, operating, and follow up than goats. The rat plays an important role in 
studies of biocompatibility, including subcutaneous or intramuscular implantation of 
biomaterials[17,24] to bone defect repair[68,69]. The availability of rats with distinctive 
characteristics, such as athymic nude[69] or transgenic animals not easily available in larger 
animal models, amplifies the study possibilities in xenograft research and, consequently the 
implantation of human cells in a non-human host. 
Despite the fact that AFS cells are unlikely to cause any minimal immune reaction, due to 
their described non-immunogenic features, AFSCs were used in critical-sized defects in nude 
rats. Several main reasons can justify this selection since in the human fetus, precursor cells, 
which will lately evolve into immune cells, can be found as early as 4-8 weeks of gestation, and 
we wanted to prevent any possible interference with a human cell source. Furthermore, AFSCs 
present exciting properties that can be used as an alternative source to autologous 
approaches, as a highly proliferative and universally available source of stem cells. 
Geriatric animals were used to better mimic the regenerative process in bone, which is 
particularly affected in elder patients. Thus, male athymic nude rats (36-40 week old) weighing 
420-560 g (n=60) were purchased from Charles River and used in the study described in 
chapter VIII. Since this study was performed in collaboration with WIRM, all procedures were 
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performed in accordance with Wake Forest University Animal Care and Use Committee (ACUC) 
approved protocols (protocol number; A07-063/A10-032).  
During the entire study, adequate measures were taken to minimize any pain or discomfort 
to the animals. 
 
II.7.2.1. Implantation  
 
Animals were randomly assigned into 5 groups (n=6 / group) as follows: 1) no-repair group 
(empty defects, no implant), 2) scaffold-only group, and 3) scaffold with undifferentiated 
hAFSC cell group, 4) scaffold with hAFSC osteogenically committed group, and 5) scaffold with 
hAFSCs differentiated into osteoblast-like cells group. 
Anesthesia was induced with 3 % isoflurane (USP, Novaplus) prior to surgical procedures. 
The dorsolateral side of the right leg was shaved and sterilized with routine aseptic agent. 
Under aseptic conditions, a 20 mm long incision was made on the skin over the femur of the 
right hind limb. The skin and the gluteus muscle were dissected to approach the femur. A 
periosteal incision was made on the periosteum of the femur, and the periosteum and the 
attached muscles were elevated to expose the femur. Retracting adjacent tissues, a 3.0 mm 
thick and 2.2 cm long custom-made bone plate was placed along the intact femur and was 
fixed with 4 stainless steel screws using a micro drill system (BS72-4950, Harvard apparatus, 
USA) to stabilize the femur after scaffold implantation. 
 A 5 mm bone segment in between screwed areas at both ends was removed from the 
femur using a bone cutting bur. The created defects were thoroughly irrigated with sterile 
saline to avoid residual bone particles at the site. Subsequently, the scaffolds and cell-scaffold 
constructs from the different study groups, according to our experimental design, were 
implanted to the bony defects and fixed in a press-fit manner. After inserting the 
scaffolds/constructs, the muscle and the skin were closed layer by layer using 5-0 Vicryl sutures 
(Ethicon, USA). The animals were maintained postoperatively according to the guideline of the 
ACUC.  
Radiographic 2D images of the femoral defects were obtained from each animal every 4 
weeks, using C-arm equipment (Siremobil Compact L, Siemens) to monitor plate stability and 
select animals for micro-CT analysis. Animals were kept under general anaesthesia during both 
(x-rays and micro-CT) procedures in order to minimize stress and assure animal welfare. 
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II.7.2.2.  Explant retrieval and characterization 
  
Rats were euthanized 4 or 16 weeks after implantation accordingly to ACUC guidelines. 
Right femurs were retrieved, rinsed in PBS, placed in 10 % buffered formalin for 96 h and then 
kept in 60 % ethanol until histological processing.  
 
II.7.2.2.1.  Micro-computed tomography (bone formation assessment) 
 
Bone ingrowth studies have been investigated involving micro-CT analysis for assessment of 
structural characteristics and mineralization of a tissue in continuous regeneration[70], 
creating new possibilities for biomedical applications.  
Rats were anaesthetized during the real time live imaging of the femoral defects, obtained 
using a μ-CT equipment, Siemens MicroCAT II (Siemens Preclinical Solutions, Knoxville, TN), 
where a MicroCAT II version 1.9d software was used to acquire raw data.  
Scans were performed with an x-ray voltage of 70 kVp / 500 μA, and an exposure time of 
1600 ms (BIN Factor of 2, 360° rotation, 360 steps, 36 micron isotropic voxel dimension).   
RVA version 4.2.9 and COBRA EXXIM version 4.9.52 were used to reconstruct the raw data 
into raw slice images, and then Amira version 3.1 was used for conversion to DICOM images. 
Analysis was done after transfer of images to TeraRecon AquariusNET Server (TeraRecon, Inc., 
San Mateo, CA) using TeraRecon software AquariusNET version 1.8.1.6. Another software 
packages used for image analysis and volumetric measurements included Mimics version 13 
(Materialise, Leuven, Belgium). 
 
II.7.2.2.2.  X-rays 
 
X-ray is a form of electromagnetic radiation that can penetrate solid objects, which has 
proved useful for medical purposes, including the detection of pathological conditions of the 
skeletal system as well as some disease process in soft tissues.  
In this Thesis (chapter VIII), radiographic 2D images of the femoral defects were obtained 
from each animal every 4 weeks up to a maximum of 16 weeks, using C-arm equipment 
(Siremobil Compact L, Siemens) to monitor plate stability and select animals for micro-CT 
analysis.  
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II.7.2.2.3.  Histological Characterization 
 
Explants were decalcified using an acid solution of Immunocal® (Decal Chemical Corp), and 
tissue processed in a graded series of ethanol, xylene and embedded in paraffin blocks. 
Sections of 10 m were obtained using a microtome, and stained with H&E. For this purpose, 
slides were stained with Mayer’s hematoxylin for 4 minutes, followed by a rinse in water to 
remove excess of stain and 3 immersions in ammonia water. Then, samples were washed in 
tap water for 3 minutes and stained with eosin for another 3 minutes. 
Hematoxylin, a base dye, stains nuclei blue due to an affinity to nucleic acids in the cell 
nucleus; eosin, an acidic dye, stains the cytoplasm pink.  
After staining, samples were rinsed again in water and dehydrated before mounting the 
slides with non-aqueous medium, and observed under a microscope (Imager Z1m, Zeiss) 
equipped with an AxioCam MRc5 camera (Zeiss). 
Immunocytochemistry was performed for bone related markers: collagen I and osteocalcin, 
as well as an angiogenic marker, VEGF, in explant sections from chapter VIII.  
Primary antibodies anti- collagen I (1310-01, Southern Biotech; 1:20 dilution), osteocalcin 
(V-19, Santa Cruz Biotechnology, 1:100) and VEGF (147, Santa Cruz Biotechnology, 1:100) were 
diluted in antibody diluent with background reducing components from Dako (Denmark). 
Biotinylated secondary antibodies were obtained from Vector Lab (Burlingame, CA, USA) as 
well as R.T.U. HRP/Straptavidin (SA-5704). Immunochemistry visualization was assessed by 
NovaRED substrate kit (SK-4800, Vector Lab).  
Specimen slides were observed under a microscope (Imager Z1m, Zeiss, Germany) 
equipped with a digital camera (AxioCam MRc5). 
 
II.7.2.2.4. Histomorphometric analysis 
 
Histomorphometrical analysis was carried out to quantify stained areas in samples 
retrieved from in vivo experiments of chapter VIII, after immunostaining for bone related 
markers, namely osteocalcin and collagen I as well as vascular markers by VEGF expression. For 
this purpose, an interest area was selected, and kept constant for all slides, where protein 
expression was detected and analyzed using the Cell D software (analysis image processing) 
and MicroImage software from Olympus Optical Co. 
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II.8. Statistical analysis 
 
Several statistical methods were used in this Thesis, accordingly to the experimental assay 
requirements.  
In chapter III, the statistical analysis was carried out using One Way ANOVA test and Tukey's 
Multiple Comparison Test (p<0.05), and results presented as mean  standard deviation.  
In chapter IV, results are also presented as means  standard deviation. Statistical 
differences between sample groups (p<0.001 or p<0.05) were assessed by two Way ANOVA. 
Statistical analysis was also carried out in chapter VII by mean  standard error of mean 
using T-Test and 2-way ANOVA for in vitro and for in vivo measurements, respectively. At least 
4 samples were considered in the in vitro assays (DNA, ALP, SEM) while 16 samples were 
considered in vivo for each condition; A) empty drill, B) drill with SPCL scaffold, drills with SPCL 
seeded with gBMSCs for either C) 1 or D) 7 days in osteogenic medium). 
Results from chapter VIII, are presented as means  standard deviation in in vitro assays, 
while results from histomorphometric analysis are presented as means  standard error of 
mean. Two Way ANOVA test was applied to assess statistical significant differences between 
sample groups followed by Bonferroni’s Multiple Comparison test (*=p<0.05). 
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Chapter III 
SYNERGISTIC EFFECT OF SCAFFOLD COMPOSITION AND DYNAMIC CULTURING ENVIRONMENT 
IN MULTI-LAYERED SYSTEMS FOR BONE TISSUE ENGINEERING 
 
III.  
III.1.  Abstract 
Bone extracellular matrix (ECM) is composed of mineralized collagen fibrils which support 
biological apatite nucleation that participates in bone outstanding properties. Understanding 
and mimicking morphological and physiological parameters of bone at a biological scale is a 
major challenge in tissue engineering scaffolding. Emergent new (nano)technologies offer the 
possibility to improve scaffold design that may be critical to obtain highly functional tissue 
substitutes for bone applications. 
This study aims to develop novel biodegradable composite scaffolds made of tricalcium 
phosphate (TCPs) and electrospun nanofibers of poly(ε-caprolactone) (PCL), in order to 
combine the osteoconductivity of TCPs with the biocompatibility and elasticity of PCL, thereby 
mimicking bone structure and composition. We hypothesized that scaffolds with such 
structure/composition would stimulate the proliferation and differentiation of bone marrow 
mesenchymal stromal cells (BMSCs) towards the osteogenic phenotype. 
Composite scaffolds were developed by electrospining using consecutive stacked layers of 
PCL and TCPs, and then characterized by Fourier Transform Infrared spectroscopy, X-Ray 
diffraction and scanning electronic microscopy. To assess cellular behavior, goat bone marrow 
mesenchymal stromal cells (gBMSCs) were seeded onto composite scaffolds and cultured in 
either static or dynamic conditions, using both basal and osteogenic differentiation medium 
during 7, 14 or 21 days. Cellular proliferation was quantified and osteogenic differentiation 
was confirmed by alkaline phosphatase activity, alizarin red staining and 
immunocytochemistry for osteocalcin and type I collagen. The results suggest that these PCL-
TCP scaffolds provide a 3D support for gBMSCs proliferation and osteogenic differentiation, 
including the production of ECM matrix. In fact, the presence of TCPs is shown to positively 
stimulate the osteogenic process, especially under dynamic conditions, where the 
environment induced by PCL-TCP scaffolds is sufficient to promote osteogenic differentiation 
even in basal medium conditions. The enhancement of the osteogenic potential in dynamic 
conditions evidences the synergistic effect of scaffolds composition and dynamic stimulation in 
gBMSCs osteogenic differentiation.  
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III.2. Introduction 
 
Bone fracture defects, bone loss, infection or bone tumoral resections are serious problems 
requiring for bone surgery, and the implantation of auto- or allo-grafts has long been used as a 
standard procedure for bone reconstruction. Nevertheless, graft strategies are associated with 
significant disadvantages, namely tissue morbidity at the harvesting site, donor scarcity and 
immune response and disease transmission risks. To overcome these limitations, the challenge 
stands for designing novel tissue engineered products. 
The selection of a biomaterial plays a key role in the development of an engineered product 
aimed at tissue regeneration and repair, as materials can tailor the biophysical and 
biochemical milieu at a molecular level, directing cellular behavior and function.  
Synthetic polymers, such as poly ε-caprolactone (PCL) are typically more versatile in 
tailoring a wide range of properties and structure features. Also, they represent a reliable 
source of raw materials, with adequate mechanical properties, and avoid immunogenicity 
problems[1, 2]. Nevertheless, polymers lack properties to stimulate biological functions, such 
as osteoconductivity, and cell bioactivity[3]. Concerning these properties, ceramic materials 
offer advantages over polymers, but their high modulus yet brittle behavior[4] limit their 
processability into 3D scaffolds[5, 6]. 
Designing scaffolds using nanotechnology tools aims at mimicking the extracellular matrix 
(ECM) structure and complexicity at a biological scale, as bone natural matrix is mainly 
composed of an intricate nanofiber structure of nonstoichometric hydroxyapatite integrated in 
collagen fibers. At a submicron level, this organic-inorganic combination confers the intrinsic, 
unique biomechanical and functional properties of bone 3D architecture.  
The products of electrospining technology are micro- and nano-structured scaffolds made 
of an ultra-fine and continuous fiber network with variable pore-size distribution, high micro-
porosity and high surface-to-volume ratio, morphologically similar to natural ECM[7]. Several 
materials, including synthetic- and natural-origin polymers[8-16]  and proteins[9, 10, 12, 17, 
18], have been successfully electrospun into nanofiber scaffolds, which interacted positively 
with intercellular communications by sustaining cell adhesion, proliferation and differentiation 
towards the osteogenic phenotype both in vitro[9, 11, 14, 16, 18] and in vivo[9, 11, 15]. 
Considering the properties and flexibility of electrospun nanofiber meshes, the 
incorporation of biologically active factors, like matrix proteins[19] or minerals as calcium 
phosphates[8, 11-13], either in the spun fibers or as coatings, makes them attractive to 
improve scaffold designs for bony functional substitutes. Moreover an integrated composite 
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scaffold of a polymer with a ceramic material offers a chemical environment that would 
resemble the organic and inorganic components of bone native matrix[20].  
In this study, we formulated a novel multilayer composite structure combining the 
osteoinductive properties of beta-tricalcium phosphate powder with a degradable polymer. 
PCL was selected due to its degradability and cellular compatibility, and because this material 
has been widely studied for biomedical applications[8, 9, 13-15]. Several studies suggested 
hydroxyapatite as the ceramic material preferred for bone strategies[8, 12, 19]. Nevertheless, 
the osteoconductive and bioreabsorvable nature of beta-tricalcium phosphate together with 
an earlier incorporation into surrounding bone in vivo may be advantageous to hydroxyapatite, 
which remains unremodeled despite long periods upon implantation[21]. 
The design of these 3D fibrous scaffolds is expected to enhance the synergistic effects of 
ceramic (osteoconductivity and bioactivity) and biopolymer features (elasticity and shape 
control). The possibility to combine and stack layers in such simple and thin structures can 
improve their tridimensionality, which has been described to be critical in structure, function 
and morphology of body tissues. 
The limited diffusion in standard static culture environments is another important issue to 
considering when designing bone regeneration strategies, since this may constrain cell 
proliferation and uniform distribution in tissue engineered constructs[10, 22]. Therefore, we 
also propose to evaluate the effect of dynamic culturing in the osteogenic differentiation 
process of goat bone marrow mesenchymal stromal cells (gBMSCs), cultured in the multi-layer 
scaffolds, either in the presence of basic or osteogenic differentiation media.  
 
 
III.3.  Materials and Methods 
 
III.3.1.  Development of the nanofibrous multilayered composite scaffolds 
 
The ceramic material, beta-tricalcium phosphate (-TCP), was obtained from a solid state 
reaction between stoichiometric amounts of calcium phosphate dibasic anhydrous (Fluka) and 
calcium carbonate (Sigma) followed by a 24 h sinterization at 800 ºC. The powders were hand-
sieved with stainless steel sieves (mesh 225 - 106 μm). A polymeric solution of 17 % (w/v) 
polycaprolactone (PCL) in a mixture of chloroform (Aldrich) and N,N-dymethylformamide 
(Aldrich) at a 7:3 ratio was processed by electrospinning technique. This solution was 
electrospun at 9-10 kV, with a flow rate of 1.0 mL/h collecting a random fiber mesh (20 cm 
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away from the collector) on a flat aluminium foil. Composite scaffolds were then developed by 
assembling three stacked layers of electrospun PCL fibers and TCPs at a ratio of 0.5 g TCP per 
PCL mesh. 0.25 g of TCP powder was dispersed between each two consecutive PCL layers. The 
resulting PCL-TCP scaffolds, as well as TCPs powder and PCL meshes alone, were characterized 
by FTIR, XRD and SEM, as described below.  
 
III.3.2.  Characterization of the composite scaffolds 
 
III.3.2.1.  Thin-film X-ray diffraction (TF-XRD) 
 
TF-XRD patterns were recorded on a Philips X’Pert MPD (Philips, The Netherlands) 
diffractometer using CuKα radiation to analyze the surface composition of the specimens. 
 
III.3.2.2.  Fourier Transformed Infrared Spectroscopy with attenuated total reflectance 
(FTIR-ATR)  
 
FTIR-ATR was performed using IRPrestige-21 (Shimadzu, Japan) equipment. Spectra were 
taken with a resolution of 2 cm-1 and averaged over 64 scans, covering the wave number range 
of 4400-400 cm-1. 
 
III.3.2.3.  Scanning electron microscopy (SEM)  
 
SEM analysis was performed to characterize the morphology of the developed structures 
using Hitachi S-2600N (Hitachi Science Systems, Ltd) equipment. Prior to any SEM 
observations, sample surfaces were gold sputtered. 
 
III.3.3.  In vitro culture of bone marrow mesenchymal stromal cells onto nanofibrous 
scaffolds 
 
To assess cellular behavior, scaffolds were cut into 5 mm diameter discs, and then sterilized 
by means of two 30 minute-cycle of UV irradiation.  
PCL nanofiber meshes without TCPs were considered as controls of the experiment. 
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Goat bone marrow mesenchymal stromal cells (gBMSCs) were harvested from iliac crests of 
adult goats and expanded in basal medium composed of DMEM (Dulbecco Modified Eagle 
Medium, Sigma-Aldrich), supplemented with 10 % FBS (Invitrogen) and 1 % antibiotic-
antimicotic solution (A/A) (Gibco), and then seeded onto the PCL-TCP composites at a 
concentration of 5.0 x104 cells/mesh or scaffold. After the seeding, cell-scaffold constructs 
were maintained in non treated 48 multi-well plates (Costar) in basal medium for 24 h and 
then cultured under static or dynamic conditions in either basal or osteogenic differentiation 
medium during 7, 14 or 21 days.  
Dynamic conditions were provided by an orbital shaker (Digisystem) under constant mild 
agitation (60 rpm), working permanently until the end of the experiment and kept in the same 
CO2 incubator where constructs under static conditions were also cultured. 
Osteogenic medium was prepared with -MEM (Minimal Essential Medium Eagle alpha 
modification, Sigma-Aldrich), 10 % FBS and 1 % A/A and osteogenic supplements namely 
ascorbic acid (50 g/ml) (Sigma-Aldrich), dexamethasone (10-8 M) (Sigma-Aldrich) and -
glycerophosphate (10 mM) (Sigma-Aldrich). In all conditions, cell culture medium was changed 
twice a week.  
 
III.3.3.1.  Cell proliferation and osteogenic differentiation in multi-stacked nanofibrous 
scaffolds 
 
Cell proliferation was assessed by a DNA quantification assay while the osteogenic 
differentiation was assessed by ALP quantification, alizarin red staining and 
immunocytochemistry (ICC) for osteocalcin (OCa) and type I collagen. 
 
III.3.3.1.1.  DNA assay 
 
 Proliferation potential of gBMSCs seeded onto the developed scaffolds was considered by 
double strand DNA quantification (dsDNA). For this purpose, a fluorimetric dsDNA 
quantification kit (PicoGreen, Molecular Probes) was used.  
The fluorescence was read using a microplate ELISA reader (BioTek) at an excitation of 
485/20 nm and an emission of 528/20 nm. 
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III.3.3.1.2. ALP assay 
 
 ALP activity was measured in this study, as an osteogenic cell marker. A substrate solution 
consisting of 0.2 % (wt/v) p-nytrophenyl phosphate (Sigma) in a substrate buffer with 1 M 
diethanolamine HCl (Merck), at pH 9.8 was added to each sample. The plate was incubated in 
the dark for 45 minutes at 37 ºC, followed by the addition of a stop solution (2 M NaOH 
(Panreac) plus 0.2 mM EDTA (Sigma)). Samples and standards (the latter prepared with p-
nytrophenol (10 µmol.ml-1) (Sigma)) were analyzed in triplicates. The absorbance was read 
using a microplate ELISA reader (BioTek) at 405 nm. 
 
III.3.3.1.3.  Alizarin Red staining 
 
Cell-scaffold constructs were removed from culture and fixed in 4 % formalin (Sigma) 
solution overnight at 4 ºC. A 2 % Alizarin Red solution (Sigma) was prepared (pH adjusted to 
4.1-4.3) to stain calcium ions that might be present resultant from mineral ECM produced by 
cells. Constructs were stained with alizarin red solution for about 2 minutes, washed with PBS 
until removal of excess of stain and let dry.  
 
III.3.3.1.4.  Immunocytochemistry 
 
After overnight fixation with 4 % formalin, samples were kept in PBS until 
immunocytochemistry (ICC) analysis. ICC was performed according to R.T.U. Vectastain 
Universal Elite ABC kit (PK 7200) kit from VectorLabs, using R.T.U Normal Horse Serum to avoid 
unspecific reactions, a biotinilated secondary antibody (R.T.U. Biotinylated Universal Antibody) 
and a Peroxidase Substract Kit (Vector SK-4100). Primary antibodies Collagen I (MAB339, 
Chemicon) and Osteocalcin (Ab13418, Abcam) were prepared using a 1/100 dilution.  
 
 
III.3.4. Statistical Analysis 
 
Statistical analysis was carried out using One Way ANOVA test and Tukey's Multiple 
Comparison Test (p<0.05). All results are presented as mean  standard deviation.  
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In the present study controls of the experiment were considered using PCL nanofiber 
meshes without TCPs.  
 
 
III.4. Results and Discussion 
 
Goat model is a popular animal model for orthopedics, whose stem cells can be applied to 
autologous approaches in bone TE. Previous studies have demonstrated the potential of 
gBMSCs to differentiate into the osteogenic lineage[23-25]. Furthermore, PCL nanofiber 
meshes, used in this study as positive controls for determining the applicability and 
improvement of multi-layered PCL-TCP scaffolds in bone-related strategies, have shown to 
promote cellular adhesion, proliferation and osteogenic differentiation of mesenchymal stem 
cells[26]. 
Multi-layered composite scaffolds were achieved through the dispersion of TCP onto 
electrospun PCL fibers. The calcium phosphate obtained from the chemical reaction presented 
a rhombohedrical structure, typical of -TCP, and the vibrational bands associated to the 
phosphate groups, as demonstrated by FTIR (Figure III.4.1) and XRD (Figure III.4.2) data.  
 
 
Figure III.4.1 - FTIR-ATR analysis of multi-layered scaffolds. Membranes of PCL nanofiber mesh 
(PCL) were used as controls. 
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Figure III.4.2 - XRD analysis of multi-layered PCL-TCP scaffolds. Membranes of PCL nanofiber 
mesh (PCL) were used as controls. 
 
SEM observation indicated a dispersion of TCPs granules within the electrospun PCL 
nanofibers structure, in the produced composite scaffolds (Figure III.4.3).  
 
 
Figure III.4.3 – SEM analysis of multilayer scaffolds; the upper SEM micrographs refer to the 
PCL-TCP multilayer scaffolds while the lower pictures correspond to the control of PCL 
nanofiber mesh (left to right: 100 x, 300 x and 1000 x magnifications). 
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A random distribution was observed not only with TCPs granules but also in nanofibers of 
the mesh-like stratified structure. Adittionally, TCPs mineral particles were integrated within 
the structure of multi-layered nanofiber scaffolds.  
In our study, gBMSCs attached, and proliferated into the PCL-TCP scaffolds, both in static 
and dynamic conditions, as well as in basal and osteogenic culture conditions. Similar results 
were achieved in control PCL meshes. 
In terms of proliferation, gBMSCs showed two different behaviors (p>0.05); cell 
proliferation in PCL meshes increased with time in culture, while in PCL-TCP constructs, cells 
increased up to 14 days in basal or osteogenic culture conditions and then, the cell number 
decreased at week 3 (Figure III.4.4). This decreasing tendency of proliferation in PCL-TCP 
scaffolds may be a result of the osteogenic differentiation process, undertaken by the gBMSCs. 
Some studies indicate an inverse relationship between proliferation and differentiation of 
osteoprogenitor cells during bone formation[27].  
 
Figure III.4.4 – gBMSCs proliferation given by DNA quantification was assessed onto PCL-TCP 
scaffolds and PCL membranes (control) after 7, 14 or 21 days in basal or osteogenic media in 
either static (st) or dynamic (dyn) conditions. Symbols *, **, and *** denote study groups with 
statistically significant differences (p<0.05), as using One Way ANOVA method. 
 
ALP activity levels (Figure III.4.5) were not detected for samples cultured for 7 or 14 days, 
probably due to low basal concentrations of ALP enzyme in the samples.  
The ALP/DNA ratio in PCL meshes cultured under dynamic conditions using osteogenic 
media is very similar to that found for PCL-TCP constructs cultured under static conditions in 
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the same medium, after 3 weeks in culture. Nevertheless, ALP is highly expressed in PCL-TCP 
constructs cultured under dynamic culture conditions in osteogenic medium as compared to 
all the remaining study groups (p<0.05). ALP activity data indicated a positive and synergistic 
effect of TCPs and mechanical stimulation on the formation of ECM by osteogenically 
differentiated gBMSCs.  
 
Figure III.4.5 – gBMSCs osteogenic differentiation given by ALP/DNA ratio was assessed onto 
PCL-TCP scaffolds and PCL membranes (control) after 7, 14 or 21 days in basal or osteogenic 
media in either static (st) or dynamic (dyn) conditions. Symbols *, and ** denote st groups 
with statistically significant differences (p<0.05), as using One Way ANOVA method. 
 
Furthermore, to confirm gBMSCs differentiation onto PCL-TCP scaffolds, osteogenic 
phenotype characterization was assessed by immunocytochemistry analysis for type I collagen 
and osteocalcin (OCa), and alizarin red staining for calcium detection, after 21 days in culture 
(Figure III.4.6). 
Collagen I is the major protein present in bone ECM. All PCL-TCP scaffolds seeded with 
gBMSCs were positively stained for Collagen I, although a more intense immunostain was 
observed in constructs cultured under dynamic conditions (Figure III.4.6). In gBMSC-PCL 
meshes (control), collagen I was more intense in basal medium culture. These results showed 
that a collagen I-rich ECM is being produced by gBMSCs either in PCL-TCP scaffolds or PCL 
meshes. 
In addition to a collagen matrix, a calcified milieu is an important part of the native bone 
tissue. Osteocalcin (OCa) is a non-collagenous protein, produced by osteoblasts that 
participates in the matrix mineralization of bone[28]. OCa was found to be present in gBMSC-
PCL-TCP constructs under dynamic environment, while in static cultures, OCa was only 
detected in the presence of constructs cultured in osteogenic medium. Furthermore, in 
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gBMSC-PCL meshes (control), OCa was only detected under static conditions in osteogenic 
differentiation medium (Figure III.4.6). 
 
Figure III.4.6 – Osteogenic phenotype characterization of gBMSCs seeded onto PCL-TCP 
scaffolds after 21 days in culture with basal or osteogenic media, either in static or dynamic 
conditions. Immunocytochemistry (ICC) was performed for Collagen I and Osteocalcin, as well 
as Alizarin Red staining. Insets represent PCL meshes (control) under the same conditions. 
 
Alizarin red staining was assessed to detect calcium ions, essential for the ECM 
mineralization. After 21 days in culture, gBMSC-PCL-TCP constructs exhibited a stronger stain 
when compared to gBMSC-PCL membrane controls (Figure III.4.6). The stain was more intense 
under dynamic conditions, both in basal or osteogenic media, as well as in constructs cultured 
in osteogenic differentiation medium in a static environment, indicating the production of 
calcified ECM.  
OCa and alizarin red staining followed a similar pattern in gBMSC-PCL-TCP constructs, which 
confirms the formation of a mineralized ECM, as OC is thought to bind to hydroxyapatite in a 
calcium-dependent manner[29], during the natural development of bone.  
Even if in all culture conditions, gBMSC-PCL-TCP constructs expressed osteogenic markers 
to some extent, the combination of these markers was stronger in dynamic conditions, 
especially for Alizarin Red staining. It is important to highlight that mineralization nodules 
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(observed as darker red spots) are visible only in the dynamic culture conditions and in the 
multilayer composite scaffolds, corroborating the previous results of ALP activity. The fact that 
ALP, an enzyme associated to ECM development and maturation[27], is not expressed by cells 
seeded onto PCL-TCP constructs in basal/dynamic environment is quite interesting, since these 
cells are able to produce calcified ECM (Figure III.4.6). Salasznyk et al. reported the bone 
isoform of ALP is found only in osteogenic supplemented mesenchymal stem cells[30], which 
justifies the basal ALP activity levels in basal/dynamic environment, despite the mineralization 
of ECM. In their study, cells in basal medium did not differentiate when ALP was not 
expressed; but the presence of PCL-TCP constructs could stimulate gBMSCs to select a 
different pathway in the absence of osteogenic medium that could be also encouraged by the 
dynamic environment, as calcified ECM is reduced in basal/static conditions.  Furthermore, in 
the presence of PCL-TCP scaffolds, gBMSCs achieved osteogenic differentiation and ECM 
mineralization even in the absence of osteogenic supplements after 3 weeks in culture.  
Mechanical stimuli are required to maintain a healthy bone, and described to induce the 
up-regulation of osteogenic marker genes and increase matrix mineralization of the ECM in the 
presence of substrates coated with ECM proteins[31]. Furthermore, cyclic mechanical 
stretching was also described to participate in an increased ALP activity and mineralized matrix 
deposition[31]. 
In our study, the particular structure of PCL-TCP scaffolds mimicking bone natural ECM, 
both in structure and composition, stimulated gBMSCs to produce ECM matrix (collagen I and 
OCa). Under dynamic conditions, the environment induced by PCL-TCP scaffolds is sufficient to 
promote osteogenic differentiation even in basal medium conditions. 
In summary, PCL-TCP scaffolds participate in the osteogenic process of gBMSCs, even in 
basal medium and static conditions. Nevertheless, the osteogenic potential is enhanced in 
dynamic environments, evidencing the synergistic effect of TCPs and mild mechanical 
stimulation in gBMSCs osteogenic phenotype. 
 
 
III.5. Conclusions 
 
The production of multi-layered PCL-TCP scaffolds was successfully achieved as well as the 
in vitro assessment of their application aiming at bone tissue strategies. Moreover, considering 
that bone ECM is essentially an organic-inorganic composite and nano-scaled organized, the 
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developed multi-layered composite can be a promising system in the regenerative medicine 
field.  
The results obtained suggest that the combination of PCL with calcium phosphates 
generated scaffolds with improved capacity to promote gBMSCs adhesion, proliferation, and 
expression of osteogenic phenotype, when compared to the synthetic polymer alone. 
Furthermore, the dynamic environment positively affected the gBMSCs behavior, and 
enhanced gBMSCs phenotypic expression and mineralized matrix synthesis. Interestingly, the 
synergistic effect of mild agitation and PCL-TCP scaffolds stimulated gBMSCs differentiation 
and production of a calcified ECM, even in the absence of osteogenic supplements from the 
culture medium. 
The development of PCL nanofibers with ceramic materials, in a multi-layered structure, is 
an innovative methodology with great potential for the development of more adequate 
scaffolds for bone tissue engineering approaches. 
 
 
 
III.6.  References  
 
1. Tsuji H, Ikada Y: Blends of aliphatic polyesters .1. Physical properties and morphologies of 
solution-cast blends from poly(DL-lactide) and poly(epsilon-caprolactone). Journal of Applied 
Polymer Science 1996, 60: 2367-2375. 
2. Bezwada RS, Jamiolkowski DD, Lee IY, Agarwal V, Persivale J, Trenkabenthin S, Erneta M, 
Suryadevara J, Yang A, Liu S: Monocryl(R) Suture, a New Ultra-Pliable Absorbable 
Monofilament Suture. Biomaterials 1995, 16: 1141-1148. 
3. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR: Biodegradable and bioactive porous 
polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials 2006, 27: 
3413-3431. 
4. Collins AM, Skaer NJV, Gheysens T, Knight D, Bertram C, Roach HI, Oreffo ROC, Von-Aulock S, 
Baris T, Skinner J, et al.: Bone-like resorbable silk-based scaffolds for load-bearing 
osteoregenerative applications. Advanced Materials 2009, 21: 75-78. 
5. Yang S, Leong KF, Du Z, Chua CK: The design of scaffolds for use in tissue engineering. Part I. 
Traditional factors. Tissue Eng 2001, 7: 679-689. 
6. Chen GP, Ushida T, Tateishi T: Scaffold design for tissue engineering. Macromolecular 
Bioscience 2002, 2: 67-77. 
7. Martins A, Reis RL, Neves NM: Electrospinning: processing technique for tissue engineering 
scaffolding. International Materials Reviews 2008, 53: 257-274. 
C 
Chapter III – Synergistic effect of scaffold composition and dynamic culturing environment in multi-layered systems 
for bone tissue engineering 
- 80 - 
 
8. Gupta D, Venugopal J, Mitra S, Giri Dev VR, Ramakrishna S: Nanostructured biocomposite 
substrates by electrospinning and electrospraying for the mineralization of osteoblasts. 
Biomaterials 2009, 30: 2085-2094. 
9. Srouji S, Kizhner T, Suss-Tobi E, Livne E, Zussman E: 3-D Nanofibrous electrospun 
multilayered construct is an alternative ECM mimicking scaffold. J Mater Sci Mater Med 2008, 
19: 1249-1255. 
10. Hosseinkhani H, Hosseinkhani M, Tian F, Kobayashi H, Tabata Y: Ectopic bone formation in 
collagen sponge self-assembled peptide-amphiphile nanofibers hybrid scaffold in a perfusion 
culture bioreactor. Biomaterials 2006, 27: 5089-5098. 
11. Ko EK, Jeong SI, Rim NG, Lee YM, Shin H, Lee BK: In vitro osteogenic differentiation of 
human mesenchymal stem cells and in vivo bone formation in composite nanofiber meshes. 
Tissue Eng Part A 2008, 14: 2105-2119. 
12. Ngiam M, Liao S, Patil AJ, Cheng Z, Yang F, Gubler MJ, Ramakrishna S, Chan CK: Fabrication 
of mineralized polymeric nanofibrous composites for bone graft materials. Tissue Eng Part A 
2009, 15: 535-546. 
13. Araujo JV, Martins A, Leonor IB, Pinho ED, Reis RL, Neves NM: Surface controlled 
biomimetic coating of polycaprolactone nanofiber meshes to be used as bone extracellular 
matrix analogues. J Biomater Sci Polym Ed 2008, 19: 1261-1278. 
14. Li WJ, Tuli R, Huang X, Laquerriere P, Tuan RS: Multilineage differentiation of human 
mesenchymal stem cells in a three-dimensional nanofibrous scaffold. Biomaterials 2005, 26: 
5158-5166. 
15. Shin M, Yoshimoto H, Vacanti JP: In vivo bone tissue engineering using mesenchymal stem 
cells on a novel electrospun nanofibrous scaffold. Tissue Eng 2004, 10: 33-41. 
16. Xin X, Hussain M, Mao JJ: Continuing differentiation of human mesenchymal stem cells and 
induced chondrogenic and osteogenic lineages in electrospun PLGA nanofiber scaffold. 
Biomaterials 2007, 28: 316-325. 
17. Li M, Mondrinos MJ, Gandhi MR, Ko FK, Weiss AS, Lelkes PI: Electrospun protein fibers as 
matrices for tissue engineering. Biomaterials 2005, 26: 5999-6008. 
18. Sefcik LS, Neal RA, Kaszuba SN, Parker AM, Katz AJ, Ogle RC, Botchwey EA: Collagen 
nanofibres are a biomimetic substrate for the serum-free osteogenic differentiation of human 
adipose stem cells. J Tissue Eng Regen Med 2008, 2: 210-220. 
19. Li C, Vepari C, Jin HJ, Kim HJ, Kaplan DL: Electrospun silk-BMP-2 scaffolds for bone tissue 
engineering. Biomaterials 2006, 27: 3115-3124. 
20. Zhang YZ, Su B, Venugopal J, Ramakrishna S, Lim CT: Biomimetic and bioactive nanofibrous 
scaffolds from electrospun composite nanofibers. Int J Nanomedicine 2007, 2: 623-638. 
21. Ogose A, Hotta T, Kawashima H, Kondo N, Gu W, Kamura T, Endo N: Comparison of 
hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone 
tumors. J Biomed Mater Res B Appl Biomater 2005, 72: 94-101. 
Chapter III – Synergistic effect of scaffold composition and dynamic culturing environment in multi-layered systems 
for bone tissue engineering 
- 81 - 
 
22. Yu X, Botchwey EA, Levine EM, Pollack SR, Laurencin CT: Bioreactor-based bone tissue 
engineering: the influence of dynamic flow on osteoblast phenotypic expression and matrix 
mineralization. Proc Natl Acad Sci U S A 2004, 101: 11203-11208. 
23. Oliveira JM, Rodrigues MT, Silva SS, Malafaya PB, Gomes ME, Viegas CA, Dias IR, Azevedo 
JT, Mano JF, Reis RL: Novel hydroxyapatite/chitosan bilayered scaffold for osteochondral 
tissue-engineering applications: Scaffold design and its performance when seeded with goat 
bone marrow stromal cells. Biomaterials 2006, 27: 6123-6137. 
24. Rodrigues MT, Gomes ME, Viegas CA, Azevedo JT, Dias IR, Guzón F, Reis RL: Tissue 
Engineered Constructs based on SPCL Scaffolds Cultured with Goat Marrow Cells: Functionality 
in Femoral Defects. J Tissue Eng Regen Med 2011, 5: 41-49. 
25. Leonor I, Rodrigues MT, Gomes ME, Reis RL: In Situ Functionalization of Wet-Spun Fibre 
meshes for Bone Tissue Engineering: One Step Approach. J Tissue Eng Regen Med 2011, 5: 
104-111. 
26. Binulal NS, Deepthy M, Selvamurugan N, Shalumon KT, Suja S, Mony U, Jayakumar R, Nair 
SV: Role of Nanofibrous Poly(Caprolactone) Scaffolds in Human Mesenchymal Stem Cell 
Attachment and Spreading for In Vitro Bone Tissue Engineering-Response to Osteogenic 
Regulators. Tissue Eng Part A 2010, 16: 393-404. 
27. Lian JB, Stein GS: Concepts of osteoblast growth and differentiation: basis for modulation 
of bone cell development and tissue formation. Crit Rev Oral Biol Med 1992, 3: 269-305. 
28. Lian JB, Stein GS, Stewart C, Puchacz E, Mackowiak S, Aronow M, Vondeck M, Shalhoub V: 
Osteocalcin - Characterization and Regulated Expression of the Rat Gene. Connective Tissue 
Research 1989, 21: 391-399. 
29. Lian J, Stewart C, Puchacz E, Mackowiak S, Shalhoub V, Collart D, Zambetti G, Stein G: 
Structure of the Rat Osteocalcin Gene and Regulation of Vitamin-D-Dependent Expression. 
Proceedings of the National Academy of Sciences of the United States of America 1989, 86: 
1143-1147. 
30. Salasznyk RM, Klees RF, Westcott AM, Vandenberg S, Bennett K, Plopper GE: Focusing of 
gene expression as the basis of stem cell differentiation. Stem Cells Dev 2005, 14: 608-620. 
31. Huang CH, Chen MH, Young TH, Jeng JH, Chen YJ: Interactive effects of mechanical 
stretching and extracellular matrix proteins on initiating osteogenic differentiation of human 
mesenchymal stem cells. J Cell Biochem 2009, 108: 1263-1273. 
 
 
 
   
- 82 - 
 
 
 
 
 
 
 
  
   
- 83 - 
 
 
 
 
 
 
 
 
Chapter IV 
 
FUNCTIONAL BIODEGRADABLE SCAFFOLDS FOR 
BONE TISSUE ENGINEERING: BIOACTIVITY PROFILE AND OSTEOGENIC 
DIFFERENTIATION OF MARROW MESENCHYMAL STROMAL CELLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based on the following publication: 
Rodrigues MT, Gröen N, Leonor I, Carvalho PP, Caridade S, Mano JF, Dias IR, van Blitterswijk 
CA, Gomes ME, and Reis RL, Functional biodegradable scaffolds for Bone Tissue Engineering: 
bioactivity profile and osteogenic differentiation of marrow mesenchymal stromal cells, 
submitted 
   
- 84 - 
 
  
 - 85 - 
 
 
Chapter IV  
FUNCTIONAL BIODEGRADABLE SCAFFOLDS FOR BONE TISSUE ENGINEERING: 
BIOACTIVITY PROFILE AND OSTEOGENIC DIFFERENTIATION OF MARROW MESENCHYMAL 
STROMAL CELLS 
 
 
IV.1.  Abstract 
Bone is a complex tissue, whose functionality can be restricted by trauma or degenerative 
diseases. Tissue engineering plays a key role in developing alternative strategies for bone 
regeneration, where scaffolds are expected to guide cellular distribution and colonization, 
similarly to the natural occurring communications between cells and tissue, and provide for 
needed support during tissue regeneration. 
Cell behavior has been suggested to be mostly based on the response to the surface 
composition and topography of the support material. Surface design of biodegradable 
polymers has gained much attention and specifically the coating of an apatite layer is 
considered to be a promising approach in bone strategies, in order to stimulate the direct 
bonding to living bony tissue. Incorporation of functional groups into the surface of polymeric 
scaffolds has been also described to be capable of inducing an apatite layer formation, critical 
for cellular and molecular communications to most of implanted scaffolds aiming functional 
tissue regeneration. Therefore, the present study focuses on a fiber mesh scaffold produced 
from a blend of starch with polycaprolactone (SPCL) using wet-spinning technology by a 
method that enables the in situ incorporation of silanol groups (Si-OH).  
These scaffolds (SPCL-Si) were designed into a well-defined 3D porous-architecture, highly 
interconnected, whose bioactive behaviour was analyzed considering its possible role in vivo 
during the regeneration/repair of bone tissue.  
Results indicated that apatite nucleation is induced by SiOH groups incorporated on SPCL 
scaffolds after incubation in simulated body fluid (SBF), confirming its bioactive properties. 
Cell culture assays indicated that goat marrow mesenchymal stromal cells not only 
proliferate and differentiate into the osteogenic phenotype onto SPCL-Si scaffolds, but seem to 
prefer SPCL-Si scaffolds alone rather than SPCL-Si scaffolds coated with an apatite layer formed 
by immersion in SBF. Therefore, SPCL-Si scaffolds present intrinsic properties to sustain in vitro 
osteogenic features, with great potential aiming at bone engineered approaches.  
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IV.2.  Introduction 
 
Bone is one of the major tissues affected by trauma, age- and metabolic-related diseases 
which translate to a decline in the quality of life of thousands of patients worldwide, thus 
representing a major medical and a socio-economical problem. The challenge stands for 
developing multifunctional biomaterials[1] to keep up with the process of tissue repair, and 
restoring functionality by promoting polymer interactions with in vivo biological materials, and 
substitute currently used autografts, the gold standard for bone replacement. 
The degree of success of bone tissue engineering (TE) approaches is greatly dependent on 
the intrinsic properties of materials used to obtain a biocompatible and biodegradable scaffold 
with osteoinductive, osteoconductive and osteogenic properties in order to assist the 
attachment, proliferation and differentiation of seeded cells toward the desired bone tissue[2, 
3].  
The use of starch blended with polycaprolactone to develop new scaffolds has been earlier 
investigated for TE, including bone regenerative approaches, demonstrating promising 
results[4-10]. However, all biodegradable polymers used within the TE field present a 
drawback for bone applications as they do not disclose osteoinductive properties, i.e., they are 
not able to induce bone formation by themselves[11]. 
It is well known that the direct bonding between an implant and bone may occur if a layer 
of bone-like mineral forms on the surface of the implant. Therefore, the focus on the surface 
design of biodegradable polymers has gained much attention as bioactivity can be induced on 
non-bioactive surfaces. Functional groups, as for example, silanol (Si‐OH), can be incorporated 
on the surface of polymeric scaffolds, inducing apatite nucleation in a simulated body fluid 
(SBF) solution, resulting in the formation of an apatite layer[12-15]. Although calcium and 
phosphorus are the main elements of inorganic bone, other ions, whose role has not been fully 
studied yet, are key elements in the functionality of the bone metabolic system. Among them, 
the silicium (Si), a trace element found in animals and human nutrition, has been associated 
with calcium in the mineralization process, and is extremely important in active calcification 
sites in young bones[16], as a regulatory factor in bone formation. Furthermore, silicon 
compounds stimulate the DNA synthesis in osteoblast-like cells[17], the osteogenic 
differentiation of mesenchymal stem cells[15, 18, 19], and the collagen I synthesis at a 
physiological level[19]. 
A previous work[15] by our group, described the development of bioactive fiber meshes, in 
a new reliable and economical methodology that enables the control of pore size, shape and 
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orientation, based on a simple wet-spinning technique, using a calcium silicate solution as 
coagulation bath. Si-OH groups were successfully incorporated on the surface of the fibers, 
thus allowing for obtaining a bioactive scaffold without the need for further coating or 
chemical modifications.  
The present study analyzed the effect of Si-OH groups on the structure and properties of 
wet spun SPCL fiber mesh scaffolds, in terms of bioactivity profile and biological response of 
bone marrow stromal cells (BMSCs), aiming at bone regeneration strategies. For this purpose, 
the bioactivity of wet spun SPCL fiber mesh scaffolds was assessed in vitro by means of soaking 
the samples in simulated body fluid (SBF), whose ion concentration is similar to those of 
human plasma. Dynamical-mechanical analysis was performed in order to assess the 
mechanical properties of SPCL and SPCL with silanol groups scaffolds under simulated 
physiological conditions. Bone marrow stromal cells have been described to have a great 
potential for bone regeneration strategies[20-23] as these cells can be easily guided into the 
osteogenic lineage, with applicability for autologous approaches[8, 24, 25]. The presence of 
seeded cells onto scaffolds should assist bridging the gap between structural support and in 
locus cellular and molecular communication towards functional tissue regeneration. Since 
apatite is naturally present in bone tissue, the apatite coating of the scaffold is expected to 
play an important role in the integration of the implant with the native tissue[19]. Thus, in this 
study it was also assessed the response of goat BMSCs towards the influence of the apatite 
coating on the surface of the scaffolds as compared with the bioactive uncoated wet spun 
starch‐PCL fiber mesh scaffolds with functionalized silanol groups, in terms of osteogenic 
differentiation and extracellular matrix maturation. 
 
 
IV.3.  Materials and Methods 
 
IV.3.1.  Materials 
 
A biodegradable thermoplastic blend of corn starch with polycaprolactone (30/70 wt %), 
SPCL, previously described in other works by our group[4, 5, 8-10] has been selected for this 
study. Chloroform (CHCl3) and methanol (CH3OH) were obtained from Sigma-Aldrich. 
Tetraethoxysilane (TEOS: Si(OC2H5)4) and calcium chloride (CaCl2) were obtained from 
Sigma-Aldrich. Ethyl alcohol (C2H5OH) was obtained from Panreac. 
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IV.3.2. Wet-spun fiber mesh scaffolds processing 
 
The polymer, a blend of corn starch with polycaprolactone (SPCL) was dissolved in 
chloroform at a concentration of 30 % (w/v). Then, the polymer solution was loaded into a 
disposable syringe, with a 0.8 mm internal diameter needle. A programmable syringe pump 
(KD Scientific, World Precision Instruments, UK) controlled the injection rate of the polymer 
solution in order to form the fiber mesh in the coagulation bath.  
Two different coagulation baths were used: (i) methanol, the control, and (ii) a calcium 
silicate solution with a molar ratio Si(OC2H5)4 / H2O / C2H5OH / HCl / CaCl2 of 1.0 / 4.0 / 4.0 / 
0.014 / 0.20 [15, 26], where the HCl was used as a catalyst. Control scaffolds in the methanol 
bath (SPCL scaffolds), were dried overnight at room temperature while fiber mesh scaffolds 
produced calcium silicate solution (SPCL-Si scaffold) were air dried at 60 ºC for 24 h.  
All scaffolds were cut into 5 mm diameter discs and sterilized by ethylene oxide. 
 
IV.3.3.  Evaluation of the in vitro bioactivity of wet-spun fiber mesh scaffolds 
 
The in vitro bioactivity tests of the SPCL and SPCL-Si wet-spun fiber meshes were carried 
out by soaking samples in 10 mL of acellular simulated body fluid (SBF) at 36.5 ºC for up to 7 
days. The SBF presents ions concentration similar to the one found in the human blood 
plasma[13, 27]. 
After each period of immersion the test samples were removed from SBF, washed with 
distilled water and dried at room temperature. The wet-spun fiber mesh scaffolds before and 
after bioactivity tests were analyzed by several techniques, as described in the sub-sections 
below.  
 
IV.3.3.1. Scanning electron microscopy (SEM)  
 
SEM with an attached energy dispersive electron probe X-ray analyser (EDS) (Leica 
Cambridge S360, UK) was used to observe the morphology of the wet-spun mesh scaffolds 
(SPCL and SPCL-Si) after the assays.  
Previously to EDS and SEM analysis, sample surfaces were carbon coated (Fisons 
Instruments, Evaporation PSU CA508, UK) and gold sputtered (Fisons Instruments, Sputter 
Coater SC502, UK), respectively. 
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IV.3.3.2. Thin-film X-ray diffraction (TF-XRD) 
 
TF-XRD was performed using a RINT2500 equipment (Rigaku Co., Japan) aiming to identify 
crystalline phases present on the polymeric wet-spun fiber mesh, with or without silanol 
groups, after immersion in SBF (results were compared to non immersed controls), and to 
characterize the crystalline/amorphous nature of the calcium phosphate films.  
The data was collected by 2 scan method with 1º as incident beam angle using CuK X-ray 
line and a scan speed of 0.05 º/min in 2. 
 
IV.3.3.3. Micro-computed tomography (µ-CT) analysis: 
 
Micro-CT analysis was conducted to evaluate morphology, porosity, pore interconnectivity 
as well as mean pore size, and mean fiber thickness after bioactivity assays, using a high-
resolution μ-CT, Skyscan 1072 scanner (Skyscan, Kontich, Belgium).  
X-ray scans were performed in triplicate using a resolution of pixel size of 5.86 µm and 
integration time of 1.9 sec. The X-ray source was set at 40 keV of energy and 248 μA of 
current. Approximately 400 projections were acquired over a rotation range of 180º with a 
rotation step of 0.45º. Data sets were reconstructed using standardized cone-beam 
reconstruction software (NRecon v1.4.3, SkyScan).  
Representative data sets of 200 slices were segmented into binary images with a dynamic 
threshold of 50 to 255 (grey values) in order to identify the organic and inorganic phase. This 
data was used for morphometric analysis (CTAnalyser, v 1.5.1.5, SkyScan) and to build 3D 
models (ANT 3D creator, v2.4, SkyScan).  
 
IV.3.3.4. Dynamic mechanical analysis (DMA): 
 
Viscoelastic measurements were performed using a TRITEC8000B DMA from Triton 
Technology (Belgium)[14], equipped with a tensile mode. SPCL and SPCL-Si scaffolds were cut 
in 5 mm diameter discs to meet the distance between the clamps. The geometry of the 
samples was measured, samples clamped in the DMA apparatus and then immersed in a PBS 
solution. DMA spectra were obtained during a frequency scan between 0.1 and 25 Hz. The 
experiments were performed under constant strain amplitude (30 µm). A static pre-load of 0.7 
N was applied during the test to keep the sample tight. During the DMA analysis, scaffolds 
were immersed in a liquid bath in a Teflon® reservoir. Three samples were used per condition. 
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IV.3.3.5.  Induced-coupled plasma emission spectroscopy (ICP) 
 
Elemental concentrations were measured in SBF, before and after immersing wet-spun 
fiber meshes (with or without Si groups), using inductively coupled plasma atomic emission 
spectrometry (ICP: JY2000-2, Jobin Yvon, Horiba, Japan). 
Samples were collected at the end of each test period, filtered with a 0.22 µm filter and 
kept at -80ºC until usage; for each condition and immersion time triplicate samples were 
analyzed. 
 
IV.3.4.  Cell culture study 
 
In a previous study[15], SPCL (control) and SPCL-Si scaffolds produced by wet spinning 
were seeded with goat bone marrow stromal cells (gBMSCs) in osteogenic medium for up to 
14 days. Preliminary data indicated that gBMSCs preferred SPCL-Si for cellular proliferation and 
osteogenic differentiation, evidencing the importance of silanol groups in SPCL-Si scaffolds for 
bone strategies. Thus, the present study focused on assessing the response of gBMSCs to SPCL 
scaffolds functionalized with silanol groups as compared to SPCL-Si pre-coated with an apatite 
layer, obtained by 7 days of immersion in SBF. 
 
IV.3.4.1.  Harvesting and seeding gBMSCs onto wet-spun fiber mesh scaffolds 
 
Goat bone marrow mesenchymal stromal cells (gBMSCs) were harvested from the iliac 
crests of adult goats and cultured in DMEM (Dulbecco Modified Eagle Medium, Sigma) 
supplemented with 10 % foetal bovine serum (Gibco) and 1% antibiotic/antimicotic solution 
(Gibco) and cryopreserved. Cells were thawed, expanded and sub-cultured twice (2 Pa) before 
being seeded onto SPCL-Si scaffolds or SPCL-Si scaffolds after a 7 day incubation in SBF (SPCL-
Si-7SBF) at a concentration of 100,000 cells/scaffold. After seeding, cells were cultured in 
alpha-MEM (Sigma) and in the presence of osteogenic supplements, namely 10-8 M 
dexamethasone (Sigma), 50 g/ml ascorbic acid (Sigma), 10 mM -glycerophosphate (Sigma) 
for 7 and 14 days. 
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IV.3.4.2.  Cell viability assay 
 
The MTS test (Promega, USA) was used to assess cell viability in SPCL-Si or SPCL-Si-7SBF 
scaffolds seeded with gBMSCs, after 7 and 14 days of culture.   
After each culturing end point, cells were rinsed in PBS and then incubated in a MTS 
solution (1 fraction of MTS reagent + 5 fraction of basal culture medium without phenol red 
(Sigma)) for 3 hours at 37 ºC in a 5% CO2 environment. Afterwards, absorbance was read at 
490nm in a microplate ELISA reader equipment (BioTek). 
 
IV.3.4.3.  Cell proliferation assay 
 
Proliferation of gBMSCs seeded onto constructs was also analyzed by double strand DNA 
quantification (dsDNA). For this purpose, a fluorimetric dsDNA quantification kit (PicoGreen, 
Molecular Probes) was used. The fluorescence was read using a microplate ELISA reader 
(BioTek) at an excitation of 485/20 nm and an emission of 528/20 nm. 
 
IV.3.4.4.  ALP assay 
 
ALP activity has been considered an early osteogenic marker to assess osteogenic 
differentiation of gBMSCs seeded onto scaffolds under study. A substrate solution was added 
to each sample consisting of 0.2 % (wt/v) p-nytrophenyl phosphate (Sigma, USA) in a substrate 
buffer with 1 M diethanolamine HCl (Merck, Germany), at pH 9.8. Samples were then 
incubated in the dark for 45 minutes at 37 ºC. After the incubation period, a stop solution (2 M 
NaOH (Panreac, Spain) plus 0.2 mM EDTA (Sigma, USA)), was added to each well containing 
the sample.  
Standards were prepared with p-nytrophenol (10 µmol.ml-1) (Sigma, USA). Samples and 
standards were prepared in triplicates. The absorbance was read using a microplate ELISA 
reader (BioTek) at 405nm. 
 
IV.3.4.5. SEM 
 
gBMSCs morphology after culturing onto SPCL-Si and SPCL-Si-7SBF fiber meshes was 
observed by SEM. Before sputter coat with gold, cell-scaffold constructs were rinsed in PBS, 
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fixed in a 2.5% solution of gluteraldehyde (Sigma) overnight, dehydrated in a series of ethanol 
concentrations and air dried. 
  
IV.3.5.  Statistical Analysis 
 
Results from ICP and DMA tests as well as biology assays are presented as means  
standard deviation. 
Statistical analysis was carried out using two Way ANOVA test was also applied to check the 
existence of statistical differences between sample groups (p<0.001, or p<0.05). 
 
 
IV.4.   Results and Discussion 
 
IV.4.1.  Bioactivity assessment 
 
To understand the mechanism of apatite formation on bioactive materials, Kokubo et 
al.[13, 28] proposed a protein-free and acellular simulated body fluid (SBF) with pH 7.40 and 
ionic composition (Na+ 142.0, K+ 5.0, Ca2+ 2.5, Mg2+ 1.5, Cl- 147.8, HCO3
- 4.2, HPO4
2- 1.0, SO4
2- 
0.5 mM) similar to the ones found in the human blood plasma. The bioactivity of artificial 
materials is commonly evaluated by examining the formation of apatite on the surface of the 
scaffold after immersion in SBF.  
The figure IV.4.1 exhibits the TF-XRD patterns obtained for the SPCL fiber meshes produced 
by wet-spinning, and SPCL fiber mesh functionalized with silanol groups (SPCL-Si), after soaking 
in SBF for 7 days. 
The TF-XRD patterns of the surface of the SPCL-Si sample, after a 7 day immersion in SBF, 
exhibit several broad diffraction peaks, whose position and intensities can be  assigned to an 
apatite-like phase (ASTM JCPDS 9-432) (Figure IV.4.1). The peaks in 2 and their 
correspondence to the diffraction planes of apatite are: 10.82º (1 0 0), 25.87º (0 0 2), and 
31.75º (2 2 1). The apatite film formed presents low crystallinity, as the apatite peaks were 
comparatively broader than the crystalline apatite. 
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Figure IV.4.1 - TF-XRD patterns of SPCL fiber meshes produced by wet-spinning, where a 
calcium silicate solution was used as a coagulation bath (SPCL-Si), and after 7 days of 
immersion in SBF (SPCL-Si 7d in SBF). SPCL was used as control. Apatite characteristic peaks are 
represented in the spectrum with black dots (). 
 
SPCL scaffolds, obtained by precipitation in methanol, could not induce the formation of an 
apatite layer even after 7 days in SBF. Conversely, in SPCL-Si scaffolds, obtained by 
precipitation in a calcium silicate bath, the formation of an apatite layer can be observed after 
only 1 day of immersion in a SBF solution, despite the fact that, after that time, the scaffold 
was not completely covered with the apatite layer, as observed by SEM (Figure IV.4.2).  
Micro-CT analysis was used to follow up the formation and growth of an apatite layer (blue 
color) as function of time (Figure IV.4.2). Scaffold porosity, around 49.77 %, is similar to the 
values found before soaking the scaffolds in SBF, 56.84 %. As the immersion time in SBF 
increases, the apatite layer becomes more dense and compact but still homogeneously 
distributed, and thus without compromising the overall morphology and interconnectivity of 
the 3D-fiber mesh scaffolds.  
These results clearly indicate that the presence of functional silanol groups is responsible 
for apatite formation in SPCL scaffolds after immersion in SBF solution (Figure IV.4.2). 
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Figure IV.4.2 - Morphological characterization by means of micro-CT and SEM micrographs of 
SPCL-Si scaffolds before and after 1, 3 or 7 days of immersion in SBF. Control (CTR) scaffolds of 
SPCL (without silanol groups) after 7 days in SBF. The blue color regions in micro-CT images 
correspond to the apatite deposition.  
 
The concentrations of calcium, phosphorus and silicon in the SBF solution, after immersion 
of SPCL with and without Si-OH groups, measured by ICP analysis, are shown in Figure IV.4.3.  
 
Figure IV.4.3 - Changes in calcium (Ca), phosphorus (P) and silicon (Si) concentration in the SBF 
solution after different immersion periods of the SPCL or SPCL-Si scaffolds. Symbols o and + 
denote study groups with statistically significant differences (o=p<0.001 and +=p<0.05, 
respectively), as using Two Way ANOVA method. 
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For up to 7 days, an increment in silicon concentration was observed for SPCL-Si scaffolds. 
This increment is related to the release of silicon ions from the SPCL-Si fiber mesh scaffold, 
leading to the formation of Si-OH groups, responsible for the apatite nucleation. These results 
indicate that an organized arrangement of functional groups, Si-OH groups, on SPCL-Si fiber 
mesh scaffold is the key point to render a bioactive behavior, as the classic ceramic materials, 
such as Bioglass[29]. For example, when this bioactive ceramic is soaked in SBF, the first 
reaction of this type of bioactive glass surface is ion exchange, in which Ca2+ and Na+ in the 
glass exchange for H3O
+ in the solution, resulting in an increase in pH of the solution as well as 
in the formation of a hydrated silica gel layer[29]. The formation of hydrated silica gel layer on 
the surface of Bioglass, which is abundant in Si – OH groups, provides favourable sites for the 
calcium phosphate nucleation[30, 31]. Furthermore, the water molecules in the SBF react with 
the Si-O-Si bond to form additional Si-OH groups[32]. Then, these functional groups induce 
apatite nucleation, and the released Ca2+ and Na+ ions accelerate apatite nucleation by 
increasing of the ionic activity product (IAP) of apatite in the fluid. Also, Tanashi et al.[33] 
reported that Si-OH groups were effective in apatite nucleation. Therefore, the mineralization 
induced by the bioactive ceramics is due to the formation of specific surface functional groups 
such as Si-OH, which serve as effective sites for heterogeneous nucleation of calcium 
phosphate[34]. Additionally, an increase of IAP in the surrounding fluid could thereby promote 
the calcium phosphate nucleation and growth on the surface of bioactive ceramics[34]. 
In the case of SPCL scaffolds, no traces of Si element were detected in the control. For SPCL-
Si, the differences in Si concentration are not statistically significant (p>0.05) along consecutive 
soaking periods, since the amount of Si released is just enough to promote the formation of 
the apatite layer, detected by TF-XRD and µ-CT. 
A slightly decrease in the calcium concentration is observed for the first 24 hours, which 
can be explained by the release of calcium ions available in the silica phase bond to the SPCL 
(Figure IV.4.3). This release into the SBF can lead to an increase of the ionic activity product of 
the surrounding fluid with respect to apatite. The Si-OH groups induced the apatite nucleation, 
and the increased ionic activity product accelerates the nucleation rate of apatite. Once 
apatite nuclei are formed, they can spontaneously grow into a uniform layer by consuming the 
calcium and phosphate ions from the SBF, since SBF is already highly supersaturated with 
respect to apatite[35].  
As the soaking time in SBF increases, the calcium and phosphorus concentrations decreased 
gradually, as the apatite layer is forming on the fiber mesh scaffolds while consuming the 
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calcium and phosphate ions in SBF solution. The decrease in Ca and P concentrations is more 
evident in SPCL-Si scaffolds (p<0.001) after 3 and 7 days in the SBF solution. 
In summary, the results obtained from the in vitro bioactivity tests clearly indicated that the 
presence of Si-OH functional groups in wet spun SPCL fiber meshes is a prerequisite for the 
apatite formation in simulated body fluid. 
 
IV.4.1.1. DMA analysis 
 
Figure IV.4.4 presents the dynamical mechanical behavior of the SPCL and SPCL-Si scaffolds 
with the variation of the frequency, assessed under simulated physiological condition, i.e., in a 
hydrated environment and at 37 ºC [36-38]. The storage modulus (E’) of all samples tends to 
increase with increasing frequency as observed in Figure IV.4.4.  
However, for the SPCL samples E’ increases from 5.54 MPa to 7.04 MPa while for the SPCL-
Si samples, E’ increases (p<0.001) from 11.38 MPa to 14.81 MPa indicating that the SPCL-Si 
possess a higher stiffness than SPCL’s. This is possibly explained by the fact that the in situ 
functionalization improves the mechanical properties of the scaffold.  
Thus, these results demonstrate that the described methodology allows obtaining bioactive 
polymeric scaffolds without prejudice to its mechanical properties. 
 
 
Figure IV.4.4 - Variation of the storage modulus as a function of frequency between 0.1 and 15 
Hz after equilibration at 37 ºC with the samples immersed in PBS solution. 
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IV.4.2. Biological assays 
 
Results obtained from previous experiments showed that the presence of silanol groups in 
SPCL scaffolds enhanced the proliferation and osteogenic differentiation of gBMSCs[15], 
evidencing the importance of these groups for bone TE strategies. Since studies on SPCL vs 
SPCL-Si wet spun scaffold were already conducted, in our study we did not include SPCL as 
experimental control, and focus the evaluation on the effect of pre-coating SPCL-Si scaffolds 
with an apatite layer.   
In general, gBMSCs kept a good cell viability and proliferation rate when seeded onto both 
types of scaffolds. Nevertheless, viability levels are higher in the presence of SPCL-Si scaffolds 
alone, without the apatite coating, which tends to increase with the culturing time (p<0.01) 
(Figure IV.4.5).  
 
 
Figure IV.4.5 - Results obtained from the MTS test performed on gBMSCs seeded onto SPCL-Si 
scaffolds (SPCL-Si) and SPCL-Si scaffolds pre-coated with an apatite layer (SPCL-Si-7SBF),  and 
cultured in osteogenic medium for 7 or 14 days. Symbol * denote study groups with 
statistically significant differences (p<0.05), as using Two Way ANOVA method. 
 
The ALP/dsDNA ratio represents the amount of activity of ALP produced by the cells seeded 
on the scaffolds. In SPCL-Si previously coated with an apatite layer and seeded/cultured with 
gBMSCs, the ALP/dsDNA values are lower and decreased from day 7 to day 14, while in SPCL-Si 
constructs, ALP/DNA ratio seems to be stabilized and maintained through the culturing time 
(Figure IV.4.6).  
Since ALP is a glycoprotein associated with the formation and maturation of the 
extracellular matrix[39], lower ALP levels indicate that the presence of an apatite layer on the 
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surface of SPCL-Si scaffolds may interfere with the development and maturation of the ECM 
produced by gBMSCs in SPCL-Si scaffolds. Also, and considering the expression of this 
osteogenic marker, cells seeded onto SPCL-Si and SPCL-Si pre-coated scaffolds are likely to be 
at different stages of the osteogenic process. 
 
Figure IV.4.6 - Results from ALP assays performed on seeded onto SPCL-Si scaffolds (SPCL-Si)  
and SPCL-Si pre-coated with an apatite layer layer (SPCL-Si-7SBF) and, after culture in 
osteogenic medium for 7 or 14 days. 
 
In SEM micrographs (Figure IV.4.7), cells are shown to be more proliferative and 
homogeneously distributed onto SPCL-Si scaffolds both after 7 and 14 days in osteogenic 
culture. Furthermore, cells tend to proliferate by bridging between fibres, yet without closing 
the pores. 
 
Figure IV.4.7 - SEM pictures showing the gBMSCs morphology when seeded onto SPCL-Si 
(SPCL-Si) scaffolds and SPCL-Si scaffolds pre-coated with apatite (SPCL-Si-7SBF), followed by 
culture in osteogenic medium for 7 or 14 days. Inset micrographs refer to scaffolds, SPCL-Si 
(C2) and SPCL-Si pre-coated (C4) after 7 days in osteogenic medium. 
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Although calcium phosphate coating is considered to be excellent in promoting cell 
adhesion and stimulating cells into the osteogenic phenotype, the viability, colonization of the 
scaffolds, and osteogenic related markers indicate that the presence of silanol groups has a 
stronger positive impact in cells response. This was confirmed by the results obtained from all 
assays performed on samples for both for 7 and 14 days in culture. 
Images obtained from the micro-CT analysis performed on constructs cultured for 14 days 
in osteogenic medium, showed the formation of a mineralized matrix in SPCL-Si scaffolds 
indicating that the presence of silicium improved the deposition of a calcified matrix produced 
by gBMSCs (Figure IV.4.8). 
 
 
Figure IV.4.8 - Assessment of calcified matrix production by gBMSCs seeded onto SPCL-Si 
scaffolds (SPCL-Si) after 14 days in osteogenic medium by µCT analysis. 
 
Cells seeded onto SPCL-Si scaffolds seem to prefer the superficial silicium molecules to 
proliferate and to support the biomimetic growth of natural apatite for ECM synthesis. The 
favorable results of SPCL-Si alone may indicate that the mechanism involving silicium is likely 
to be more similar to the in vivo natural process than the SBF coating. Although silicium exists 
in minimal amounts in bone, has an important role in bone metabolism and osteoblast 
behaviour in terms of proliferation and differentiation[15-19]. 
These results also explain the ALP activity levels of gBMSCs seeded on SPCL-Si scaffolds as 
osteogenesis in guided bone regeneration has been described to be preceded by a localized, 
marked expression of ALP in an organized connective tissue environment[40].  
The development of an apatite layer in SPCL-Si scaffold is atypical for biodegradable 
polymeric scaffolds, which has been commonly associated to ceramic materials[41]. Moreover 
the results suggest that SPCL-Si scaffolds interact more actively with cells without the presence 
of a calcium phosphate coating, confirming the osteoconductive properties associated to 
scaffolds containing silicium[15, 42] aiming at bone tissue strategies. 
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IV.5.  Conclusions 
 
In this study, the potential of functionalized wet-spun fibers for bone TE was assessed by 
physical, chemical and biological characterization.  
The precipitation of SPCL in the calcium silicate solution leads to an incorporation of Si-OH 
groups in the structure of SPCL-Si scaffold and SPCL-Si scaffolds were shown to induce apatite 
nucleation (but not SPCL scaffolds) when incubated with SBF, confirming its bioactive 
properties. Dynamic mechanical analysis showed that SPCL-Si scaffold present higher stiffness 
than SPCLs, thus improved mechanical properties which are likely to be beneficial for bone 
related applications. Thus, the developed wet spun fiber meshes with incorporated Si-OH 
functional groups combine the properties of classical bioactive ceramics, and the degradability 
of an organic polymer.  
The current work also confirms that not only Si–OH groups improve cellular functionality 
towards the osteoblastic phenotype, evidencing osteogenic and osteoconductive properties, 
but gBMSCs seems to prefer SPCL-Si scaffolds instead of SPCL-Si scaffolds coated with an 
apatite layer. The results obtained in SPCL-Si-gBMSC constructs may be related to the 
biological importance of silicium in bone metabolic processes, underlying the potential of 
SPCL-Si scaffolds for bone regeneration strategies.  
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V.  
V.1.  Abstract 
 
The development of osteochondral (OC) tissue engineered interfaces would be a novel 
treatment for traumatic injuries and aging associated diseases that affect body joints. This 
study reports the development of a bilayered osteochondral construct based on biodegradable 
and natural based polymers. Amniotic fluid-derived stem cells (AFSCs) were either 
differentiated into cells of the osteogenic lineage after seeding onto starch-polycaprolactone 
(SPCL) scaffolds or into cells of the chondrogenic lineage after encapsulation in agarose gels. 
After these two constructs were assembled into a single construct, this bilayered system was 
cultured for 1 or 2 weeks in OC-defined culture media containing bone and cartilage growth 
factors (glycerol-2-phosphate, L-ascorbic acid, dexamethasone, and sodium pyruvate, ITS, L-
proline, respectively). Additionally, the effect of the presence or absence of insulin-like growth 
factor-1 (IGF-1) in the culture medium was assessed. Cell viability and expression of bone- and 
cartilage-specific markers were analyzed in order to determine the influence of the culture 
media on cell phenotype. The results indicated that, after osteogenic differentiation, AFSCs 
that had been seeded onto SPCL scaffolds did not require OC medium to maintain their 
phenotype. In fact, they produced a protein-rich, mineralized extracellular matrix (ECM) for up 
to 2 weeks. However, AFSCs differentiated into chondrocyte-like cells appeared to require OC 
medium, but not IGF-1, to synthesize an ECM and maintain the chondrogenic phenotype. Thus, 
the results obtained show that IGF-1 was not essential for creating osteochondral constructs 
with AFSCs, and the OC supplements used appear to be quite important to generate cartilage 
in long-term tissue engineering approaches for osteochondral interfaces. In summary, this 
study suggests that constructs generated from agarose-SPCL bilayered scaffolds containing 
pre-differentiated AFSCs may be useful for potential applications in regeneration strategies for 
damaged or diseased joints. 
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V.2.  Introduction 
 
Osteochondral (OC) interfaces are one of the most susceptible areas in the human body to 
traumatic injuries and aging associated diseases, such as, for instance, osteoarthritis[1-3]. 
Understanding and mimicking the complexity of the OC system is critical for designing a 
successful tissue engineering approach that can restore the functionality of a joint. However, 
bone and cartilage, which are the tissues that make up the OC interface, have different 
molecular compositions and cellular organizations, and consequently, differences in structural 
and mechanical properties between these tissues. Thus, current tissue engineering strategies 
are hampered by the difficulties inherent in designing a seamless interface between these two 
distinct tissues. 
First, the ideal cell source for OC engineering strategies has not yet been found. The cell 
source should be proliferative, yet it should possess the phenotypic plasticity to differentiate 
into the various cell types that make up the OC interface. In addition, the cells should be able 
to maintain the differentiated phenotype in the presence of other cell types and after removal 
of the selective differentiation medium used in culture. The amniotic fluid has been recently 
appointed as a source of stem cells[4, 5, 6]. Amniotic fluid-derived stem cells (AFSCs) have the 
capacity to differentiate along both the chondrogenic[4, 5] and osteogenic[4] lineages. 
Importantly, they also share certain phenotypic characteristics with both adult and embryonic 
stem cells[6], and they have shown to be multipotential cells with no expansion limitations[4]. 
Also, the use of AFSCs does not raise the ethical concerns that are associated with the use of 
embryonic stem cells for research and therapy[6, 7]. 
OC interfaces are exposed to a number of different in vivo stresses and strains that result 
from the patient’s daily activities and movements. Therefore, any cells used for OC tissue 
engineering must be supported by a scaffold that can withstand these stresses while 
regeneration takes place. In addition to providing mechanical support, a scaffold for OC 
regeneration should generate an efficient and integrated interface which enables different cell 
types to communicate and interact while keeping these various cells and their functions in the 
proper structural compartment.  
Agarose gels have previously been used for cell culture and cartilage tissue engineering 
strategies[8-10]. The soft, flexible structure of this natural based gel recreates a 3D 
environment suitable for chondrocyte maintenance[11] as well as the differentiation of 
mesenchymal stem cells (MSCs) into the chondrogenic lineage[11]. In contrast, SPCL scaffolds, 
which are a blend of starch and polycaprolactone, have been previously used in tissue 
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engineering strategies designed for bone regeneration and replacement[12-15], as well as for 
cartilage applications[16, 17]. SPCL scaffolds are biodegradable and biocompatible, and they 
are based on naturally occurring materials. These scaffolds support the adhesion and 
proliferation of several cell types, including endothelial[12] and stem cells[13]. Furthermore, 
these scaffolds assist bone neoformation in vivo, especially when seeded previously with 
cells[13]. 
In addition to physical support (scaffold) and a biological interface (cells), the biochemical 
factors involved in stimulating cell communication, differentiation, and maintenance of 
phenotype should also be considered when designing a tissue engineering approach. 
Transforming growth factor-beta (TGF-) is frequently used as a standard factor in media 
designed to induce chondrogenic differentiation. TGF- is part of the bone morphogenic 
protein (BMP) superfamily, and is involved in chondrogenesis, including differentiation of 
progenitor cells into chondrocytes[18]. Additionally, TGF- also induces proliferation and ECM 
production in articular chondrocytes[19, 20].  
In bone differentiation, dexamethasone, ascorbic acid and -glycerophosphate are 
commonly used supplements for culture media designed to induce osteogenic differentiation 
of various cell types. Dexamethasone, a synthetic glucocorticoid, has been shown to induce 
osteogenic differentiation of osteoprogenitor cells from adult bone marrow stromal-derived 
cells[21, 22]. Ascorbic acid plays an essential role in the structure and function of skeletal 
tissues as it is required for human collagen synthesis. Moreover, when a potential source of 
phosphate ions, such as -glycerophosphate[22], is also present, a zone of hydroxyapatite-
containing mineralized ECM is formed within the collagen fibrils[23], and this mineralization of 
the matrix is essential for formation of bone tissue. However, although osteo- and 
chondrogenic media are frequently described in the literature and are used to induce the 
differentiation of cells into these lineages, an efficient osteochondrogenic medium, which 
would be able to support both osteo- and chondrogenesis and the co-culture of both bone and 
cartilage cells, has not been completely established, although some attempts have been 
described[24]. 
In this study, we aimed to develop a novel approach for designing functional scaffolds that 
would support an OC interface. A novel OC medium, designed to support differentiation and 
maintenance of both bone and cartilage cell phenotypes, was also developed by combining 
some of the growth factors and nutrients associated with osteo- and chondrogenic media. 
Furthermore, insulin-like growth factor (IGF) was also evaluated as a potential factor for 
supporting OC constructs in vitro, since it is involved in several developmental and 
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physiological functions[25] of bone and cartilage, including cartilage and bone development; 
chondrocyte proliferation and ECM synthesis[26, 27], and osteoblast proliferation and bone 
formation[28]. 
In order to test the OC media and our novel scaffold design, human AFSCs were either 
cultured on SPCL scaffolds and differentiated into osteogenic cells or encapsulated in agarose 
gel and differentiated into chondrogenic cells. These two cell seeded scaffolds were then 
brought together in order to form a combination of scaffolds that would provide a highly 
supportive scaffold for bone formation as well as a soft matrix for cartilage growth. The 
resulting single constructs were cultured for 1 or 2 weeks in our novel OC media, either with or 
without IGF-1. At each time point, the constructs were characterized regarding the expression 
of bone and cartilage specific markers to evaluate the influence of the culture media on the 
osteogenic or chondrogenic phenotype of the differentiated cells.  
 
 
V.3. Materials and Methods 
 
Human AFSCs were cultured in basic amniotic fluid cell (BAFC) medium. The BAFC medium 
(500 mL) contained liquid α-MEM (HyClone Laboratories Inc., USA) with 18 % Chang B (Irvine 
Scientific, USA) and 1 % Chang C (Irvine Scientific) media as well as 2 % L-glutamine (HyClone 
Laboratories Inc.) and 15 % embryonic screened fetal bovine serum (ES-FBS, HyClone 
Laboratories Inc.) as previously described[4]. Briefly, back-up human amniocentesis cultures 
were harvested by trypsinization, and immunoselected with c-kit. AFS cells were then 
subcultured at a dilution of 1:8 and not permitted to expand beyond 60 % of confluence. The 
AFS cells passaged 2–3 times (passage 18-20) in BAFC medium. Then AFSCs were either 
encapsulated in agarose discs (2 %, Invitrogen, USA) at a concentration of 2 x106 cells/mL for 
the chondrogenic layer of the bilayered scaffold or seeded onto SPCL scaffolds at a 
concentration of 8.6 x105 cells/scaffold for the osteogenic layer. SPCL fibers were obtained by 
a fiber melt extrusion/fiber bonding process. Fiber-mesh scaffolds were prepared by cutting 
and sintering SPCL fibers by a melt-spinning process as previously described[14]. SPCL 
scaffolds were selected as 3D environment as these scaffolds have been extensively studied 
and characterized for bone TE strategies[12-16]. Prior to the cell culture assays, all scaffolds 
were cut into cylinders of 4 mm diameter and 5 mm length, and sterilized using ethylene 
oxide.  
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SPCL scaffolds seeded with hAFSCs and agarose gels with encapsulated hAFSCs were 
cultured for 2 days in BAFC culture medium, and then the medium was exchanged for either 
osteogenic or chondrogenic media, respectively. The chondrogenic medium consisted of 
DMEM (HyClone Laboratories Inc.) supplemented with 1 % antibiotic/antimicotic solution, 50 
µg/mL L-ascorbic acid (Sigma, St Louis, MO, USA), 1 mM dexamethasone (Sigma), 40 g/mL L-
proline (Sigma), 100 g/mL sodium pyruvate (Sigma), 1 % ITS (100x, Sigma) and 10 ng/mL TGF-
1 (Sigma). The osteogenic medium was composed of DMEM (HyClone Laboratories Inc.) 
supplemented with 10 % FBS (HyClone Laboratories Inc.) and the following osteogenic 
supplements: 100 nM dexamethasone (Sigma), 50 µM L-ascorbic acid and 10 mM glycerol-2-
phosphate disodium salt hydrate (Sigma). Chondrogenic differentiation of AFSCs in the 
agarose gels was assessed after 7, 14 and 21 days in the chondrogenic media, and then the 
gels were characterized for cellular viability with a Calcein AM assay, safranin-O staining, and 
immunofluorescence for aggrecan and collagen type II. 
After both chondrogenic and osteogenic differentiation occurred in the two scaffolds, the 
constructs were combined by adding a drop of agarose (2 %) between the cell-encapsulated 
and the SPCL scaffolds to promote bonding of the two layers. Then, the bilayered constructs 
were cultured for 2 additional weeks in co-culture medium under static conditions to evaluate 
whether this medium could maintain differentiated AFSCs in both chondrogenic and 
osteogenic phenotypes simultaneously. The co-culture media was composed of DMEM-LG 
(HyClone Laboratories Inc.), 4 g/mL sodium pyruvate, ITS (1x), 5 mM glycerol-2-phosphate, 
50 µg/mL L-ascorbic acid, 10 mM dexamethasone, and 40 g/mL L-proline.  In some studies, 
the growth factor IGF-1 (100 ng/mL, Invitrogen) was added to the co-culture medium (IGF-1 
(+)). 
After 7 and 14 days in the co-culture media, constructs were removed and characterized 
for the osteo- or chondrogenic markers mentioned above. BAFC medium (i.e., the basal 
conditions) was used as a control for this experiment. 
 
V.3.1. Viability assay with Calcein AM 
 
AFSCs encapsulated in the agarose gels were rinsed in PBS (HyClone Laboratories Inc.) and 
then were incubated in PBS containing 3 µM Calcein AM (Molecular Probes, Invitrogen) for 30 
min at 37 ºC in a 5 % CO2 environment. This incubation was followed by a quick rinse in PBS 
and overnight fixation in 10 % buffered formalin (Surgipath Medical Ind., Inc, USA) at 4 ºC. 
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AFSC viability was detected using a confocal microscope (Axiovert 100 M, Zeiss, Germany) 
equipped with argon/He-Ne laser sources. 
 
V.3.2.  SEM (scanning electronic microscopy) 
 
Bilayered constructs were rinsed in PBS, fixed in 10 % buffered formalin overnight, and 
dehydrated in a series of ethanol concentrations and critical point dried (EMS850X, Electron 
Microscopy Sciences, USA). The scaffolds were then sputtered with gold (Hummer 6.2 
sputtering system, Anatech Ltd, USA). This procedure destroys the structure and morphology 
of AFSC-agarose systems and therefore, SEM observation was only used for the AFSC-SPCL 
constructs of the OC system (Hitachi S-2600N, Hitachi Science Systems, Ltd, Japan). 
Additionally, in order to detect specific ions that eventually became present at the surface of 
cell seeded SPCL constructs on the ECM, such as calcium (Ca) and phosphorus (P), an energy 
dispersive spectroscopy (EDS) analysis was performed with EDAX (Pegasus X4M, EDS/EBSD, 
EDAX B.V., Netherlands). 
 
V.3.3.  Histological characterization 
 
For histological evaluation, the samples were rinsed in PBS, fixed in 10 % buffered formalin 
overnight and processed using a tissue processor (Microm STP120, MICROM International 
GmbH, Germany). Next, each sample was embedded in paraffin blocks (Microm EC 350-2, 
ThermoScientific, Spain), and 10 m thick sections were cut and stained with safranin-O 
(Fluka, Switzerland). Following deparaffinization of AFSC-agarose samples, slides were stained 
with Weigert’s iron hematoxylin working solution (Sigma-Aldrich, Germany) for 7 minutes. 
Samples were rinsed in tap water for 10 minutes, and subsequently rinsed quickly in 1 % 
acetic acid (Fluka) solution for about 10 to 15 seconds and stained in 0.1 % safranin O solution 
for 5 minutes.  
Immunofluorescence analysis for collagen type II and aggrecan was also carried out. 
Sections were cut from the paraffin blocks, deparaffinized and rehydrated with a graded series 
of ethanol concentrations. Prior to incubation with primary antibodies for either mouse anti-
collagen II (MAB1330, Millipore, Spain) or mouse anti-human aggrecan (MCA1452, Serotec, 
Germany), slides were blocked with bovine serum albumin (BSA; 3 % in PBS) (Sigma-Aldrich, 
Germany) for 40 minutes. Samples were incubated with primary antibodies overnight in a 4 ºC 
room. After washing, the samples were incubated with rabbit anti-mouse Alexa Fluor 488-
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conjugated secondary antibody (A11059, Invitrogen, Spain) for 1 hour at room temperature. 
Samples were observed under a microscope (Zeiss Imager Z1m, Germany) and images were 
acquired using a digital camera (AxioCam MRm5). 
 
 
V.4.  Results and Discussion 
 
V.4.1.  AFSCs-agarose system 
 
The AFSCs remained viable during the 21-day culture period regardless of the type of media 
used (basal or chondrogenic), as shown in Figure V.4.1.  
 
 
Figure V.4.1 – Calcein AM stained samples of AFSCs encapsulated in agarose gels after 7, 14, 
and 21 days in chondrogenic and basal medium (control). 
 
Nevertheless, the intensity of Calcein AM fluorescence found in samples cultured in basal 
culture media appeared to be higher than that observed in samples cultured in chondrogenic 
media. 
Since basal medium is specifically formulated for cell maintenance and expansion, AFSCs 
may have been able to proliferate at a higher rate when cultured in basal medium. 
Conversely, chondrogenic medium directs AFSCs towards the chondrogenic differentiation 
process and thus, stimulates the cells to stop proliferating and begin expressing ECM proteins. 
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This result is expected, because during mammalian development, proliferation usually inhibits 
differentiation, while differentiation is accompanied by cell cycle withdrawal[29]. The inverted 
relationship between proliferation and differentiation has been previously reported in 
osteoprogenitor cells[30].  
Besides water, the cartilage matrix consists of macromolecules in which collagen type II 
(around 80 % of the total tissue collagen) and proteoglycans (aggrecan) are the main structural 
representatives[31], and these molecules are responsible for tissue formation. Therefore, the 
differentiation of AFSCs into chondrocyte-like cells was assessed by examining the expression 
of collagen type II and aggrecan by immunofluorescent analysis.  
Collagen type II expression was detected as early as 7 days into culture of AFSCs 
encapsulated in agarose gels, and by the end of week 3, the expression appeared to increase, 
especially when chondrogenic medium was used for culture. This is particularly evident if the 
amount of collagen type II in chondrogenic and basal medium cultured constructs is compared, 
as expression of collagen type II in the latter tends to decline with time in culture (Figure 
V.4.2).  
 
 
Figure V.4.2 – Immunofluorescent analysis of collagen type II expression in AFSCs encapsulated 
in agarose gels after 7, 14, and 21 days in chondrogenic and basal media (control). 
Magnification, 200X. 
 
Collagen type II expression is observed throughout the differentiation process of MSCs into 
chondrocytes[32]. Collagen is initially expressed at the final stage of undifferentiated MSCs, 
and then increases significantly as cells became chondroprogenitors, and again as fully 
differentiated chondrocytes[32]. This continuous expression of collagen II during chondrogenic 
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differentiation may explain why collagen type II is expressed at all time points in this study. 
Since AFSCs share several markers with MSCs[4, 33]; the chondrogenic differentiation of AFSCs 
may also follow a similar time course in terms of collagen type II expression, and be 
continuously expressed during our experiment.  
 However, it has been shown that the aggrecan is available in smaller amounts in cartilage 
ECM than collagen type II[31], and we have also observed this in our study (Figure V.4.3).  
 
 
Figure V.4.3 - Immunofluorescent analysis for aggrecan expression in AFSCs encapsulated in 
agarose gels after 7, 14 and 21 days in chondrogenic or basal media (control). Magnification, 
200X. 
  
In basal medium, AFSCs encapsulated in agarose gels expressed a low level of aggrecan for 
the 3 weeks of this experiment. Conversely, in chondrogenic culture medium, aggrecan 
expression is more evident, reaching a peak at 2 weeks that is followed by a slight decrease at 
3 weeks. This pattern of expression is supported by data showing that during skeletogenesis, 
chondroprogenitor determination and chondrocyte differentiation are accompanied by 
dynamic ECM remodeling[32]. Aggrecan expression in the ECM increases as chondrocytes 
differentiate and become hypertrophic[32]. In addition, chondroprogenitor cells and 
chondrocytes express high levels of collagen type II and increasing levels of aggrecan in the 
ECM. Nevertheless, as chondrocytes move into a hypertrophic state, low expression levels of 
collagen type II and high aggrecan levels are observed[32]. Our results show that in the 
agarose gels, strong collagen type II expression and lower expression of aggrecan are present 
with some fluctuations from week 2 to week 3. This suggests that by week 3, AFSCs may still be 
in an early stage of chondrocyte differentiation. 
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V.4.2. Agarose-SPCL bilayered system 
 
V.4.2.1. AFSCs-SPCL layer 
 
The AFSCs seeded onto the SPCL scaffold proliferated well and were able to differentiate to 
osteogenic cell types in the different culture media. In the SEM micrographs of these 
constructs (Figure V.4.4), the cells were distributed throughout the scaffold, and some 
mineralization nodules could be seen at the surface of the SPCL fibers, suggesting the 
formation of a calcified ECM. Larger mineralized aggregates were found when IGF-1 was 
added to the OC culture medium after 1 week of culture in this medium. Although these 
nodules did not increase in size with time, the mineralization observed in the SPCL constructs 
was stable and was still evident after 2 weeks of culture in the OC medium. 
 
Figure V.4.4 - SEM micrographs of the osteogenic layer (AFSCs seeded onto SPCL scaffold) of 
the bilayered scaffolds after 7 or 14 days in OC culture media. IGF-1(+) indicates culture 
medium supplemented with IGF-1 while IGF-1(-) refers to the same culture medium without 
IGF-1. The basal culture medium consisted of the basic medium currently used for AFSC 
expansion and maintenance, and was used as the control medium in these studies. 
 
EDS analysis was also performed at the surface of the constructs after assembly of the OC 
constructs. Two EDS analyses were considered; the first was broader and included several 
areas of the construct that contained cells with and without mineralization nodules (Table 
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V.4.1), and the second analysis included only areas in which mineralization was present (Table 
V.4.2).  
 
Table V.4.1 - Results obtained from EDS analysis of the atomic percentage (At %) of several 
ions present in AFSCs-SPCL layer after 7 and 14 days in the OC culture media.  
At (%) Si P Ca Ca/P 
7 d IGF-1 (+) 0.22 0.66 0.95 1.439 
7 d IGF-1 (‒)  0.09 0.56 0.55 0.982 
7 d Basal 0.20 1.52 1.61 1.059 
14 d IGF-1 (+) 0.13 0.58 0.47 0.810 
14 d IGF-1 (‒) 0.07 0.55 0.57 1.036 
14 d Basal 0.08 0.46 0.46 1.000 
Represented ions: Si-silicium, P-phosphorus, Ca-calcium. Ca/P stands for the ratio 
Calcium/Phosphorus. 
 
Silicon (Si), a trace element that has an essential role in bone formation and is thought to 
be involved in the synthesis and/or stabilization of collagen[34] was found in all of the 
constructs at different end points. Si levels tended to decrease with culture time in OC media, 
although this decrease was larger in constructs cultured in basal medium.  
The detection of calcium (Ca) and phosphorus ions (P) via EDS has been associated with the 
production of mineralized matrices by cells. In this study, although Ca and P levels decreased 
with culture time when the constructs were maintained in both basal and OC media without 
IGF-1, the Ca/P ratio was close to 1 at all time points. However, when IGF-1 was added to the 
media, the Ca/P ratio detected in the constructs cultured for 7 days was 1.439. This ratio is 
more similar to tricalcium phosphate (TCP) ratio[35]. 
 In general, the decrease observed in the percentage of atomic concentrations with the 
culture end points may be related to the presence of a saturation point at which a balance of 
mineralized matrices might be established. When osteoblasts become entrapped in bone ECM, 
these cells eventually begin to die as part of the natural process of bone formation. 
Furthermore, if the cell proliferation rate is reduced because the cells have become entrapped 
in the mineralized matrices they produced, the synthesis of ECM will also decrease and 
stabilize. Nevertheless, when the analysis was performed specifically on mineralized nodules, 
some variations in the amounts of the studied ions were observed (Table V.4.2).  
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Table V.4.2 - Results obtained from EDS analysis of the atomic percentage (At %) of several 
ions present in AFSCs-SPCL layer after 7 and 14 days in the OC culture media. EDS analysis was 
performed on areas of the constructs containing mineralized aggregates. 
At (X) Si P Ca Ca/P 
7 d IGF-1 (+) 0.41 4.44 4.94 1.113 
7 d IGF-1 (‒)  0.28 3.06 3.34 1.092 
7 d Basal 0.33 5.78 6.85 1.185 
14 d IGF-1 (+) 0.14 2.51 2.53 1.008 
14 d IGF-1 (‒) 0.10 2.88 3.07 1.066 
14 d Basal 0.24 3.73 6.19 1.660 
Represented ions: Si-silicium, P-phosphorus, Ca-calcium. Ca/P stands for the ratio 
Calcium/Phosphorus. 
 
When only mineralized areas were studied, Si values decreased with time. Although 
calcium and phosphorus slightly decreased with culture time, the atomic concentrations of 
both of these minerals were higher than the ones observed in the broader analysis shown in 
Table V.4.1. This result is expected, since the EDS focused on areas of mineralization in the 
second analysis. When the Ca/P was calculated, all culture conditions but one resulted in a 
ratio around 1. The constructs cultured for 14 days in basal medium after the OC assembly 
were found to have a Ca/P ratio of 1.66, which is nearly the same as the Ca/P ratio found in 
naturally occurring bone hydroxyapatite, which is 1.67[35, 36]. During the process of bone 
hardening during aging, the Ca:P ratio gradually increases from 1 to 1.67, the hydroxyapatite 
ratio reported for healthy bone[37].  
Although IGF-1 has been shown to be important for bone and cartilage tissue development, 
we did not find that the presence of this growth factor had any effect on the maintenance of 
the osteogenic phenotype of cells cultured in OC medium with IGF-1. Furthermore, the best 
results in terms of mineralization were observed in basal medium conditions after 2 weeks in 
culture, when the constructs demonstrated a Ca/P ratio similar to that seen in natural bone. 
Runx-2 is an important transcription factor involved in osteogenic development and 
exogenous expression, which has been shown to enhance osteoblast-specific gene expression 
in rat bone marrow stromal cells as well as biological mineral deposition[38]. In our previous 
study, hAFSCs were shown to express RunX-2 during osteogenic differentiation over a period 
of up to 3 weeks in osteogenic medium. In the present study, we analyzed possible differences 
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in RunX-2 expression 2 weeks after the novel OC media was added to the constructs (Figure 
V.4.5). 
 
Figure V.4.5 - Immunofluorescence for RunX-2 expression in the osteogenic layer (AFSCs 
seeded onto SPCL scaffolds) of the bilayered scaffolds after 14 days (14d) in the OC culture 
media. IGF-1(+) indicates culture medium supplemented with IGF-1 while IGF-1(-) refers to the 
same culture medium without IGF-1. “Basal” refers to the basic medium currently used for 
AFSC expansion and maintenance, and was used as a control in this assay. 
 
Runx-2 expression was higher when the cells were cultured in OC media than when they 
were cultured in basal medium. In the basal medium, RunX-2 expression was almost 
nonexistent, which indicates that in OC media, with or without IGF, the osteogenic process is 
dynamic and evolving, and that mineralization may be taking place, since high levels of Runx2 
expression have been shown to maintain the mineralization capacity of expanded marrow 
cells[38].  
 
Cell viability in the hAFSC-containing agarose gels was qualitatively analyzed using a Calcein 
AM assay after the chondrogenic differentiation process.  
Figure V.4.6 indicates that most cells remained viable during the culture period, and 
viability was independent of the medium used for culture. Furthermore, cellular viability was 
high both at the surface/border and in the center areas of the gels, indicating that the agarose 
gels were permeable enough to allow the exchange of nutrients and gases between the 
culture media and the encapsulated cells.  
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Figure V.4.6 - Viability of the chondrogenic layer (AFSCs in agarose gels) of the bilayered 
scaffold after 7 (7d) or 14 days (14d) in the OC culture media. IGF-1(+) indicates culture 
medium supplemented with IGF-1 while IGF-1 (-) refers to the same culture medium without 
IGF-1. “Basal” represents the basic medium currently used for AFSC expansion and 
maintenance, and was used as a control. 
 
Collagen type II expression within the gels was assessed by immunofluorescence. Figure 
V.4.7 indicates that collagen type II was present in the constructs for up to 14 days after the 
addition of OC media. However, expression of this chondrogenic marker was lower in the 
assembled bilayered construct than in AFSC-containing agarose gels alone, and this was true 
whether the constructs were cultured in basal or chondrogenic media.  
A possible explanation is that the OC media is a rich cocktail that, together with the 
presence of the AFSC-SPCL constructs, might interfere with the chondrogenic process of 
encapsulated AFSCs.  
 
Aggrecan levels were also measured in the bilayered constructs. They were found to be 
similar to the levels observed in the AFSC-agarose gels alone. This suggests that aggrecan 
expression is more stable than collagen type II expression in the presence of OC media (Figure 
V.4.8). 
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Figure V.4.7 - Collagen type II expression (200x magnification) in the chondrogenic layer (AFSCs 
in agarose gels) of the bilayered scaffold after 7 or 14 days in OC culture medium. IGF-1(+) 
indicates culture medium supplemented with IGF-1 while IGF-1 (-) refers to the same culture 
medium without IGF-1. Cultures maintained in basal medium were used as controls. 
 
 
Figure V.4.8 - Aggrecan immunofluorescence (200 x magnification) in the chondrogenic layer 
(AFSCs in agarose gels) of the bilayered scaffold after 7 or 14 days in OC culture medium. IGF-
1(+) indicates culture medium supplemented with IGF-1 while IGF-1(-) refers to the same 
culture medium without IGF-1. Culture in basal medium was used as a control. 
 
Safranin-O staining is used to identify areas of cartilage production in tissue sections. When 
we performed this stain on sections taken from the bilayered OC constructs, the chondrogenic 
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layer (AFSC-agarose gel) stained positively in sections from all samples cultured in OC medium 
without IGF-1 after 14 days of culture, as shown in Figure V.4.9. 
 
 
Figure V.4.9 - Safranin-O (cartilage-specific) staining of the chondrogenic layer (AFSCs in 
agarose gels) of the bilayered scaffold after 14 days in OC culture medium. IGF-1(+) indicates 
culture medium supplemented with IGF-1 while IGF-1 (-) refers to the same culture medium 
without IGF-1. “Basal” represents the basic medium currently used for AFSC expansion and 
maintenance, and was used as a control. Magnification, 200X. 
 
In basal medium as well as in medium containing IGF-1, the safranin-O staining intensity is 
very low. This suggests that the combination of other factors besides IGF-1 in the 
osteochondral medium maintains a higher level of chondrogenesis in the constructs, thus 
increasing the safranin-O staining in the constructs cultured in the OC medium. 
Despite the fact that collagen type II and aggrecan expression were lower in the OC 
medium than in regular chondrogenic medium, these proteins were still present in the 
chondrogenic layer of the bilayered constructs cultured in OC medium, indicating that in this 
media, AFSCs continue to produce ECM.  
However, because aggrecan levels remain low with time, and are independent of the 
culture media, it is unlikely that AFSC-derived chondrocyte-like cells became hypertrophic in 
these constructs. The decrease in protein production may have been a result of the reduced 
proliferation rate observed in these samples, which is typical of differentiated chondrocytes.  
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V.5. Conclusions 
 
The results obtained in this study demonstrated that AFSCs seeded onto SPCL scaffolds or 
encapsulated in agarose gel systems remained viable even after these constructs were 
cultured for additional time in the novel OC culture media described here. Furthermore, in the 
osteogenic layer (SPCL), osteogenically differentiated AFSCs did not require the OC media to 
maintain an osteogenic phenotype for up to 14 days, as they were able to continue producing 
mineralized ECM even when cultured in basal medium. In agarose gels, encapsulated AFSCs 
differentiated into chondrocyte-like cells that produced an ECM rich in collagen type II and 
aggrecan. When cultured in OC media, the expression of these markers decreased, but 
safranin-O staining clearly indicated that the cells continued to produce a cartilage-like ECM in 
OC medium without IGF supplement.  
In this bilayered system, IGF was not essential for the maintenance of chondrogenic or 
osteogenic phenotypes in differentiated AFSCs as evidenced by marker expression studies. 
However the other supplements in the OC medium were shown to be very important for 
achieving long-term differentiation results.  
This OC co-culture medium could be advantageous not only to simplify cell culture 
procedures but also to allow physical interaction between osteogenic and chondrogenic 
phenotypes while ensuring that the induced phenotype of chondrocytes and osteoblasts is 
maintained. In addition, this medium would reduce the time and production costs of a tissue 
engineered product and move it closer to a clinically applicable strategy for joint repair. Finally, 
the development of a bilayered OC system for tissue engineering of bone/cartilage interfaces 
could better mimic the integration of bone and cartilage in an OC defect by providing scaffolds 
that address tissue specific needs.  
In this study, a bilayered scaffold of this type was successfully created in which both 
osteogenically and chondrogenically differentiated AFSCs maintained long term viability and 
phenotypic expression in vitro. Thus, the integrated agarose-SPCL scaffold proved to be 
functional in vitro and may lead to the development of new strategies for OC repair and 
regeneration. 
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Chapter VI 
AMNIOTIC FLUID STEM CELLS VERSUS BONE MARROW MESENCHYMAL STEM CELLS 
AS A SOURCE FOR BONE TISSUE ENGINEERING 
 
 
 
 
 
 
 
 
 
 
VI.1.  Abstract 
 
The ideal or universal cell source for tissue engineering (TE) is yet to be found. The widely 
studied bone marrow mesenchymal stem cells (BMSCs) have been evidencing important 
osteogenic characteristics, therefore becoming the gold standard for orthopaedic regeneration 
strategies. However, novel stem cell sources, for instance, amniotic fluid stem cells (AFSCs) are 
arising showing important and unique features that might lead to novel successful approach 
towards bone regeneration.  
This study aims to originally compare the osteogenic potential of BMSCs and AFSCS towards 
bone TE strategies, under distinct culturing environments. The purpose is to analyse the origin-
related response of stem cells to different external environments during the osteogenic 
differentiation process. Thus, the osteogenic differentiation was evaluated both on 2D and 3D, 
using a culture treated plate, and by means of seeding/culturing the cells onto fiber bonding 
SPCL scaffolds (a blend of starch and poly-caprolactone), respectively.  
BMSCs and AFSCs were successfully differentiated into the osteogenic lineage, and 
developed mineralized ECM. Nevertheless, cells presented different expression patterns of 
bone-related markers as well as different timings of differentiation, indicating that both cell 
origins and the culturing environment have a significant impact in the progression of the 
osteogenic phenotype in AFSCs and BMSCs. 
 
Chapter VI – Amniotic fluid stem cells versus bone marrow mesenchymal stem cells as a source for bone tissue 
engineering 
- 132 - 
 
VI.2. Introduction 
 
The human body has an endogenous system of regeneration and repair through stem cells, 
which can be found in almost every living tissue[1-4]. Therefore, stem cells are an obvious 
choice for regenerative medicine applications, including bone tissue engineering therapies. 
Nevertheless, the selection of the most appropriate source of stem cells for efficient bone 
regeneration is still a major issue to be considered in the tissue engineering field[3, 5]. 
The ideal cell source should combine insignificant donor morbidity or tissue scarcity with no 
amount limitations, be easy to harvest, isolate and maintain in vitro, be available according to 
patients needs, have no issues of immunogenicity, no diseases transmission risks and be of low 
cost. So far, different cell sources match some of the parameters in this list, thus directing the 
applicability of cell sources into more specific strategies, yet always with some limitations. 
Among adult stem cells, bone marrow mesenchymal stem cells (BMSCs) are possibly the 
ones most investigated. Their multipotential to differentiate into different lineages was 
confirmed by several research groups, including a high potential for bone regeneration 
strategies[5-8]. Nevertheless, BMSCs harvesting is an invasive and rather painful procedure to 
the donor. Furthermore, their numbers, proliferation, and differentiation potential decline 
with age[9, 10]. Some studies suggest that BMSCs are also sensitive to subculturing 
methodologies, and their stability in long-term in vitro culture is controversial[11, 12]. 
Nevertheless, BMSCs represent a promising cell source for cell-based therapeutics showing 
great promise in animal studies and some clinical trials[1, 13, 14]. 
Amniotic fluid derived stem cells (AFSCs) were recently introduced to bone TE [2, 15, 16] 
whose behavior and characteristics are not so deeply investigated so far. Nevertheless, these 
cells have demonstrated interesting characteristics, since they derive from embryonic and 
extra-embryonic tissues during the process of foetal development and growth. In fact, AFSCs 
have shown to be highly proliferative[12], with high self-renewal capability and have the 
potential to differentiate into several lineages, including the osteogenic phenotype[2, 17]. 
AFSCs are easy to obtain, representing an an almost unlimited stem cell source with 
immunosuppressive properties[18] and, whose harvesting procedure does not raise ethical 
concerns, sometimes associated with human embryonic stem cell research[15, 16]. AFSCs have 
been also described to be in an intermediate stage between embryonic stem cells and adult 
stem cells due to their extensive ability for expansion and differentiation into functional cells 
of the three embryonic germ layers[1, 2], and thus exhibiting important potential in future 
regenerative strategies. 
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Few studies[12, 18, 19] established a comparison between human BMSCs and AFSCs to 
determine how the origin could influence the osteogenic differentiation potential of stem cells.  
In mice, mesenchymal stem cells (MSCs) from different origins are known to vary in 
clonogenic capacity, surface markers and differentiation potential[19]. Studies with human 
cells indicate that MSCs isolated from fetal tissues are more plastic and grow faster than adult 
MSCs, while evidencing similar immunophenotypic characteristics and maintaining long and 
stable telomeres[12]. 
The culturing environment provided by the substrate/scaffold characteristics, such as the 
structure and mechanical properties may also deeply affect cell behavior[20, 21]. In this sense, 
we also propose to evaluate herein human AFSCs and BMSCs in 2D and 3D cultures by seeding 
and culturing these cells onto tissue culture well plates or onto a fiber bonding mesh scaffold 
made of a blend of starch and poly ε-caprolactone (SPCL). SPCL scaffold, obtained by a fiber 
melt extrusion/fiber bonding process[22] were selected as 3D environment for osteogenic 
differentiation of both types of cells as these scaffolds have been extensively studied and 
characterized in the context of bone tissue engineering strategies [23-26]. 
The main objective of this study was to compare the osteogenic potential of marrow 
derived mesenchymal stem cells (BMSCs) and amniotic fluid stem cells (AFSCs) aiming at bone 
TE strategies. We proposed to evaluate osteogenic differentiation of these cells both on 2D 
and 3D cultures, and to compare the development of the osteogenic phenotype for up to 3 
weeks in conditioned osteogenic medium. Furthermore, we selected a well characterized fiber 
bonding mesh scaffold made of a blend of starch and poly-caprolactone (SPCL) to analyse the 
osteogenic phenotype of both BMSCs and AFSCs when cultured in a 3D matrix.  
Cells in both 2D and 3D conditions were cultured in the presence of osteogenic media for 0, 
7, 14 and 21 days and then characterized for cellular viability using a MTS assay while 
osteogenic phenotypic expression and matrix formation were assessed by 
immunofluorescence for RunX-2, collagen I and ALP activity, and by EDS and calcium 
quantification, respectively.  
This study may provide important cues of the cell behaviour of AFSCs and BMSCs when 
differentiating into the osteogenic phenotype and the variations induced by 2D and 3D seeding 
substrates.  
 
Chapter VI – Amniotic fluid stem cells versus bone marrow mesenchymal stem cells as a source for bone tissue 
engineering 
- 134 - 
 
VI.3.  Materials and Methods 
 
VI.3.1.  Cell culture  
 
Human BMSCs, purchased from Lonza® (Walkersville, USA), were expanded in basal BMSCs 
medium composed of α-MEM (HyClone Laboratories Inc.) supplemented with 10 % ES-FBS 
(HyClone Laboratories Inc.) and 1 % penicillin/streptavidin solution.  
hAFSCs were isolated as previously described[2], and cultured in basic amniotic fluid cell 
(BAFC) medium composed of α-MEM (HyClone) with 18 % Chang B (Irvine Scientific) and 1 % 
Chang C (Irvine Scientific) media as well as 2 % L-glutamine (HyClone Laboratories Inc.) and 15 
% ES-FBS. 
hBMSCs and hAFSCs were seeded onto tissue culture 6-well plates at passage 5 and 
passage 24, respectively, at a concentration of 30,000 cells/well. Cells were cultured in the 
well-plates for 3 days with basal medium, and then, exchanged to osteogenic medium, 
composed of DMEM (HyClone Laboratories Inc.) supplemented with 10 % FBS (HyClone) and 
100 nM dexamethasone (Sigma), 50 µM L-ascorbic acid (Sigma) and 10 mM glycerol 2-
phosphate disodium salt hydrate (Sigma), for up to 3 weeks (0, 7, 14 and 21 days). Before 
osteogenic characterization, cells were briefly rinsed in PBS (HyClone Laboratories Inc.) and 
fixed in 10 % neutral buffered formalin (Surgipath Medical Industries, Inc.). 
In order to study the  behavior  of hBMSCs and hAFSCs  in a 3D environment, both type of 
cells were seeded onto SPCL scaffolds (7 mm x 4 mm cylinders) at a concentration of 1.2x106 
cells/scaffold and cultured in basal medium for 3 days and then in osteogenic media for up to 3 
weeks. SPCL scaffold is a blend of starch and polycaprolactone, 30:70 (wt %) (Novamont) 
produced by fiber bonding technique as previously described[22].  
Samples were retrieved after every 7 days in culture to be characterized for cellular viability 
with Calcein AM and for assessing the presence of osteogenic markers and matrix formation by 
alkaline phosphatase (ALP), Alizarin Red (AR) stainings as well as the presence of runx-2 and 
collagen I in the matrix by immunofluorescence. Cell morphology and matrix formation were 
also assessed by scanning electronic microscopy (SEM) in the 3D environment.  
 
VI.3.2. Calcein AM assay 
 
AFSCs- and hMSCs-SPCL constructs were rinsed in PBS and incubated in cell culture medium 
with 3 µM Calcein AM (Molecular Probes, Invitrogen) for 30 minutes at 37 ºC in a 5 % CO2 
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environment. Then, constructs were rinsed in PBS and fixed in 10 % buffered formalin 
(Surgipath Medical Industries, Inc.) overnight at 4 ºC. AFSCs viability was observed under a 
confocal microscope (Axiovert 100 M, Zeiss) equipped with argon/He-Ne laser sources. DAPI 
(Molecular Probes, Invitrogen) was used as a nuclei marker in cells (live or dead). 
 
VI.3.3.  Alkaline Phosphatase (ALP) staining 
 
ALP staining was performed in 2D cultures to evaluate the osteogenic differentiation 
process of hAFSCs and hBMSCs in the tissue culture-well plates. Cells were fixed with 10 % 
buffered formalin solution overnight at 4 ºC and then rinsed, and kept in PBS until incubating 
the cells in a staining solution of 0.25 % Napthol AS-MX phosphate alkaline solution (Sigma-
Aldrich) and Fast Violet B salt (Sigma) for 30 minutes.  Afterwards, to remove excess of non-
specific staining, samples were rinsed in PBS and observed under an inverted microscope 
(Leica, DMI4000B), and images acquired using a camera Q-Imaging (Retiga-2000RV). 
 
VI.3.4.  Alizarin Red Staining (AR)  
 
Alizarin Red staining was performed in both 2D and 3D osteogenic constructs after fixing 
the constructs as described above. For this purpose, a 2 % alizarin red solution (Sigma-Aldrich) 
was prepared (pH adjusted to 4.1-4.3) and samples stained by immersion for 2 minutes. After 
image acquisition of the stained cells and cells-scaffold constructs, AR staining was solubilized 
in cetylpyridinium chloride (Sigma) at pH 7.0 for 15 minutes under milt agitation and calcium-
bounded to AR quantified at 562 nm, using a plate reader (SpectraMax MS, Molecular 
Devices). 
 
VI.3.5.  Immunofluorescence 
 
Immunofluorescence analysis was performed in samples retrieved from 2D and 3D 
conditions in order to assess the presence of bone related proteins, namely RunX-2 and 
Collagen type I. RunX-2 and Collagen type I (1:100 and 1:20 dilution, respectively), diluted in 
antibody diluent with background reducing components from Dako, were assessed by a 
regular immunofluorescence procedure using AlexaFluor 488 or 594 (Molecular Probes, 
Invitrogen, 1:200 dilution) as a secondary antibody. Protein-block serum free (Dako, Denmark) 
was used in the blocking step.  
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VI.3.6.  Scanning electronic microscopy (SEM)  
 
Cell seeded scaffolds (3D condition) were observed by scanning electron microscopy 
(Hitacho S-2600N, Hitachi Science Systems, Ltd) to assess cell morphology, proliferation as well 
as the presence/absence of a mineralized ECM matrix produced by either AFSCs or BMSCs. 
SEM was performed in fixed constructs, after dehydrating the samples in a series of ethanol 
concentrations followed by drying in a critical point drying equipment (EMS850X, Electron 
Microscopy Sciences), and gold sputtered (Hummer 6.2 sputtering system, Anatech Ltd). 
 
 
VI.4.  Results and Discussion 
 
VI.4.1.  Osteogenic differentiation of AFSCs and BMSCs in a 2D culture environment 
 
Immunofluorescence imaging (Calcein and DAPI staining) showed that both AFSCs and 
BMSCs attached and proliferated for up to 3 weeks in 2D cultures (Figure VI.4.1).  
 
Figure VI.4.1 – Viability assay (green) and Alizarin Red (red) staining of hAFSCs and hBMSCs 
cultured in 2D environment for 0, 7, 14 or 21 days in osteogenic medium. 
 
The same pictures suggest an increase in AFSCs viability for 2 weeks in osteogenic medium 
while BMSCs maintained high viability levels during the 3 weeks of experiment (Figure VI.4.1).  
Alizarin red staining was detected in both cell types after 14 days in culture (Figure VI.4.1), 
which tends to become more intense in hAFSCs by the end of week 3 in osteogenic medium. 
The increase in staining intensity is not so evident for hBMSCs for the same period of time. 
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Concerning the ALP staining that is associated to ECM maturation, hBMSCs cells express the 
highest ALP levels of the experiment after 2 weeks in osteogenic culture, indicating an active 
phase for the development of ECM. In contrast, AFSCs do not express significant amounts of 
ALP during the 2D experimental study (Figure VI.4.2). 
 
Figure VI.4.2- ALP staining of hAFSCs and hBMSCs cultured in 2D environment for 0, 7, 14 or 21 
days in osteogenic medium. 
 
RunX-2 is an important transcription factor (TF) involved in the osteogenic development 
which was also considered for the characterization of the osteogenic differentiation of AFSCs 
and BMSCs. In cell culture plates, RunX-2 is expressed by AFSCs and BMSCs at day 0. After 7 
days, a weak signal is also detected in osteogenic culture, being more evident in BMSCs. After 
14 days in culture, the presence of RunX-2 is hardly registered (data not showed).  
Immunofluorescence for collagen I, an important protein in bone ECM, was not detected 
either in AFSCs or BMSCs (data not showed) for up to 3 weeks in 2D cultures.  
Calcium levels were quantified using a microplate reader after solving alizarin red staining 
(Figure VI.4.3).  
 Up to week 2, calcium deposition by both cell types followed a similar pattern, exhibiting 
relatively low values during the first 14 days in osteogenic medium. After 21 days of culturing, 
the calcium amounts deposited by AFSCs increased dramatically (Figure VI.4.3), showing that 
AFSCs produce a higher amount of mineralized matrix in the 2D culturing environment when 
compared to hBMSCs. 
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Figure VI.4.3 – Calcium quantification (g/ml/well) of AFSCs and BMSCs in 2D cultures in 
osteogenic medium for 0, 7, 14 or 21 days. 
 
 
VI.4.2. Osteogenic differentiation of hAFSCs and hBMSCs seeded on SPCL scaffolds (3D 
environment) 
 
According to immunofluorescence observations, both stem cell types kept high viability 
when cultured on SPCL scaffolds (3D cultures) for up to 3 weeks (Figure VI.4.4).  
 
Figure VI.4.4 – Viability assay of AFSCs and BMSCs seeded onto SPCL scaffolds and cultured in 
osteogenic medium for 0, 7, 14 or 21 days. 
 
SEM micrographs revealed a good AFSCs and BMSCs proliferation and distribution on the 
SPCL scaffolds, clearly evidenced by the thick layer of cells throughout the entire scaffold 
(Figure VI.4.5). The same images suggest the presence of extracellular matrix in BMSCs-SPCL 
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constructs after 2 weeks in culture as well as some mineralization nodules (white dots in the 
SEM images), which increased in number after 3 weeks in osteogenic supplemented medium. 
In AFSCs constructs these nodules are only observed at week 3. 
 
Figure VI.4.5 - Scanning electron microscopy of AFSCs and BMSCs seeded onto SPCL scaffolds 
in osteogenic culture for 0, 7, 14 or 21 days. 
 
The formation of mineralization nodules was also evaluated in BMSCs- and AFSCs-SPCL 
constructs by Alizarin Red staining (Figure VI.4.6) and in order to determine the presence of 
CaP in these aggregates.  
 
 
Figure VI.4.6 - Calcium quantification (g/ml/construct) of AFSCs- and BMSCs-SPCL constructs 
in osteogenic medium for 0, 7, 14 or 21 days. 
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Concerning Alizarin Red staining, AFSCs required more calcium in the first days for 
metabolic processes, but this tendency changes after 2 weeks in osteogenic medium and by 3 
weeks in culture, the calcium concentration produced by BMSCs in SPCL scaffolds is 
dramatically higher than in AFSCs-SPCL constructs (Figure VI.4.6).  
SEM data are in agreement with results obtained from the calcium quantification assay in 
AFSCs- and BMSCs-SPCL constructs, showing that BMSCs are faster in achieving a calcified 
matrix in 3D fiber bonding SPCL scaffolds.  
In SPCL scaffolds, BMSCs and AFSCs expressed similar RunX2 for the first week of 
osteogenic differentiation (Figure VI.4.7).  
 
 
Figure VI.4.7 – Immunofluorescence of RunX2 expression in AFSCs- and BMSCs-SPCL 
constructs in osteogenic medium for 0, 7, 14 or 21 days. 
 
The intensity decreases from day 0 to day 7, increasing again after 2 weeks in osteogenic 
medium, especially for AFSCs. By the end of the third week, RunX2 expression is kept high with 
a bright green intensity, evidencing that the osteogenic process continues in the 3D constructs 
throughout a 3 week-time line and even in the presence of mineralized matrix. 
Collagen I was strongly stained in cells seeded onto SPCL scaffolds during the experimental 
time (Figure VI.4.8).  At day 0, an undifferentiated stage, similar detection levels were 
observed for AFSCs and BMSCs. After 7 and 14 days of culture in osteogenic media, a more 
intense fluorescence is observed in AFSCs constructs that tends to decrease on week 3, while 
in BMSCs-SPCL scaffolds, collagen I showed an increment in fluorescence intensity.  
Furthermore, collagen fibers seem to be somehow oriented in some directions over the 
SPCL fibers, forming a dense ECM.  
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Figure VI.4.8 – Immunofluorescence of Collagen I expression in AFSCs- and BMSCs-SPCL 
constructs in osteogenic medium for 0, 7, 14 or 21 days. 
 
 
VI.5. Discussion 
 
In a 2D culturing environment (tissue culture plates), both AFSCs and BMSCs were able to 
differentiate into the osteogenic lineage and produce mineralized ECM, even in the absence of 
collagen I and RunX2 expression. Although collagen I accounts for the majority of the organic 
matrix of bone tissues, collagen I cannot initiate tissue mineralization since is not responsible 
for nucleation and post-nucleation growth of apatite crystallites[27]. Osteogenic cells can 
produce a layer of non-collagenous matrix in vitro, at the surface of nonbiological substrata, 
prior to a calcium and phosphorus rich ECM. This layer is described to be similar to the cement 
line in vivo[28]. In summary, despite some differences found between cells, AFSCs showed 
higher proliferation rates and enhanced mineralization of the ECM in 2D cultures when 
compared to BMSCs. However, the mineralization seems to compromise the viability of AFSCs 
in 2D cultures. 
In a 3D environment, i.e., when cells are cultured onto the SPCL scaffolds, the 
mineralization observed at 14 days and 21 days for BMSCs and AFSCs, respectively, seems not 
to influence cell viability. AFSCs and BMSCs also showed changes in the expression of bone 
related markers from 2D to 3D cultures, indicating that culture environments play an 
important role in cellular response during the osteogenic differentiation process. Stem cells 
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have been described[20, 29, 30] to be quite sensitive to microenvironments and to respond to 
topographical patterns suggesting a physical contribution to the cellular expansion and 
differentiation process. Some osteoblast responses seem also to be rather substrate-
dependent[31], evidencing the importance of culture surface in modulating cell proliferation, 
matrix and inflammatory factor expression. 
Unlike the results registered for 2D cultures, in 3D scaffolds collagen I is present before the 
mineralization occurs in both AFSCs and BMSCs-SPCL scaffolds, providing the framework and 
spatial constraint for ordered crystal deposition and thus assisting formation of calcium 
phosphate nodules. The collagen fibers covering the scaffolds seem to be aligned, showing 
some degree of organization, which may be important in the process, since a natural 
regeneration typically involves an organized distribution of ECM rather than a random 
dispersed matrix, which, in the in vivo scenario, is associated to scar or fibrotic tissue 
formation. 
Despite similar viability and RunX2 levels during the experimental study, as well as collagen 
I levels after 21 days in osteo culture, BMSCs and AFSCs showed a different behavior in terms 
of mineralization; not only mineralization occurs latter in AFSCs constructs but BMSCs also 
produced more mineralized matrix, when seeded onto SPCL scaffolds.  
Besides culture substrate-ECM interactions, inductive factors also influence the 
programming of MSCs by matrix[20]. Multiple in vitro and in vivo studies confirmed that bone-
specific growth factors exert autocrine and paracrine effects on the proliferation, 
differentiation, and maturation of osteoprogenitor cells. In this study, the participation of 
growth factors in the culture medium is quite evident, due to their pivotal role in achieving the 
osteogenic differentiation process. The continuous expression of RunX-2 in constructs also 
indicates that osteoblast differentiation process is likely to continue in time, reinforcing the 
ECM production and maturation.  
In both environments, AFSCs and BMSCs were able to proliferate and differentiate into the 
osteogenic phenotype with the production of a mineralized matrix. The final goal was achieved 
although differences in osteo markers expression, such as ALP activity, RunX2 and collagen I 
were clearly observed. These differences may be related to different contribution from the 
external environment, as well as the influence of stem cell source in cellular responses towards 
the osteogenic differentiation process, which directly affects ECM production and 
composition.   
AFSCs higher proliferative capacity and their ability to maintain their pluripotency at higher 
passages could be exploitable as a ready available source for large numbers of osteo 
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progenitor cells with applicability for allogenous strategies, a broader spectrum than BMSCs, 
which may be limited to autologous interventions and to donor’s age. Despite the limitations, 
BMSCs represent a promising cell source for cell-based therapeutics, especially in 
orthopaedics, since BMSCs are predisposed in a certain extent to follow the osteogenic 
phenotype due to their natural commitment to the mesenchymal lineage. The hBMSCs used in 
this study were at passage 5, as hBMSC gene expression profiles were demonstrated[32] to 
remain stable in vitro between passage 3 and passage 6, thus validating results obtained in this 
study from BMSCs. AFSCs share embryonic stem cells and adult stem cells characteristics, and 
described to be genetically and phenotypically stable pluripotent cells[11, 18]. Furthermore, 
these cells can be extensively expanded, while keeping long telomers and a normal kariotype 
to over 250 population doublings, and differentiated into functional cells[2]. 
The origin of stem cells may also influence cellular response towards external signals, 
causing changes in ECM production and composition. Studies describe stem cells differences in 
proliferation[15] and differentiation[3, 15] potential, survival capacity[15], cytokines 
expression[16] and immunomodulatory properties[19], depending which tissues cells were 
obtained from. This is also observed for lineage specific markers such as ALP activity and RunX-
2 expression[15]. Our data follows this trend, as cells from bone marrow and amniotic fluid 
derived stem cells act differently to different substrate matrices, affecting the timing of 
differentiation and bone related protein synthesis. 
Animal studies are envisioned to understand the full potential and behaviour of both types 
of cells while observing the influence of cell source and 3D scaffold when implanted in vivo in a 
pre-clinical situation. 
 
 
VI.6. Conclusions 
 
The application of stem cells might be an adequate alternative for translational practice, 
since these cells can be used to enhance the body’s own regenerative potential or developing 
new therapies.  
The present data showed cellular proliferation of AFSCs and BMSCs, and subsequent 
colonization of the substrate. In fact, in both 2D and 3D cultures, the surface was covered with 
adherent cells, forming a network that followed the osteogenic differentiation process for up 
to 3 weeks in inductive osteo medium. Osteogenic specific markers were detected and 
mineralized matrix was formed in 2D as well as 3D substrates seeded with AFSCs and BMSCs. 
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Interestingly, cells from different origins seem to express different bone-related markers at 
different end points, which may correlate to cell origin and to substrate properties. The 
interplay of ECM molecules, cells and culture surface results in a dynamic and balanced system 
with different possible outcomes.  
In the adaptative process of osteogenic differentiation, the cell source origin seems to have 
an important role in selecting pathways involved in ECM synthesis, resulting in different cell 
responses to time frames, protein synthesis and culture substrate variations. Thus, AFSCs 
might be an interesting alternative to BMSCs for bone tissue engineering applications. 
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Chapter VII 
TISSUE ENGINEERED CONSTRUCTS BASED ON SPCL SCAFFOLDS 
CULTURED WITH GOAT MARROW CELLS: FUNCTIONALITY IN FEMORAL DEFECTS  
 
 
 
 
 
VII.1.  Abstract 
 
This study aims to assess in vivo performance of cell-scaffold constructs of goat marrow 
mesenchymal stromal cells (gBMSCs) and SPCL (a blend of starch with polycaprolactone) fiber 
mesh scaffolds at different stages of development, using an autologous model. gBMSCs, from 
iliac crests, were seeded onto SPCL scaffolds and in vitro cultured for 1 or 7 days in osteogenic 
media. After 1 and 7 days, constructs were characterized for proliferation and initial 
osteoblastic expression by alkaline phosphatase (ALP) activity. Scanning electron microscopy 
analysis was performed to investigate cellular morphology and adhesion to SPCL scaffolds.  
Non-critical defects (6 mm diameter, 3 mm depth) were drilled in posterior femurs of 4 
adult goats, from which bone marrow and serum were previously collected. Drill defects alone 
and defects filled with scaffolds without cells were used as controls. After implantation, 
intravital fluorescence markers: xylenol orange, calcein green and tetracycline were injected 
subcutaneously after 2, 4 and 6 weeks, respectively for bone formation and mineralization 
monitoring. Subsequently, samples were stained with Lévai Laczkó for bone formation and 
histomorphometric analysis.  
gBMSCs adhered and proliferated on SPCL scaffolds and an initial differentiation into pre-
osteoblasts was detected by an increasing level of ALP activity with the culturing time. In vivo 
experiments indicated that bone neoformation occurred in all femoral defects.  
Results obtained provided important information about the performance of gBMSC-SPCL 
constructs in an orthotopic goat model that enable to design future studies to investigate in 
vivo functionality of gBMSC-SPCL constructs in more complex models, namely critical sized 
defects and evaluate the influence of in vitro cultured autologous cells in the healing and bone 
regenerative process. 
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VII.2.  Introduction 
 
Skeletal regeneration is initiated by a traumatic episode involving bone damage that often 
includes the periosteum, bone marrow spaces, and surrounding soft tissues. Trauma, such as 
fracture or surgical cutting and drilling, causes a physical disruption of the mineralized tissue 
matrix, death of many cell types, and interruption of the local blood supply. A key stage in 
bone regeneration is the differentiation of pluripotential mesenchymal cells from the initial 
granuloma containing several cellular types, towards cartilage, fibrous cartilage, fibrous tissue 
or bone[1]. 
Bone marrow mesenchymal cells (BMCs) have been widely used in studies involving TE 
strategies for bone and cartilage as they provide a potential autologous source of cells[2-5] 
that are able to differentiate into chondrogenic and osteogenic lineages in the presence of 
specific differentiation supplements such as transforming growth factor-beta and 
dexamethasone, respectively[6]. 
Though BMCs are abundant in skeletal tissues, damaged bone may fail to heal 
spontaneously and, in most cases, the use of marrow cells alone is not ideal to accomplish the 
necessary requirements for the repair and or replacement of injured tissues. In order to 
overcome the limitations of current treatments, the TE field proposes the use of bioactive or 
inductive factors as well as a scaffold structure to support and complement the role of 
reparative cells (differentiated or non-differentiated) when implanted on injured or 
dysfunctional areas.  
The selection of a scaffold material for bone TE purposes is therefore of extreme 
significance[7]. Scaffolds must be biocompatible, biodegradable and, simultaneously, promote 
the easy diffusion of nutrients and cellular waste products as well as present suitable 
mechanical properties for cell support and new tissue ingrowth. Furthermore, the scaffold 
must possess adequate porosity, good interconnectivity and a degradation rate[8] adapted to 
the time required for tissue regeneration. 
Several biodegradable polymers have been proposed to obtain three-dimensional scaffolds 
for bone TE, including a new range of natural origin polymers based on starch[8-10]. Starch-
based polymers, such as starch-polycaprolactone blends (SPCL), are degradable and 
biocompatible polymers with distinct structural forms which had shown to be suitable for 
bone TE applications in several previous studies[11-15]. 
The seeding and extended in vitro culturing of cells within a biodegradable scaffold before 
implantation is a widespread TE approach. Some studies also report the importance of cell in 
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vitro pre-culture period onto scaffolds as it may influence the osteogenic potential of bone 
marrow cells[16]. During the in vitro culturing, seeded cells are expected to proliferate and 
secrete growth factors and matrix proteins that possibly will stimulate other cells to accelerate 
or recover and, in more dramatic situations, to stimulate the natural regenerative functionality 
when transferred to the in vivo environment.  
Ultimately and despite the relevance of achieved results from in vitro studies, the use of 
animal models is an essential step to evaluate TE constructs prior to their clinical application. 
Different animal models, such as rat, rabbit, dog, goat, sheep or monkey have been projected 
with the purpose of fairly accurate human model requests[17] and guide potential clinical 
applications. 
In the last few years, goats are becoming increasingly popular as a valid animal subject in 
this research field. In fact, due to its nature of a higher level vertebrate and the non pet status 
when compared to dogs, goats play a significant role in the orthopaedics field as a feasible 
model for orthotopic applications. In addition, goats not only have metabolic and bone 
remodelling rates similar to that of humans but also comparable sequence of events in bone 
graft incorporation and healing capacities[18], which explains the fact that this model has been 
frequently used in studies of bone formation and regeneration[19-21], biocompatibility[10], 
and osteochondral[22, 23] regeneration. 
Cell based strategies sustained by a support material have been applied to generate ectopic 
or orthotopic bone[24-27]. Although the latter presents a major potential for skeletal 
regeneration procedures, most of the in vivo studies are conducted using an ectopic approach 
and/or performed in small animal models, such as mice or rats[14, 26, 28-31]. Although non-
critical sized defects are usually evaluated in ectopic models, orthotopic location provides a 
more accurate idea of the influence or local effects of implanted cells or cell-scaffold 
constructs where they were initially designed to be functional. 
Autologous approaches have also been considered in recent studies[19, 21, 23] avoiding 
immune complex problems that interfere with the regenerative process as well as with the 
patient follow up. 
The present work describes the assessment of the in vivo osteogenic ability of cell-scaffold 
constructs based on seeding marrow mesenchymal stromal cells onto SPCL fiber mesh 
scaffolds and in vitro cultured during different periods of time (using an autologous goat 
model). As mentioned before, these scaffolds have demonstrated a very good in vitro 
functionality in several studies performed by our group. Therefore, the aim of this work is to 
obtain the first data concerning the in vivo functionality of SPCL scaffolds and gBMSCs 
Chapter VII – Tissue engineered constructs based on SPCL scaffolds cultured with goat marrow cells: functionality in 
femoral defects 
- 154 - 
 
constructs, in new bone formation of a orthotopic non critical defect in order to better 
understand the behaviour of cell-scaffold constructs implanted in femurs and to design future 
in vivo studies to be performed in the critical size defect model, which will be the ultimate 
applications for such TE strategies. 
 
 
VII.3.  Materials and Methods 
 
VII.3.1.  Production of SPCL scaffolds 
 
The polymer scaffolds used in this study are based on a blend of corn starch and -
polycaprolactone) (SPCL, 30/70 % wt) and were produced by a fiber bonding method into 
mesh structures with a porosity of around 75 % and cut into discs (6 mm diameter, 2 mm 
height) as described previously[12, 13]. All samples were sterilized using ethylene oxide and, 
prior to cell seeding, the scaffolds were immersed in 20 mL of serum free medium in 50 mL 
tubes for 30 minutes. 
 
VII.3.2.  gBMSCs harvesting  
 
In order to harvest the gBMSCs, the animals were placed under general anaesthesia and 
iliac regions were shaved and disinfected. Animals were submitted to a preanesthetic 
medication with acepromazine maleate (5 mg EV, Calmivet, Vetóquinol, France) and placed 
under general anaesthesia by induction with thiopenthal sodium (20-25 mg/Kg EV, Pentothal 
sodium, Abbott Labs, USA), maintained by inhalation of a mixture of 1.5 % isoflurane (IsoFlo, 
Abbott Labs, USA) and oxygen for a maximum of 30 minutes. 
From each iliac crest of the goats, 10 mL samples of bone marrow aspirate were obtained, 
using a bone marrow aspiration needle (Inter.V, Medical Device Technologies, Inc.) and a 10 
mL syringe, containing 1 mL heparin (5,000 U.I., Heparin sodium, B. Braun Medical, Inc.) to 
avoid marrow coagulation. The content of each syringe was then transferred into sterile 50 mL 
tubes and mixed with 30 mL of RPMI-1640 culture medium (Sigma-Aldrich), containing 1 % 
penicillin/streptomycin (Gibco) and an additional 1 mL of heparin (5,000 U.I.). Afterwards, 
gBMSCs were centrifuged for 10 minutes at 1200 rpm and a dense cellular pellet was collected 
and cultured in 75 cm2 flasks (Corning) using basic culture medium – DMEM (Dulbecco’s 
Modified Eagle’s Medium) (Sigma-Aldrich) supplemented with 10 % of autologous serum 
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isolated from goat peripheral blood and 1 % antibiotic/antimicotic solution (A/B, Invitrogen). 
Four days after the harvesting procedure, the medium containing non-adherent cells was 
removed and the adherent cells were rinsed with a sterile phosphate buffered saline (PBS, 
Sigma) solution and fresh medium was added. Cells were expanded in basic culture medium 
until about 80 % of confluence before being seeded onto SPCL scaffolds at 3 Pa.  
During this study, every 3 weeks, goat peripheral blood samples were collected from 
jugular vein of each animal, in order to obtain autologous serum, and collected into serum 
tubes without anticoagulant (Sarstedt – Monovette® - Serum Gel S). Thirty minutes after 
collection, blood samples were centrifuged at 3,000 rpm for 10 minutes. Harvested sera was 
immediately stored in appropriate tubes and preserved at -20 ºC until usage.  
 
VII.3.3.  In vitro cell seeding and culture  
 
In order to cell seed the scaffolds, gBMSCs cells were thawed and expanded until 90 % 
confluence. Afterwards, cells were enzymatically lifted with 0.05 % trypsin-EDTA (Invitrogen) 
and at 2 Pa, a cell suspension was prepared (2,500,000 cells/mL) and seeded onto the SPCL 
porous scaffolds in a drop-wise manner, at a cellular density of 500,000 cells per scaffold and 
using seeding chambers in order to improve cell seeding efficiency by avoiding cellular 
dispersion. 
After in vitro seeding, cell-scaffold constructs were cultured in non-adherent 12-well plates 
(Costar, Becton Dickinson), to avoid cellular adhesion to the bottom of the plates, and using 
alpha-MEM (Minimal Essential Medium Eagle alpha modification, Sigma-Aldrich), autologous 
sera (10 %), A/B (1 %) and osteogenic supplements, namely, dexamethasone (10-8 M) (Sigma-
Aldrich), ascorbic acid (50 g/mL) (Sigma), and -glycerophosphate (10 mM) (Sigma) for 1 and 
7 days prior to implantation. An in vitro control of the experiment was kept, consisting of cell-
scaffold constructs seeded and cultured under the same conditions and for the same periods 
of time. Autologous culture medium was changed twice a week in all cell cultures.  
 
VII.3.4. In vitro characterization of cells-scaffold constructs  
 
Samples were collected on day 1 and day 7 after seeding for the assessment of proliferation 
by DNA quantification and initial osteogenic differentiation studies by ALP activity analysis. For 
these purposes, samples removed from culture were rinsed twice in a PBS solution and 
transferred into 1.5 mL microtubes containing 1 mL of ultra-pure water. Then, gBMSC-SPCL 
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constructs were incubated for 1 hour at 37 ºC in a water-bath and stored in a -80 ºC freezer, 
promoting a thermal shock variation and thus inducing cell lysis, until testing. Before assessing 
DNA and ALP levels, constructs were thawed and sonicated for 15 minutes. 
A fluorimetric dsDNA quantification kit (PicoGreen, Molecular Probes) was used to 
determine the proliferation of cells in gBMSC-SPCL constructs. Samples and standards (ranging 
between 0 and 2 µg.mL-1) were prepared. Triplicates were made for samples and standards. 
Afterwards, the 96 well white plate (Costar, Becton Dickinson) was incubated for 10 minutes in 
the dark and the fluorescence was read using a microplate ELISA reader (BioTek, USA) at an 
excitation of 485/20 nm and an emission of 528/20 nm. A standard curve was developed in 
order to read DNA values of samples from the standard graph. 
ALP activity was measured to detect initial osteogenic differentiation on day 1 and day 7. 
For this purpose, to each well of a 96-well plate (Costar, Becton Dickinson) were added 20 µl of 
sample plus 60 µl of substrate solution consisting of 0.2 % (wt/v) p-nytrophenyl phosphate 
(Sigma) in a substrate buffer with 1 M diethanolamine HCl (Merck), at pH 9.8. The plate was 
then incubated in the dark for 45 minutes at 37 ºC. After the incubation period, 80 µl of a stop 
solution (2 M NaOH (Panreac) plus 0.2 mM EDTA (Sigma), was added to each well. Standards 
were prepared with p-nytrophenol (10 µmol.mL-1) (Sigma) in order to achieve final 
concentrations ranging between 0 and 0.3 µmol.mL-1. Samples and standards were prepared in 
triplicates. Absorbance was read at 405 nm and sample concentrations were read off from 
standard graph.  
gBMSCs adhesion and morphology was also investigated using scanning electronic 
microscopy (SEM) by previously fixing cells-scaffold constructs in a 2.5 % glutaraldehyde 
solution (Sigma), rinsing and dehydrating through a series of ethanol concentrations, before 
coating them in a gold sputter.  
 
VII.3.5. Animals Study 
 
Four skeletally adult female goats weighting 30-45 kg were used in this study. The housing 
care and experimental protocol were performed according to the national guidelines, after 
approval by the National Ethical Committee for Laboratory Animals (2007-07-27, document 
number 018939) and conducted in accordance with international standards on animal welfare 
as defined by the European Communities Council Directive of 2 November 1986 (86/609/EEC). 
During the entire study, adequate measures were taken to minimize any pain and discomfort. 
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Animals were kept in light and temperature controlled rooms and health parameters, such 
as appetite, weight maintenance or signs of infection were monitored at a daily basis.  
 
VII.3.5.1.  Implantation procedures 
 
Surgical procedures were performed under standard conditions and the drill-hole technique 
selected was based on the one described by Hallfeldt et al.[32].  
After general anaesthesia each goat was positioned in lateral recumbency, prepared and 
draped in a sterile manner to perform a surgical access to the lateral diaphysis of femur. A skin 
incision was then performed from the greater throcanter and continued distally to the lateral 
femoral condyle. The subcutaneous tissue, tensor fascia lata and lateral fascia of the vastus 
muscle were incised. Biceps femoris muscles were retracted posteriorly, and the vastus muscle 
was retracted anteriorly, after being detached from the linea aspera and femora shaft, like the 
periosteum. Non-critical size defects (6 mm diameter and 3 mm depth) were drilled in the 
lateral diaphysis of both posterior femurs of the 4 adult goats with a bone drill (Synthes, 
Switzerland). Eight drills were made in each posterior femur, with a separation distance 
between drills of 3 cm, in two non parallel sections in order to avoid fracture tension in the 
bone and also to avoid new bone formation among drills. Two of those were left empty and 
two were filled with scaffolds without cells, which were the controls for this experiment. The 
remaining drills were filled in with cells-scaffold constructs cultured for 1 day (2 defects) and 7 
days (2 defects) (Figure VII.3.1).  
 
Figure VII.3.1 - Diagram of the implantation site: A) empty drill defects, B) defects filled with 
SPCL (no cells), defects filled with cell-SPCL constructs after C) 1 day of culture and D) 7 days of 
culture in osteogenic medium. Implants were placed in the same anatomical site relative to 
both posterior femurs in each animal. 
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The implants were carefully pressed fit and placed into the bilateral defects. The muscle 
was replaced over the bone, and the fascia lata and skin were closed with resorbable and non-
resorbable sutures, respectively. 
After implantation, intravital fluorescence markers, namely, xylenol orange (90 mg/kg, 
Aldrich), calcein green (10 mg/kg, Sigma) and tetracycline (25 mg/kg, Sigma) were injected 
subcutaneously (after 2, 4 and 6 weeks, respectively) for bone formation and mineralization 
monitoring, along with the implantation period. 
In the ambulation, animals were observed at a daily basis and signs of infection or pain 
were monitored. During the first post-operative week, the animals were subject to an 
analgesic medication with flunixin meglumin (1 mg/kg IM, each 24 hours, Finadyne P.A., 
Schering-Plough II) for two days and to an antibiotic therapy with amoxicillin (15 mg/kg IM, 
each 24 hours, Clamoxyl L.A., Pfizer) for 7 days. 
After implantation, animals were kept in a 25 m2 room, with freedom of movement and full 
weight-bearing of the posterior limbs during the complete post-operative period. 
 
VII.3.5.2.  Harvesting samples after implantation 
 
Six weeks after the implantation procedure, and 24 hours after tetracycline injection, 
animal euthanasia was performed using an overdose of pentobarbital sodium (Eutasil, 
Sanofi, France). The femurs were then removed and cut into single defect-sections. Sections 
were fixed in a 4 % formaldehyde solution (pH 7.2) (Sigma) and embedded in glycol 
methacrylate (Technovit 7200® VLC–Heraus Kulzer GmbH, Germany) blocks. Thin sections with 
about 30 µm were prepared using a special microtome, according to the Donath et al. 
technique[33] using an Exakt-Cutting® System (Aparatebau GMBH, Germany) in order to slide 
calcified bone. Only the mid section of each block was used for observation at the fluorescence 
microscope (Olympus BX51, Germany) and for histomorphometric analysis. 
Additional sections were also stained with Lévai-Laczkó[34] to observe the new bone 
formation using a stereo microscope (Olympus SZX9, Germany). Quantitative measurement for 
bone neoformation was carried out after selecting relevant drill surrounding areas where 
neobone was marked and quantified using Microimage 4.0 software. 
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VII.3.6.  Statistical Analysis 
 
Statistical analysis was carried out by mean  standard error of mean using T-Test and 2-
way ANOVA for in vitro and for in vivo measurements, respectively. At least 4 samples were 
considered in the in vitro assays (DNA, ALP, SEM) while 16 samples were considered in vivo for 
each condition; A) empty drill, B) drill with SPCL scaffold, drills with SPCL seeded with gBMSCs 
for either C) 1 or D) 7 days in osteogenic medium). 
In the present study, controls of the experiment were considered; indirectly by in vitro 
assessments of DNA and ALP activity studies and directly by the histometric analysis of induced 
drills performed in the posterior femurs of each animal. 
 
 
VII.4. Results and Discussion 
 
VII.4.1.  In vitro characterization of autologous gBMSCs-SPCL constructs  
 
SEM micrographs (Figure VII.4.1) indicated that gBMSCs attached to the SPCL fiber meshes, 
presented a typical elongated morphology and were homogeneously distributed throughout 
the surface of the SPCL scaffold.  
These pictures also show an increase in gBMSCs proliferation with the culturing time, as 
observed by the cell layer formed on top of the fibers, when compared to cells cultured for 1 
day in the same conditions. 
 
 
Figure VII.4.1 - SEM micrographs of SPCL scaffolds seeded with gBMSCs and in vitro cultured in 
osteogenic culture for 1 day (A) or 7 days (B). 
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Regarding cell proliferation results, data obtained from the DNA content test (Figure VII.4.2) 
indicated that proliferation of gBMSCs seeded onto SPCL scaffolds seemed to slightly decrease 
after 7 days in culture although no statistically differences were found (p<0.05, T-Test) to 
support these results. Nevertheless, the tendency to cell proliferation decrease could be 
directly associated to the increment of ALP activity of gBMSCs. 
 
Figure VII.4.2 - In vitro double strand DNA concentration in SPCL scaffolds seeded with gBMSCs 
cultured in osteogenic culture for 1 and 7 days. 
 
Results obtained from the ALP assay revealed that, after 7 days in culture with osteogenic 
medium, there was a significant increment in ALP activity levels (Figure VII.4.3) (p<0.05, T-Test) 
when compared to levels obtained for 1 day of culture as expected, since these cells were 
biochemically stimulated towards the osteogenic pathway[6, 35, 36].  
 
Figure VII.4.3 - In vitro ALP activity in SPCL scaffolds seeded with gBMSCs cultured in 
osteogenic culture for 1 or 7 days. 
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VII.4.2.  In vivo studies  
 
All animals completed the study. No weight differences were observed and no signs of 
infection or inflammation were found nearby the implantation areas after 6 weeks. 
In this pilot study, orthotopic defects were drilled to determine the influence of SPCL 
scaffolds alone and osteogenic differentiation stage of gBMSCs seeded onto SPCL scaffolds in 
bone neoformation. In this way, cells were cultured on SPCL scaffolds, after 1 day in 
osteogenic culture, practically undifferentiated, or after 7 days in culture when cells have 
already initiated the osteogenic process as indicated by in vitro ALP activity levels and by 
previous studies performed at our group. 
Prior to constructs characterization, femurs were cleaned from muscle as the induced drills 
were not easily detected 6 weeks after implantation (both controls and drills containing the 
cell-SPCL constructs) due to an excellent regeneration process, which occurred in all cases. In 
order to expose the drills and access the inner region, bone was longitudinally cut.  
Under macroscopic observation of femoral defects, defects filled with cell-SPCL constructs 
seemed to have higher bone growth than empty drill defects or defects filled with SPCL 
materials alone.  
 
VII.4.2.1. Histologic and Fluorescence analysis 
 
The observation of sections stained with Lévai-Laczkó, a specific neobone marker (Figure 
VII.4.4), shows that there was bone formation in all drill-defects as expected in non-critical 
defects. Nevertheless, there was an enhanced neobone formation in defects containing SPCL 
scaffolds seeded with gBMSCs, which suggest the importance of the presence of these cells in 
the constructs to stimulate bone formation. Giant cells were present in one of the studied 
samples, which indicated that after 6 weeks, scaffold materials are being absorbed by the 
body, according to some research works[37]. 
 
The sequentially administration of fluorescent dyes allowed to monitor bone ingrowth 
during the overall period of implantation. 
Again, the presence of gBMSCs seems to positively influence bone ingrowth with the time, 
especially two weeks after implantation when calcein green was subcutaneously injected 
(Figure VII.4.5). 
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Figure VII.4.4 - Drill sections marked with Lévai-Laczkó staining. In A) Control 1 – empty drill 
defects, B) Control 2 – defects filled with SPCL (no cells), C) defects filled with cells-SPCL 
constructs after C1) 1 day of culture and C2) 7 days of culture in osteogenic medium. 
 
Figure VII.4.5 - Drill sections marked with Xylenol Orange (red), Calcein Green (green) and 
Tetracycline (not observed) fluorescence stainings. In A) Control 1 – empty drill defects, B) 
Control 2 – defects filled with SPCL (no cells), C) defects filled with cell-SPCL. 
Chapter VII – Tissue engineered constructs based on SPCL scaffolds cultured with goat marrow cells: functionality in 
femoral defects 
- 163 - 
 
However, the degradation rate of each staining was faster than expected, likely because of 
the fast metabolism of these animals. Due to this, in some section regions, bone formation was 
dark just before the subsequent fluorescent stain was injected. In some pictures is still possible 
to observe dark neobone areas, as the new bone was formed. As tetracycline dye was injected 
just 24 hours before samples retrieval, the fluorescence mark was too light to be easily 
observed in the drill defect images. Even though the stain has reached the bone drills, 24 hours 
was probably an insufficient period of time for the fluorescence to be imprinted in the fresh 
bone.  
Besides a qualitative analysis, histomorphological parameters of bone neoformation were 
measured, to obtain quantitative data regarding the percentage of new bone formation and 
new bone roundness. The percentage of neobone present in each drill was compared with the 
remaining drills and statistically analyzed (Figure VII.4.6). 
The amount of new bone formation tended to increase in the presence of cell seeded 
scaffolds although the quantitative analysis performed did not reveal significant differences 
between the values measured for new bone formation (%) between defects with and without 
gBMSCs.  
 
Figure VII.4.6 – New bone formation percentage in the different induced drills: A) empty drill 
defects, B) defects filled with SPCL (no cells), defects filled with cell-SPCL constructs after C) 1 
day of culture and D) 7 days of culture in osteogenic medium. 
 
Other parameters namely, roundness of new bone formation, were also considered in 
order to evaluate the spreading of neobone tissue into the induced defects.  
As it can be observed in Figure VII.4.7, there was a tendency to an increment in new bone 
roundness obtained in defects filled with cell seeded scaffolds (with increasing culturing times) 
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when compared to empty defects. This fact may be associated to a cellular stimulation 
provided by autologous cells implanted in the animals.  
 
 
Figure VII.4.7 - New bone roundness measured for the different induced drills: A) empty drill 
defects, B) defects filled with SPCL (no cells), defects filled with cell-SPCL constructs after C) 1 
day of culture and D) 7 days of culture in osteogenic medium. 
 
Neither inflammatory response after 6 weeks of implantation nor animal behaviour 
modifications in terms of food intake, movement or general health was detected. The 
presence of fiber mesh SPCL scaffolds allowed for neobone ingrowth in the induced defects. 
Furthermore, traces of cell-mediated absorption were observed in one of the retrieved 
samples by the presence of fibrous tissue containing an occasional multinucleated giant cell on 
the implant surface. This may indicate that locally, material absorption can initiate at an early 
stage of bone regeneration. 
 
 
VII.5.  Conclusions 
 
In the present study it was possible to observe the neoformation of bone in all orthotopic 
induced drills in the goat femurs, as expected for non-critical defects. Nevertheless, it was 
found an increased neobone formation as well as cellular distribution into the defect where 
the gBMSC-SPCL constructs were implanted. This increment is enhanced with the in vitro 
culturing time which indicates that in vitro culturing time of gBMSCs onto the SPCL constructs 
may also play an important role in new bone growth. The data obtained concerning in vitro 
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proliferation and differentiation of these constructs suggest that, the in vitro culturing time of 
gBMSCs in osteogenic medium, though still in a very early stage, is likely to play an important 
role in bone growth onto these defects.  
However, further studies should provide better understanding of the importance of the 
number of cells and their differentiation stage as well as the time needed for osteogenic 
supplementation to induce significant changes in bone formation in vivo. Nevertheless, SPCL 
fiber mesh scaffolds showed a great potential for the development of adequate tissue 3D 
support for the regeneration of bone in non-critical defects.  
Thus, results obtained provided important information about the performance of gBMSCs-
SPCL constructs in an orthotopic goat that enable to design future studies to investigate the in 
vivo functionality of gBMSC-SPCL constructs in more complex models, namely in induced 
critical sized defects and evaluate the influence of in vitro cultured autologous cells in the 
healing and bone regenerative process. 
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Chapter VIII   
THE STAGE OF DIFFERENTIATION OF AMNIOTIC FLUID STEM CELLS 
SEEDED ONTO BIODEGRADABLE SCAFFOLDS IN THE REGENERATION OF NON-UNION DEFECTS 
 
 
 
 
 
 
 
VIII.1. Abstract 
 
Bone tissue engineering (TE) strategies mainly require cells with high proliferative and 
osteogenic potential and a suitable scaffold to support cellular development towards new 
bone tissue formation. This study aimed at evaluating the effect of the differentiation stage of 
human amniotic fluid stem cells (hAFSCs) in the regeneration of femoral critical sized defects in 
a nude rat model. For this purpose, hAFSCs were seeded onto a starch-polycaprolactone (SPCL) 
scaffold and in vitro cultured for different periods of time in osteogenic medium in order to 
obtain: i) undifferentiated cells, ii) cells committed to the osteogenic phenotype and iii) 
“osteoblastic-like” cells. In vitro results indicated that hAFSCs kept a high viability for up to 3 
weeks seeded onto SPCL scaffolds. Furthermore, hAFSCs were considered to be osteogenically 
committed by the end of week 2 and osteoblastic-like after 3 weeks in culture. 
The constructs, obtained by in vitro culturing hAFSCs onto SPCL scaffolds until reaching 
these three differentiation stages, were then implanted in femoral critical sized defects 
induced in nude rats for 4 or 16 weeks. Empty defects and defects filled with scaffold alone 
were used as controls. The quality of new tissue formed in the defects was evaluated based on 
micro-CT and histological analysis of samples retrieved at 4 and 16 weeks of implantation. In 
vivo neoformation of bone was observed in all conditions. Nevertheless, the best bridging 
between the two sections of the defect was observed in the presence of SPCL scaffolds seeded 
with osteogenically committed AFSCs after 16 weeks. Furthermore, the presence of blood 
vessels in the inner sections of the SPCL scaffold seeded with hAFSCs provides further evidence 
of the great potential of SPCL scaffolds combined with hAFSCs for bone regeneration and 
angiogenesis in non-union defects. 
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VIII.2.  Introduction 
 
Fracture healing is a complex physiological phenomenon involving the spatial and temporal 
coordinated action of different cell types, proteins and the expression of several genes working 
towards the restoration of tissue structure and function in a proper mechanical environment.  
Age, gender, mechanism of injury and type of fracture (e.g. force impact, stress or negligible 
injuries combined with particular medical conditions, such as osteoporosis, bone cancer or 
osteogenesis imperfecta), associated injuries, comorbidities, lifestyle and pharmacological 
agents are all factors that could interfere with the fracture healing response and contribute to 
the development of non-union of fractures[1]. Of all the fracture injuries, up to 10 % will 
progress into complicated fractures, which may result in non-union defects[2]. This represents 
a contemporary problem associated with an increasing clinical burden. Despite the bone 
innate fracture repair mechanisms, non-unions or critical size segmental defects are still a 
major challenge in reconstructive orthopedic surgery[3].  
The current clinical strategy to treat fracture non-union is autologous bone grafting, where 
bone chips are removed from a secondary site into the fracture to participate in the healing 
process. Although bone graft remains the gold standard treatment of non-unions[4], some 
problems may be associated to, such as bone graft tissue site morbidity and limited quantity or 
quality of autologous bone graft material. In order to find an alternative solution, synthetic 
materials have been developed with suitable degradation kinetics and interesting properties to 
match the requirements in bone applications. Nevertheless, a highly osteogenic cell source is 
required, together with a 3D scaffold, to improve the bone regenerative potential. This need is 
even more important in larger injuries to establish cellular and molecular communications in 
situ, promoting a bond between the implant and the native systems. Several studies 
emphasized the importance of implanting cells into the defect to ensure the bone regenerative 
process[5-7]. Undifferentiated stem cells are multipotent and, once at the injury site, they can 
differentiate into the type of cell necessary according to the regenerative natural timing, while 
recruiting important growth factors[8] that stimulate in situ repair. 
 Among the sources of stem cells, amniotic fluid arises as an attractive source of pluripotent 
stem cells without raising the ethical concerns associated with the use of human embryonic 
stem cells[9]. Additionally, AFSCs have a highly self-renewal capability and have the potential 
to differentiate along several lineages[10, 11], including bone[10, 12], due to their origin from 
embryonic and extra-embryonic tissues. AFSCs also present advantages compared to other 
primary cells; unlike osteoblasts or bone marrow cells, AFSCs are not limited by tissue 
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insufficient supply and morbidity, host immune responses and disease transmission risks. 
Furthermore, due to AFSCs high proliferative capacity and their ability to maintain their 
pluripotency at higher passages, these cells may be a readily available source for large 
numbers of osteo progenitor cells aimed at bone TE strategies. 
Despite the potential of cell application in a scaffold to promote the regenerative process in 
locus, few studies addressed the effect of the cell differentiation stage in the regenerative 
process of bone[13, 14]. Since the bony milieu is a rich cocktail of growth factors, and 
molecular signals, where diverse cell types are present in several stages of differentiation, it is 
likely that the number or concentration of a particular molecule or cell type might result in a 
different role in promoting bone healing. Furthermore, undifferentiated or partially 
differentiated cells, due to their plasticity potential may participate in an immediate response 
towards an injury or trauma event, and activate signaling pathways that may not be naturally 
triggered by differentiated cells, such as osteoblasts. 
In this work, we hypothesize that the stage of differentiation of human AFSCs into the 
osteogenic lineage may affect differently the evolution of the regenerative process in non-
union defects of bone. The pre-culture period of hAFSCs in osteogenic supplemented medium 
may be a critical factor, affecting the osteoinductive potential and consequently, the new bone 
formation when orthotopically implanted.  
Therefore, the main purpose of this study was to evaluate the influence of the 
differentiation stage of human amniotic fluid stem cells (hAFSCs) cultured onto starch and 
polycaprolactone (SPCL) scaffolds, and in the regeneration of bone critical sized defects.  
In order to achieve our goals, stem cells from amniotic fluid were expanded in basic 
amniotic fluid cell medium, seeded onto SPCL scaffolds and cultured in osteogenic medium for 
different periods of time in order to have i) stem cells, ii) cells committed to the osteogenic 
phenotype and iii) “osteoblastic” cells. After reaching each stage of differentiation, samples 
were implanted in critical sized defects in the right femur of nude rats and kept for 4 or 16 
weeks. In vivo bone regeneration was monitored through micro-CT and histological analysis 
was performed after each end point. 
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VIII.3. Materials and Methods 
 
VIII.3.1. In vitro Study 
 
SPCL scaffolds were produced by a fiber bonding technique described previously[15, 16, 
17], cut into cylinders with 3.8 mm diameter and 6.0 mm length and sterilized by ethylene 
oxide. 
Human AFSCs were isolated and characterized as previously described[10] and cultured in 
basic amniotic fluid cell (BAFC) medium containing α-MEM (HyClone Laboratories IncUSA), 2 % 
Chang B (Irvine Scientific, USA) and 18 % Chang C (Irvine Scientific, USA) media as well as 1 % L-
glutamine (HyClone Laboratories Inc., USA) and 15 % embryonic stem screened fetal bovine 
serum (ES-FBS, HyClone Laboratories Inc., Logan, Utah, USA). Then, hAFSCs were seeded onto 
SPCL scaffolds at a density of 1.2x106 cells/scaffold and cultured in BAFC medium for 3 days.  
hAFSCs were characterized in terms of the osteogenic differentiation process. Osteogenic 
commitment was related to hAFSCs ability to express markers associated to the osteo lineage 
while osteoblastic stage was to be accomplished with the production of a mineralized ECM. 
Following 3 days in BAFC medium, hAFSCs seeded onto the SPCL scaffolds were cultured in 
osteogenic medium, composed of DMEM (HyClone Laboratories Inc., Logan, Utah, USA) 
supplemented with 10 % FBS (HyClone Laboratories Inc., USA) and osteogenic supplements; 
100 nM dexamethasone (Sigma, USA), 50 µM L-ascorbic acid  (Sigma, USA) and 10 mM glycerol 
2-phosphate disodium salt hydrate (Sigma, USA) for different periods of time (0, 1, 2 and 3 
weeks), determined in a preliminary study, so as to obtain i) undifferentiated cells or stem 
cells, ii) cells committed to the osteogenic phenotype and iii) “osteoblastic-like” cells. After 
each culturing period, hAFSCs-SPCL samples were characterized for osteogenic phenotypic 
expression and matrix formation by alkaline phosphatase (ALP) and Alizarin Red (AR) stainings 
as well as the presence of collagen I in the matrix. The detection of a mineralized matrix was 
further analyzed by Fourier transformed infra red attenuated spectroscopy (FTIR-ATR). Cell 
morphology and matrix formation were also assessed by scanning electronic microscopy 
(SEM).  
 
VIII.3.1.1. Alizarin Red (AR) and Alkaline phosphatase (ALP) staining 
 
Alizarin Red and ALP staining were performed in hAFSCs-SPCL constructs cultured in either 
BAFC (0 days) or osteogenic medium after each culturing period namely, 1, 2 and 3 weeks. 
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Macroscopic sections of hAFSCs-SPCL construct, approximately 2 mm x 5 mm each, were 
considered for ALP and AR stainings, where constructs were fixed with 10 % buffered formalin 
solution overnight at 4 ºC and then rinsed and kept in PBS until usage.  
 
AR: Samples were stained with a photosensitive solution of AR (0.2 %, Sigma-Aldrich, USA), 
previously prepared (pH adjusted to 4.1-4.3), for about 2 minutes at room temperature using a 
bench shaker. Then, samples were rinsed in PBS and AR staining was solubilized in a 
cetylpyridinium chloride (Sigma, USA) solution at pH 7.0 for 15 minutes using a bench shaker. 
Calcium-bound AR was quantified by spectrophotometric measurements in a plate reader 
(SpectraMax MS, Molecular Devices, Sunnyvale, CA, USA) at 562 nm. 
ALP: constructs were incubated in a staining solution of 0.25 % Napthol AS-MX phosphate 
alkaline solution (Sigma-Aldrich, USA) and Fast Violet B salt (Sigma, USA) for 30 minutes. 
Samples were rinsed in PBS to remove excess of non-specific staining.  
 
VIII.3.1.2.  SEM (scanning electronic microscopy) 
 
Human AFSC-SPCL constructs were rinsed in PBS and fixed in 10 % buffered formalin 
overnight, dehydrated in a series of ethanol concentrations and kept in absolute ethanol until 
critical point drying (EMS850X, Electron Microscopy Sciences, USA). Afterwards, constructs 
were gold sputtered (Hummer 6.2 sputtering system, Anatech Ltd, USA), before SEM (Hitacho 
S-2600N, Hitachi Science Systems, Ltd, Japan) observation of the morphology of hAFSCs 
seeded SPCL scaffolds after 0, 7, 14 and 21 days in osteogenic culture.  
Also, in order to detect calcium (Ca) and phosphorus (P) ions present in the ECM matrix, an 
energy dispersive spectroscopy (EDS) equipment (Leica Cambridge S360, UK) was used. 
 
VIII.3.1.3.  FTIR-ATR (Fourier transform attenuated total reflectance infrared 
spectroscopy) 
hAFSCs-SPCL samples, obtained from each end point, were dehydrated and air dried, 
before proceeding to a FT-IR analysis. FT-IR was performed with an attenuated total 
reflectance[18] in the spectral range of 1800-600 cm-1 using the Spectrum 400 FT-IR/FT-NIR 
spectrometer (Perkin Elmer, USA). 
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VIII.3.1.4.  Immunofluorescence 
 
hAFSC-SPCL constructs were rinsed in PBS and fixed in formalin prior to the detection of 
mouse monoclonal to collagen type I (Abcam, 1:100 dilution in antibody diluent with 
background reducing components from Dako, Denmark) by a regular immunofluorescence 
procedure using anti-mouse AlexaFluor 594 (Molecular Probes, Invitrogen; 1:200 dilution) as a 
secondary antibody. Instead of animal serum, blocking step was performed using protein block 
serum free (Dako, Denmark). Constructs were then observed under a confocal microscope 
(Axiovert 100 M, Zeiss, Germany) equipped with argon/He-Ne laser sources. 
 
VIII.3.2. In vivo Study 
 
All surgical procedures were performed in accordance with Wake Forest University Animal 
Care and Use Committee (ACUC) approved protocols (protocol number; A07-063/A10-032). In 
this study, male athymic nude rats (36-40 week old) weighing 420-560 g (n=60) were 
purchased from Charles River. Animals were randomly assigned into 5 groups (n=6 / group) as 
follows: 1) no-repair group (empty defects, no implant), 2) scaffold-only group, and 3) scaffold 
with undifferentiated hAFSCs cell group, 4) scaffold with hAFSC osteogenically committed 
group, and 5) scaffold with hAFSCs differentiated into osteoblast like cells group. 
Anesthesia was induced with 3 % isoflurane (USP, Novaplus) prior to surgical procedures. 
The dorsolateral side of the right leg was shaved and sterilized with routine aseptic agent. 
Under aseptic conditions, a 20 mm long incision was made on the skin over the femur of the 
right hind limb. The skin and the gluteus muscle were dissected to approach the femur. A 
periosteal incision was made on the periosteum of the femur, and the periosteum and the 
attached muscles were elevated to expose the femur. Retracting adjacent tissues, a 3.0 mm 
thick and 2.2 cm long custom-made bone plate was placed along the intact femur and was 
fixed with 4 stainless steel screws using a micro drill system (BS72-4950, Harvard apparatus, 
USA) to stabilize the femur after scaffold implantation. A 5 mm bone segment in between 
screwed areas at both ends was removed from the femur using a bone cutting bur. The 
created defects were thoroughly irrigated with sterile saline to avoid residual bone particles at 
the site. Subsequently, the scaffolds and cell-scaffold constructs from the different study 
groups, according to our experimental design, were implanted to the bony defects and fixed 
with a press-fit manner. After inserting the scaffolds/constructs, the muscle and the skin were 
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closed layer by layer using 5-0 Vicryl sutures (Ethicon, USA). The animals were maintained 
postoperatively according to the guideline of the ACUC.  
Radiographic 2D images of the femoral defects were obtained from each animal every 4 
weeks, using C-arm equipment (Siremobil Compact L, Siemens) to monitor plate stability and 
select animals for micro-CT analysis. Animals were kept under general anaesthesia during both 
(x-rays and micro-CT) procedures.  
Rats were euthanized 4 or 16 weeks after implantation accordingly to ACUC guidelines. 
Right femurs were retrieved, rinsed in PBS, placed in 10 % buffered formalin for 96 h and then 
kept in 60 % ethanol until histological processing. 
 
VIII.3.2.1.  µ-CT scanning 
 
Real time live imaging of the rat femoral defects was obtained using an μ-CT equipment, 
Siemens MicroCAT II (Siemens Preclinical Solutions, USA) and MicroCAT II version 1.9d 
software was used to acquire raw data.  
Scans were performed with an x-ray voltage of 70 kVp, anode current of 500 μA, and an 
exposure time of 1600 ms (BIN Factor of 2, 360 ° rotation, 360 steps, 36 micron isotropic voxel 
dimension).   
RVA version 4.2.9 and COBRA EXXIM version 4.9.52 were used to reconstruct the raw data 
into raw slice images, and then Amira version 3.1 was used for conversion to DICOM images. 
Analysis was done after transfer of images to TeraRecon AquariusNET Server (TeraRecon, Inc., 
USA) using TeraRecon software AquariusNET version 1.8.1.6. Another software packages used 
for image analysis and volumetric measurements included Mimics version 13 (Materialise, 
Belgium). 
 
VIII.3.2.2.  Tissue processing 
 
Explants were decalcified using an acid solution of Immunocal® (Decal Chemical Corp, USA), 
and tissue processed in a graded series of ethanol, xylene and embedded in paraffin blocks. 
Sections of 10 m were obtained for histological characterization by Hematoxylin/Eosin (H&E) 
staining and for immunocytochemistry (ICC) for goat anti-Collagen I (1310-01, Southern 
Biotech; 1:20 dilution), goat polyclonal anti- Osteocalcin (OC) (V-19, Santa Cruz Biotechnology, 
1:100) and rabbit polyclonal anti-VEGF (147, Santa Cruz Biotechnology, 1:100) antibodies. All 
primary antibodies were diluted in antibody diluent with background reducing components 
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from Dako (Denmark). Biotinylated secondary antibodies were purchased to Vector Lab 
(Burlingame, CA, USA) as well as R.T.U. HRP/Straptavidin (SA-5704). Immunohistochemistry 
visualization was assessed by NovaRED substrate kit (SK-4800), followed by a brief 
counterstain with Gill’s hematoxylin. Specimen slides were observed under a microscope 
(Imager Z1m, Zeiss, Germany) equipped with a digital camera (AxioCam MRc5). 
 
VIII.3.2.3.  Histomorphometrical Analysis 
 
Quantitative measurement for bone related markers, namely osteocalcin and collagen I as 
well as VEGF vascular marker were carried out for the in vivo study. After selecting an interest 
area within the defect, the protein expression was detected and quantified by Cell D software 
(analysis image processing) and MicroImage software from Olympus Optical Co. 
 
VIII.3.3. Statistical Analysis 
 
Statistical analysis was carried out by mean  standard deviation for in vitro assays, while 
histomorphometric analysis was carried out by mean  standard error of mean. Two Way 
ANOVA test was also applied to check the existence of statistical differences between sample 
groups followed by Bonferroni’s Multiple Comparison test (* = p<0.05). 
 
 
VIII.4.  Results and Discussion 
 
VIII.4.1. In vitro study 
 
hAFSCs adhered and maintained viability when seeded onto the SPCL scaffolds during the 
experimental time up to 3 weeks (data not showed). According to SEM pictures (Figure 
VIII.4.1), cells, independently of their differentiation stage, bridged between scaffold 
microfibers covering the scaffold surface, without obstructing most pores, randomly 
distributed throughout the scaffold.  
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Figure VIII.4.1 - SEM micrographs of hAFSC-SPCL constructs after 0, 7, 14 or 21 days in 
osteogenic medium. 
 
When constructs were sectioned, the presence of cells was also observed inside the 
scaffold (Figure VIII.4.1; SEM insets), showing that the seeding was efficient and the scaffold is 
suitable for nourish human AFSCs.  
Furthermore, after 2 weeks in osteogenic culture medium, cells were positively stained for 
ALP (Figure VIII.4.2) and for immunofluorescence of collagen type I (Figure VIII.4.3).  
 
Figure VIII.4.2 – Characterization of AFSC-SPCL constructs for ALP staining after 0, 7, 14 or 
21 days in osteogenic culture. 
 
 
Figure VIII.4.3 - Characterization of AFSC-SPCL constructs for collagen I by 
immunofluorescence, after 0, 7, 14 or 21 days in osteogenic culture. 
 
Osteoblastic differentiation is usually accompanied by an initial decrease in the cellular 
proliferation rate, changes in gene and protein expression of several osteogenic markers, such 
as ALP and type I collagen, and later on by the deposition of minerals on the ECM matrix.  
The production of organic ECM by AFSCs after 2 weeks in osteogenic medium shows a 
cellular commitment towards the osteogenic lineage, characterized by an ALP and collagen I 
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strong expression. ALP is a glycoprotein associated with the formation and maturation of the 
ECM[19], while collagen type I is the major constituent of bone inorganic matrix. The presence 
of both markers in AFSCs-SPCL constructs point out a rich collagen-based ECM (Figure VIII.4.2 
and VIII.4.3). Besides the structural support, ECM plays a critical role in cellular interactions 
and sustains mineral nucleation, critical for bone functional properties.  
Furthermore, after 14 days in osteo culture, thin, nano sized fibers surrounding the cells 
that may represent matrix, were found at the surface and in inner sections of the construct in 
SEM micrographs. Although cells are producing an ECM by 2 weeks in osteogenic culture, the 
ECM mineralization only occurs after 3 weeks in osteogenic supplemented culture, with the 
deposition of calcium and phosphate ions. In SEM images from 3 weeks in osteo medium, 
calcium phosphate (CaPs) aggregates are found throughout the construct (Figure VIII.4.1 and 
Figure VIII.4.4), confirmed by EDS analysis, calcium quantification, and FTIR (Figure VIII.4.4, 
Figure VIII.4.5 and Figure VIII.4.6, respectively). 
 
Figure VIII.4.4 – Characterization of AFSC-SPCL constructs by SEM and EDS analysis. SEM 
magnified images of calcium phosphate nodules at the surface and inside (inset) of these 
constructs after 21 days in osteogenic medium. The presence of calcium and phosphorus 
atoms was detected by EDS analysis after 0, 7, 14 and 21 days in osteogenic culture. SPCL 
spectrum represents a SPCL scaffolds without seeded cells.  
 
Calcium quantification in the constructs indicated that the presence of calcium is kept at a 
basal level from 0 to 14 days in culture and, at the third week in culture, this value increases 
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about 50 %, which indicates that calcium is being added to the matrix, inducing the formation 
of a calcified matrix produced by AFSCs. 
 
 
Figure VIII.4.5 - Calcium content measurement in AFSC-SPCL constructs after 0, 7, 14 or 21 
days in osteogenic culture. 
 
Vibrational spectroscopy in the mid-infrared region can provide molecular structure 
information about mineralized tissue[18]. The infrared spectrum in Figure VIII.4.6 showed the 
presence of specific types of chemical bonds, associated to the major molecular species found 
in bone; phosphate (bands ~900-1100 cm-1), carbonate (from carbonate substitution for 
hydroxyl and phosphate groups, bands ~850 cm-1), and amide I, II, and III (bands ~1650 cm-1, 
1550 cm-1 and 1250 cm-1, respectively) from the protein constituents (mainly type I collagen). 
The spectrum of unseeded SPCL scaffold does not exhibit any of these bands, and the intensity 
of these bands increases with the time in osteogenic culture. An increase in the intensity 
values may be associated to the number of chemical bonds, and thus, molecular species, 
present at the surface of the scaffold. 
 
The presence of calcium phosphate (CaPs) aggregates in SEM micrographs correspond to 
ECM mineralization, either at the surface and inner section of AFSC-SPCL constructs (Figure 
VIII.4.1 and Figure VIII.4.4 – SEM after 21 days in culture), pointing toward the osteoblastic-
like status of AFSCs after 3 weeks under osteogenic supplements.  
 
The time frame of the osteogenic process confirms these results as mineral deposition is 
accomplished largely by the precipitation of hydroxyapatite, which requires the presence of 
collagen fibrils.  
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Figure VIII.4.6 - Characterization of AFSC-SPCL constructs by FT-IR analysis. The presence of 
calcium and phosphorus groups was detected after 0, 7, 14 or 21 days in osteogenic culture. 
SPCL spectrum represents a SPCL scaffolds without seeded cells. 
 
 
VIII.4.2. In vivo study 
 
No animal subjected in this study showed any infection (Figure VIII.4.7), however some 
rats (n= 14) showed bone plate loosening or small cracks during the surgery and were excluded 
from this study. 
 
Figure VIII.4.7 - Picture of dissected femurs after an end point. Femur on the left represents a 
femur post-implantation and on the right, the left rear femur, control. 
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VIII.4.2.1. Neobone formation assessment 
 
Neobone formation to some extent was observed in all experimental groups, as expected, 
both at 4 and 16 weeks by micro-CT analysis (Figure VIII.4.8).  
 
Figure VIII.4.8 - m-CT images obtained from all defect conditions after 4 and 16 weeks of 
implantation. 
 
The formation of bone is observed 4 weeks after implantation at the segment ends of the 
defect. In empty defects, new bone formation resulted in an increased appositional growth of 
the bone in the border areas of bony segments, which could have resulted as a response of the 
organism to the trauma in the femur during surgery (Figure VIII.4.8 and Figure VIII.4.9).  
In all other conditions, interstitial bone growth was observed, and bridging bone was 
evident in the presence of SPCL and SPCL seeded with cells (Figure VIII.4.9). The micro-CT 
images also suggest that the presence of osteogenically committed hAFSCs seeded in the SPCL 
scaffolds induced the best bridging with bone formation between the two sections of the 
defect after 16 weeks of implantation. In the case of undifferentiated cells, bridging structures 
were only observed in half of the specimens after 16 weeks. 
Small particles of bone were also detected within the defect gap in SPCL and SPCL seeded 
with cells conditions, suggesting that an initial new bone forming process starts as early as 4 
weeks after implantation (Figure VIII.4.9). Although this bone ingrowth is reduced, when 
compared to the 16 week group, these results also support the relevance of the SPCL scaffold 
in new bone development with the time of implantation.  
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Figure VIII.4.9 – Volumetric measurements of the defect section obtained from mCT 
analysis using Mimics software, representing the bone neoformation area.  
 
At 16 weeks, the volumetric measurements of bone increase in all conditions, but the 
attempt of new bone to penetrate into the defect gap, and establish a link between the native 
bone segments is only detected in the presence of SPCL and SPCL seeded with cells. 
Furthermore, in most specimens analysed a lateral mineralized structure was formed and 
observed in all conditions after 16 weeks but not detected in animals with empty defects by 
the end of the first end point (4 weeks) (Figure VIII.4.8). This formation tends to increase in 
length with the implantation time and is not typically described in non-union defects studies.  
We believe that this new bone formation is associated to a secondary healing process 
frequently observed in human fractures of skeletally mature or elder individuals. Not only 
marrow bone formation is more limited in adult organisms, but bone marrow cells tends to 
decrease in number and functionality with aging, and so does their stemness potential, 
compromising the bone regeneration capacity[20-22]. 
In young individuals, bone growth through medulary influence is frequent and results in a 
complete restoration of the affected tissue. In senior organisms, this route tends to be 
replaced by alternative regeneration processes in order to create stability in motion and 
sustain load bearing forces under a partial or absent medulary influence. Since the animals of 
our study are geriatric rats, the secondary healing is the most likely process of bone 
regeneration. Nevertheless, in the presence of SPCL scaffolds, the medulary effect seems to be 
stimulated by the bridging formation in the femur defect. SPCL scaffolds are likely to indirectly 
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participate in the hemostasis process that initiates the healing cascade by entrapping small 
blood clots, resultant from the initial injury (defect surgery), that together with cells, are 
important mediators for new bone formation. Thus, we believe that SPCL scaffolds assist the 
molecular communication between the segmental areas leading to a bridging effect, not 
observed in empty defects, the negative control of our experience. 
 
VIII.4.2.2.  Histology characterization   
 
In general, H&E staining showed that cells were able to migrate into all induced defects, 
colonizing between fibers of the SPCL scaffolds with matrix production at any time points. The 
matrix formed by cells also increased with the implantation time. Empty defects, in particular, 
showed a more irregular, dispersed and disorganized distribution of the cells and matrix. 
At 4 weeks of implantation, cartilage tissue was also observed in sections of the implanted 
area of several conditions, namely, empty defects, SPCL alone, SPCL-undifferentiated hAFSCs 
and SPCL seeded with osteogenic differentiated hAFSCs. After 16 weeks of implantation, only 
SPCL seeded with undifferentiated hAFSCs showed cartilagineous areas. The cartilage seems to 
be associated to the endochondral ossification process, one of the two bone formation 
processes, in which cartilage is formed and ultimately develops into new bone tissue. 
Furthermore, bone remodeling at the end of bone segments is also observed (Figure VIII.4.10), 
especially in empty, SPCL alone and SPCL seeded with undifferentiated hAFSCs by 4 weeks of 
implantation. 
 
 
Figure VIII.4.10 – Detailed image of native bone and SPCL scaffold interface in vivo after 4 
weeks showing the native bone remodeling process aiming at defect regeneration (200x 
magnified). 
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In the scaffold implanted groups, general inflammatory response appeared to be moderate 
at 4 weeks group and to be little at 16 week group which imply that our scaffold is 
biocompatible. Additionally, in analyzed sections, some giant cells were also detected in the 
defects implanted with SPCL scaffolds. The foreign body reaction, composed of macrophages 
and foreign body giant cells, is the end-stage response of the inflammatory and wound healing 
responses following implantation of a medical device, prosthesis or biomaterial[23]. The 
presence of giant cells may also be a good indicator for SPCL in vivo degradation. As previously 
showed[15, 16, 17], SPCL is a biodegradable scaffold and the adhesion of these cells to some 
surface areas of the scaffold may stimulate the releasing of degradation mediators, such as 
reactive oxygen intermediates, and expose SPCL to a higher concentration of these factors, 
increasing scaffold susceptibility to degradation[23, 24]. 
 
VIII.4.2.2.1.  Histomorphometric Analysis   
 
Histomorphometric analysis was performed for collagen I, osteocalcin, and VEGF antibodies 
so as to quantify the expression of these proteins in the regenerative process of our strategy 
for bone non-unions regeneration.  
Considering collagen I expression (Figure VIII.4.11), higher values were found in empty 
defects although no statistical significance was found when compared to all other conditions.  
 
Figure VIII.4.11 – Histometric analysis for collagen I expression (%) in the studied conditions. 
Values are represented by mean  standard error of mean. Symbol * denote study groups with 
statistically significant differences (p<0.05), as using Two Way ANOVA method. 
 
Although collagen I is the major component of bone, it is also present in scar tissue, when 
tissue heals by repair, and at the proliferation and extracellular matrix maturation during the 
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osteoblast differentiation process. In defects filled with SPCL scaffolds, the expression of 
collagen I decreases over time (p<0.05), while in SPCL with hAFSCs conditions, the expression 
seems to be stable during the experiment.  
Osteocalcin is a non-collagenous protein only secreted by osteoblasts, described to be 
involved in the pro-osteoblastic process of bone, and often associated to bone 
mineralization[25]. As observed in Figure VIII.4.12, osteocalcin expression tends to increase 
from 4 to 16 weeks of implantation in all induced defects except the empty condition. 
 
Figure VIII.4.12 – Histometric analysis for osteocalcin expression (%) in the studied conditions. 
Values are represented by mean  standard error of mean. Symbol * denote study groups with 
statistically significant differences (p<0.05), as using Two Way ANOVA method. 
 
Moreover, the percentage of osteocalcin is higher in defects implanted with SPCL alone and 
SPCL seeded with cells than in empty defect condition, which seems to indicate that tissue 
engineered implants may participate in the osteogenic mechanism for bone mineralization. 
Increasing values found in SPCL seeded with osteogenic like hAFSCs were found to be 
statistically relevant (p<0.05) with the implantation time. 
In the literature[26], higher levels of collagen I are found in osteoprogenitor to pre-
osteoblast (osteogenic committed) cells while in mature osteoblasts, collagen I levels 
decreases and osteocalcin protein increases significantly to promote mineralization. Our 
results follow this tendency showing a higher percentage of collagen I in constructs of SPCL 
seeded with hAFSCs or osteogenic committed hAFSCs, while SPCL with hAFSCs 
(undifferentiated) express lower levels of osteocalcin, conversely to SPCL seeded with osteo 
committed or osteoblast like hAFSCs. In this sense, implanted hAFSCs seem to get involved, 
and somehow participate in the regenerative process.  
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However, as observed by micro-CT analysis, bone formation (calcified matrix) is formed in 
all conditions where SPCL is present, mainly around or at the scaffold periphery, but it does 
not seem to occur inside the scaffold likewise. This demonstrates that SPCL seem to promote 
the communication between the 2 bone segments of the femur as bone is formed at the 
boundaries of the defects but degradation time of the scaffold should be optimized to 
facilitate new bone formation inside of the scaffold.  
As new bone was less formed inside the implanted scaffold, and cells were expressing 
collagen I and osteocalcin, a possible explanation could reside on the influence of 
environmental growth factors to the bone that are more widely accessible in peripheral 
regions of the scaffold.  
Since the process of a successful bone healing requires a good vascular network, as bone is 
a highly vascularised tissue, angiogenesis plays a pivotal role in skeletal development and bone 
fracture repair[27, 28]. VEGF is a signal protein associated to vasculogenesis and angiogenesis. 
During bone repair, VEGF is required not only for blood vessel formation, but also for normal 
callus volume and mineralization[29]. Furthermore, VEGF was described to inhibit osteoblast 
apoptosis and stimulate osteogenic differentiation, indicating that VEGF may be the major 
signal to couple angiogenesis and osteogenesis during bone repair[29, 30]. 
In our study, VEGF expression showed some variation among different animals from the 
same condition, especially after 16 weeks of implantation (Figure VIII.4.13).  
 
Figure VIII.4.13 – Histometric analysis for VEGF expression (%) in the studied conditions. 
Values are represented by mean  standard error of mean. 
 
Again, a basal expression of around 0.15 % was detected in empty controls, in which no 
vascularization was significantly observed. VEGF expression tends to increase from 4 to 16 
weeks in all conditions except SPCL with osteoblastic like cells.  
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In this study, blood vessels were also microscopically visualized in all retrieved samples, 
corresponding to all the different conditions analyzed, at both implantation periods (Figure 
VIII.4.14). 
 
Figure VIII.4.14 – Detection of blood vessel formation in H&E stained sections for all conditions 
studied after 4 or 16 weeks of implantation. Pictures were 200x magnified.  
  
In accordance to VEGF histometric data, after 4 weeks of implantation, the smallest vessels 
were found in the empty defects while the largest sized vessels were found in defects filled 
with SPCL scaffolds cultured with undifferentiated hAFSCs. After 16 weeks of implantation, 
blood vessels in empty defects are only observed close to the bone segment top. The largest 
vessels were found in seeded SPCL scaffolds with undifferentiated cells, followed by SPCL 
seeded with osteogenic-like cells. These observations are in accordance to VEGF 
histomorphometical data as the highest levels of VEGF are expressed in SPCL-hAFSCs 
condition. 
These findings suggest that hAFSCs may have a role in the angiogenic/inflammatory 
processes, particularly the undifferentiated hAFSCs seeded on the SPCL scaffolds.  
The innate stem cell nature of hAFSCs, as compared to the hAFSCs osteogenically 
committed, can induce the production or migration of secreting factors, or responding to the 
presence of local environmental contributions, towards angiogenesis[27] and consequently 
bone formation. The fact that SPCL-osteoblast-like hAFSCs present larger vessels in Figure 
VIII.4.14 but low percentage of VEGF in Figure VII.4.13 can be explained together with the data 
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obtained for collagen I and osteocalcin. In SPCL-osteoblast-like hAFSC constructs, 
mineralization is being achieved and the blood vessels have been already form, as observed in 
Figure 12 so VEGF expression decreases, and a bigger input is given to the mineralization stage 
of regeneration. Nonetheless, the presence and distribution of blood vessels in all SPCL 
conditions indicated that SPCL scaffolds assist a good angiogenesis of the defect area, since an 
active blood vessel network is an essential pre-requisite for constructs maintenance and 
integration with existing host tissue.  
 
 
VIII.5.  Conclusions 
 
In vitro results indicated that hAFSCs proliferated and differentiated into the osteogenic 
lineage, when seeded onto SPCL scaffolds. hAFSCs were considered to be osteogenically 
committed after 2 weeks in osteogenic medium with the expression of some bone related 
markers and a protein rich extracellular matrix. By the end of week 3, cells became osteoblast-
like with the production of a mineralized matrix. 
After assessing in vitro functionally, in vivo studies were performed and, accordingly to 
micro-CT analysis, all defect conditions showed new bone formation to some extent from 4 to 
16 weeks of implantation. The amount of new bone was increased over time. No bridging 
formation was observed in empty defects, and despite the fact that the bridging process was 
not complete in any of the other conditions by 16 weeks; the presence of osteogenically 
committed hAFSCs in the SPCL scaffolds showed the shortest gap (bridging) between the 
femoral bone segments, after 16 weeks of implantation.  
The presence of vascular vessels in the middle of the SPCL or hAFSCs-SPCL constructs also 
indicates that SPCL scaffolds and hAFSCs participate in the angiogenesis in the defect, showing 
that SPCL scaffolds are an interesting support for bone regeneration and angiogenesis in non-
union defects, especially when seeded with human amniotic fluid stem cells committed to the 
osteogenic phenotype.  
We conclude that our SPCL scaffold system can be a useful candidate for reconstructing a 
long bone defect in the near future. Furthermore, the presence of hAFSCs can induce a 
synergistic effect in this system, but additional studies will be needed to optimize degradation 
time of the scaffold and use of hAFSCs condition. 
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Chapter IX 
CONCLUSIONS AND FINAL REMARKS 
 
 
Theory guides. Experiment decides. 
(an old saying in science) 
 
 
IX.1.  General Conclusions 
 
The broad subject of this Thesis permitted to reach further insights in some key issues of 
tissue engineering strategies for the regeneration of bone and osteochondral tissues, namely 
on scaffold development, stem cells sources and synergies between scaffold design, stem cells, 
and culturing conditions. Additionally, in vivo studies allowed obtaining important data 
regarding the relevance of using scaffolds alone or scaffolds with stem cells at different stages 
of osteogenic differentiation in the treatment of bone defects. The results obtained are 
described below: 
 
i) Scaffold design and composition for bone and osteochondral defects regeneration 
 
The development of multi-layered PCL-TCP scaffolds was successfully achieved, as well as 
the in vitro assessment of their application aiming at bone tissue engineering (TE) strategies. In 
the study described in chapter III, a PCL polymer was used as a nanofiber mesh substrate. 
Despite the fact that PCL is a well described polymer for TE strategies, the relevance of this 
study is not so much the polymer by itself but the nano structure obtained by means of using 
electrospinning. Considering that bone extracellular matrix (ECM) is essentially an organic-
inorganic composite and nano-scaled organized, the integration of nano-structures in 3D 
scaffolds could be an interesting structural approach. The main issue in this approach is the 
fact that nano-structures do not support the mechanical needs of bone as for weight loading 
or other mechanical stresses. To fulfill this gap, the study describes the idea of developing 
multi-layered structures to adjust to the dimension of bone defects, and sustain body weight 
whenever necessary during the regenerative process. Furthermore, to induce some osteogenic 
activity, and eventually stimulate a bond between construct and native bone in an in vivo 
situation, TCP granules were added, due to their osteoconductive properties. Thus, the 
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combination of PCL with calcium phosphates was shown to be more efficient to generate 
scaffolds with higher osteoconductive ability, but this was an expected result since TCP is an 
osteoconductive material. However, particularly interesting was to conclude also that PCL-TCP 
scaffolds did not required osteogenic supplements in the culture medium to induce the 
osteogenic phenotype of gBMSCs, as long as constructs were cultured in dynamic conditions. 
Furthermore, the detection of a calcified ECM in the absence of osteogenic medium indicated 
an excellent cellular response to the scaffold and to mechanical stimuli. This study 
demonstrated for the first time a composite multi-layered structure inspired in the natural 
organic-inorganic nanostructure of bone with interesting results for bone applications.  
SPCL is a blend of PCL with starch, a natural polymer, which has been widely studied at the 
3Bs Research Group. SPCL scaffolds can be obtained by several processing methodologies as 
described in this Thesis. The processability of SPCL using different techniques allows achieving 
constructs with different designs and porous structures. For instance, with a fiber bonding 
procedure, using melt spun fibers, it is easier to obtain 3D scaffolds with higher mechanical 
properties, while wet-spinning technology produces a fiber mesh scaffold, where functional 
groups can be incorporated in a single step procedure, and thus tailor the SPCL surface 
composition. In chapter IV, the bioactivity behavior of wet-spun SPCL scaffold with silanol 
groups (SPCL-Si) was demonstrated in the presence of a SBF solution. The presence of the 
silanol groups showed to stimulate the osteogenic differentiation of bone marrow stromal 
cells in vitro, but the ability to form an apatite layer together with the osteoconductive and 
osteogenic properties might also have a significant impact in vivo, as the ideal implanted 
construct should stimulate damaged tissue regeneration and restore its functionality. 
However, presently, this process does not allow obtaining scaffolds with larger dimensions 
very easily, and their mechanical properties are slightly lower than those for SPCL meshes 
obtained from melt spun fibers. Nevertheless, SPCL-Si scaffolds might offer an alternative in 
flat bone regeneration strategies, fitting the anatomically leveled areas such as calvarian bone.  
SPCL scaffolds obtained by bonding of melt spun fibers are well characterized, and were 
described in previous studies, particularly for bone engineered strategies. Thus, in chapter VI, 
VIII and V, fiber bonding SPCL scaffolds were used in osteogenic and osteochondral studies, 
respectively. 
The application of a bilayered scaffold is quite attractive for osteochondral interfaces due 
to the natural differences in cellular and tissue needs between cartilage and bone tissues. 
Osteochondral studies from chapter V revealed that the assembly of a bilayered scaffold is 
possible, and after AFSCs differentiation is achieved, cell viability is kept high, and both osteo- 
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or chondro-genic differentiation are maintained in the osteochondral bilayered system. 
Although not essential, after assembling the bilayer system, the presence of osteochondral 
medium seems to maintain the osteogenic and chondrogenic phenotypes of human AFSCs. 
The advantages of this system relay on the individual culture layers for selective 
differentiation, which can be quickly and easily assembled, and maintained in basal culture 
medium. Besides the simplification for the maintenance of differentiated cells in culture, a co-
culture medium would assist the communication between osteoblast- or chondrocyte-like cells 
to be maintained in a bilayered system until construct implantation. With this strategy, time 
and cost of a tissue engineered product could be eventually reduced, and become closer to a 
clinical application. Again, SPCL suitability for bone applications is confirmed with great 
potential to spread out into osteochondral strategies. 
 
ii) Stem cells sources and relevance of the differentiation stage – in vitro studies 
 
Although stem cells can be found in almost every tissue, cell origin can influence their 
response either mechanically, physically or chemically. Bone marrow stem cells (BMSCs) are 
the most studied, and frequently associated to autologous approaches regardless of the donor 
age-affected and self-renewal limitations. Other stem cells sources, such as amniotic fluid 
could overcome these limitations. Despite the potential of human amniotic stem cells (AFSCs), 
few studies assessed AFSCs behavior both in vitro and implanted in an animal model. Since no 
comparative analysis has been done to assess possible differences between BMSCs and AFSCs 
due to origin outcomes, in chapter VI, a comparative study was performed to find out the cell 
response to substrate and media supplementation. Results indicated that both cell types were 
able to proliferate and differentiate into the osteogenic phenotype in 2D and 3D substrates. 
Nevertheless, cells from different origins expressed different bone-related markers at different 
end points, which may be related to cellular origin and substrate properties. In fact, besides 
the influence of cell origin, stem cells response can be further tailored by scaffold materials, 
namely by the design and chemical composition. Features, such as stiffness/softness or 
elasticity, can be tailored to induce a determined cell response, as these characteristics are 
known to be detected and understood differently by the ECM of the cells. The physical contact 
between cells-scaffold will result in a series of cellular signals, through which cells attempt to 
adapt to the surrounding environment. Additional stimulus, such as dynamic culturing 
conditions can also act synergistically with the scaffold material, as showed in chapter III, thus 
enhancing a specific cell response. Despite the fact that some stem cell sources might be more 
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sensitive to certain stimuli than others, it is likely that the combination of different physical 
and chemical signals, similarly to those present in their native environment, will lead cells 
more easily to a specific target response. Thus, the selection of a particular stem cell type may 
not be a simple and direct process and relies on the TE strategy to be assessed, firstly in vitro 
and later in an in vivo environment. 
 
iii) Functionality assessment of scaffold-stem cells based strategies in bone tissue 
engineering: in vivo studies 
 
Cell-scaffold constructs were evaluated in vitro in terms of proliferative and selective 
differentiation potential, following the evolution of the sequential stages of the differentiation 
process from stem cells into osteoblast-like cells. After in vitro assessment of the promising 
systems of SPCL-AFSCs or SPCL-BMSCs, the functionality of these constructs was evaluated in 
vivo under two different studies considered in chapter VII and VIII.  
Non-critical sized defects were induced in the rear femurs of skeletally mature goats using 
an autologous cellular approach. One of the greatest advantages of autologous approaches is 
the fact that xenogenic animal cells and medium supplements are avoided, thought to be 
critical for successful future clinical procedures with human patients. Thus, several conditions 
were acknowledged so as to comprehend the influence of scaffold, and scaffold seeded with 
bone marrow cells (BMSCs) or with osteogenic committed BMSCs in the regeneration of bone. 
This is particularly important since the stage of osteogenic differentiation can be critical for 
achieving tissue-like functional substitutes. As expected, the neoformation of bone occurred in 
all orthotopic induced defects. Nevertheless, results obtained indicated that neobone 
formation and cellular distribution increased in the presence of cell seeded SPCL scaffolds, 
which strongly shows the influence of implanted cells in the bone regeneration process. In 
addition, the pre-differentiation of goat BMSCs into the osteogenic phenotype seems to 
increase the neobone ingrowth into the defects, revealing not only the importance of 
implanted cells but also of their differentiation stage in the communication process between 
implant and native bone environment. This study also evaluated the orthotopic behaviour of 
SPCL biomaterial revealing a biocompatible scaffold that does not contribute to an 
overreaction from the immune response against the implant. Additionally, SPCL scaffolds 
showed a great potential for the development of adequate tissue 3D support for the 
regeneration of bone. 
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Although autologous approaches are the perfect tailored TE solution for individual needs, 
they are quite time demanding, and some patients may not have a healthy and available stem 
cell pool to harvest from, due to age or disease limitations. Thus, researchers have been 
looking for a novel cell source that could be used for a wide range of therapies suiting patients 
worldwide. Amniotic fluid has been studied aiming at a non-immunogenic and universal stem 
cell source. These are advantageous features that brought AFSCs into highly complex bone 
defects - non-unions or critical sized defects- to validate our strategy. Again, results indicated 
that a greater amount of neobone in the presence of SPCL scaffolds and a bridging effect is 
more prominent in the defects filled with scaffolds seeded with cells committed to the 
osteogenic phenotype. The presence of large blood vessels in the defect areas, especially in 
SPCL scaffolds seeded with undifferentiated cells, followed by SPCL seeded with osteogenic-
like cells, also indicates the suitability of these constructs for the regeneration of non-union 
defects as vascularization is important to assure local transport of nutrients, oxygen and 
growth factors to the cells. 
 
In summary, biomaterials described in this Thesis showed an interesting potential in 
different strategies aiming at bone and osteochondral TE applications. Composite scaffolds 
showed prospective interest under dynamic conditions for strategies involving flat bones and 
cell culturing media without osteogenic supplements. Bioactive wet-spun fiber meshes of 
SPCL-Si scaffolds also showed intrinsic properties able to sustain in vitro osteogenic features of 
goat BMSCs. Nevertheless, SPCL meshes obtained from melt spun fiber are one step ahead as 
scaffold structures, showing to provide the necessary support to novel and under development 
bone and osteochondral TE strategies using different sources of stem cells and animal models. 
The combination of cells and SPCL scaffolds showed the best results in pre-clinical models, 
either in autologous (goat BMSCs) or heterologous (human AFSCs) cell sources. Moreover, the 
stage of osteogenic differentiation seems to be an important factor to consider in the complex 
process of bone regeneration.  
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Research is to see what everybody else has seen,  
and to think what nobody else has thought.  
Albert Szent-Györgi (1893-1986)  
 
 
 
IX.2.  Final Remarks and Future Studies 
 
It would be exciting and very promising to develop a scaffold to stimulate osteogenic 
differentiation and new bone formation in the absence of specific osteogenic supplements. 
The cost of the tissue engineered products would decrease significantly, the culture conditions 
simplified and short-termed, and some risks concerning the use of animal origin supplements 
avoided. Herein we reported the development of multi-layered nanofiber scaffolds that may 
fulfill these requirements, yet their mechanical properties may limit their application to flat 
bone strategies.  
We also reported here the advantageous features of wet spun SPCL fiber meshes that can 
be in situ functionalized in one-step processing methodology, thus enabling a cost-effective 
technology to produce scaffolds with an osteogenic stimulating surface, onto which BMSCs 
differentiate into osteoblast-like cells, while producing a mineralized extracellular matrix. Thus, 
future studies should address the influence of SPCL-Si scaffold in osteogenic differentiation in 
basal culture medium. Since these scaffolds are bioactive, as TCP granules from composite 
scaffolds of chapter III, perhaps silanol groups could provide a similar motivation as TCPs 
towards the osteogenic differentiation of BMSCs, with or without the synergistic effect of a 
dynamic environment. Additionally, the combination of starch with PCL could accelerate the in 
vivo degradation rate, while bone tissue was naturally being regenerated.  
Furthermore, in vivo studies are envisioned to understand SPCL-Si scaffolds functionality in 
vivo, which is likely to be favorable for bone regeneration due to its intrinsic bioactivity. 
A new approach for the treatment of osteochondral interfaces was also assessed, 
demonstrating promising results. In these studies, described in chapter V, the selected 
osteochondral medium showed to maintain the phenotypic expression of pre-differentiated 
cells; future studies should investigate the influence of this medium in promoting simultaneous 
osteo- or chondro-genic differentiation of stem cells seeded onto SPCL scaffolds or 
encapsulated in agarose gels, without employing differentiation media. Also, more 
chondrogenic related markers should be assessed, especially after cell maintenance in 
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osteochondral media, to determine how medium supplements are affecting the chondrogenic 
process. 
Concerning cell culturing, stem cells from different sources were differentiated into the 
osteogenic phenotype, although cell response variations were found in commonly associated 
bone markers. It is important to understand the mechanisms associated to cellular 
communication between cells and substrate or culture medium. It is very likely that different 
molecular pathways may be involved and stimuli triggered accordingly to cell origin and 
scaffold structural and chemical properties. In addition, could osteogenic supplements be 
radically eliminated from the medium? That seems to be possible for composite scaffolds, and 
can be enlarged to other scaffolds playing with the unique properties of each type of scaffold 
as well as all the other factors (such as lineage specific supplements, dynamic environment, 
scaffold tri-dimensionality) known to participate in the progression into the osteogenic lineage 
and, consequently in bone regeneration. 
The experimental study comparing bone marrow and amniotic fluid stem cells showed 
some interesting results and rose novel questions that need to be addressed in future studies. 
Since the ideal cell source is yet to be found, currently available sources should be evaluated 
considering the aimed application. Also, animals are known to be more resilient to diseases, to 
immune reactions and to healing abilities than humans. It should be interesting to evaluate if 
different animal sources of stem cells behave similarly to human correspondent ones. 
As mentioned before, both critical and non-critical defects were studied for SPCL scaffolds 
as well as the influence of cell seeded scaffolds in the regeneration of bone. Results 
demonstrated that SPCL might fasten the repair of non-critical defects as well as to promote 
the healing of non-union defects. The presence of cells and their differentiation stage also 
impacts the new bone tissue formation. Yet, further studies are required to understand the 
importance of the number of implanted cells versus their differentiation stage and to 
determine the mechanisms that illicit such different responses in bone metabolism. It is likely 
that cells undergoing different stages of differentiation may communicate differently with the 
in vivo environment through the release of distinct cytokines and growth factors inducing 
variations in the organism healing response. Understanding how these processes occur may 
provide important cues to match the advantageous and promising features of the 
experimental setups to a fully successful route towards human clinical therapies. 
